{"DataElement":{"publicId":"4214626","version":"2","preferredName":"Biospecimen Primary Histology Subtype 1 Name","preferredDefinition":"Named histologic classification that is a subtype of the primary biospecimen histology.","longName":"PRM_HISTO_SUB1_NM","context":"OCG","contextVersion":"1","DataElementConcept":{"publicId":"4191243","version":"1","preferredName":"Biospecimen Primary Histology Subtype","preferredDefinition":"Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products._A group forming a type within a larger type._Occurring first in time or sequence; original; of greatest rank or importance or value._The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains","longName":"2859635v1.0:4265591v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2859635","version":"1","preferredName":"Biospecimen","preferredDefinition":"Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.","longName":"C70699","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biospecimen","conceptCode":"C70699","definition":"Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"66832E51-39F3-1736-E040-BB89AD4349FB","latestVersionIndicator":"Yes","beginDate":"2009-04-01","endDate":null,"createdBy":"UMLLOADER_TAVERNA","dateCreated":"2009-04-01","modifiedBy":"ONEDATA","dateModified":"2009-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4265591","version":"1","preferredName":"Subtype Histology","preferredDefinition":"A group forming a type within a larger type.:The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.","longName":"C25696:C16681","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Subtype","conceptCode":"C25696","definition":"A group forming a type within a larger type.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Histology","conceptCode":"C16681","definition":"The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6A23058-E276-8179-E040-BB89AD434D47","latestVersionIndicator":"Yes","beginDate":"2014-04-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-09","modifiedBy":"ONEDATA","dateModified":"2014-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3E0B589-5915-C26B-E040-BB89AD433ADB","latestVersionIndicator":"Yes","beginDate":"2014-03-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-05","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4214605","version":"1","preferredName":"Biospecimen Primary Histology Subtype 1 Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"4214605v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Gliomatosis cerebri","valueDescription":"Gliomatosis cerebri","ValueMeaning":{"publicId":"2578735","version":"1","preferredName":"Gliomatosis cerebri","longName":"2578735","preferredDefinition":"Gliomatosis cerebri (WHO grade II) is a diffuse glial tumor which infiltrates the brain, extensively, involving more than two lobes. It is frequently bilateral and often extends to the infratentorial structures, even to the spinal cord. It is probably of astrocytic origin, although GFAP expression may be scant or absent. (Adapted form WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gliomatosis Cerebri","conceptCode":"C4318","definition":"A diffuse glial tumor which infiltrates the brain extensively, involving more than two lobes. It is frequently bilateral and often extends to the infratentorial structures, even to the spinal cord. It is probably of astrocytic origin, although GFAP expression may be scant or absent. (Adapted from WHO.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-009C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"REEVESD","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FBEF-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Giant cell tumor","valueDescription":"Giant Cell Tumor","ValueMeaning":{"publicId":"3249738","version":"1","preferredName":"Giant Cell Tumor","longName":"3249738","preferredDefinition":"A benign or malignant connective and soft tissue tumor, characterized by the presence of multinucleated osteoclast-like giant cells.  Representative examples include the giant cell tumor of bone and the giant cell tumor of tendon sheath.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Giant Cell Tumor","conceptCode":"C3055","definition":"A benign, intermediate, or malignant tumor that arises from the bone or soft tissue. It is characterized by the presence of multinucleated osteoclast-like giant cells.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6D9FB96-3940-EB3C-E040-BB89AD435DB4","latestVersionIndicator":"Yes","beginDate":"2011-06-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FC04-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Giant cell carcinoma","valueDescription":"Giant Cell Carcinoma","ValueMeaning":{"publicId":"4264813","version":"1","preferredName":"Giant Cell Carcinoma","longName":"4264813","preferredDefinition":"A malignant epithelial neoplasm composed of giant, pleomorphic cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Giant Cell Carcinoma","conceptCode":"C3779","definition":"A malignant epithelial neoplasm composed of giant, pleomorphic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42EF-FC0F-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"COOPERM","dateModified":"2020-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FC28-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Giant cell","valueDescription":"Giant Cell","ValueMeaning":{"publicId":"2574244","version":"1","preferredName":"Giant Cell","longName":"2574244","preferredDefinition":"A large cell-like structure formed by the joining together of two or more cells.  The plural is syncytia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Giant Cell","conceptCode":"C12607","definition":"An abnormally large cell that contains multiple nuclei and an abundant amount of cytoplasm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EF11-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-30","endDate":null,"createdBy":"HARDINGR","dateCreated":"2005-03-30","modifiedBy":"ONEDATA","dateModified":"2005-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FC3C-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Germinoma","valueDescription":"Germinoma","ValueMeaning":{"publicId":"2578733","version":"1","preferredName":"Germinoma","longName":"2578733","preferredDefinition":"The most common type of germ cell tumor affecting the central nervous system.  It is composed of uniform cells with large vesicular nuclei, prominent nucleoli and clear cytoplasm.  Lymphocytic or lymphoplasmacytic infiltrates are usually seen admixed with the tumor cells.  Less frequently giant syncytiotrophoblastic cells are also present.  Germinomas are usually radiosensitive and they have a favorable prognosis.  - 2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Germinoma","conceptCode":"C3753","definition":"A malignant germ cell tumor arising in the central nervous system. It is characterized by the presence of primitive, large malignant germ cells and lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-009A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"REEVESD","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FC47-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Gastritis","valueDescription":"Gastritis","ValueMeaning":{"publicId":"2746385","version":"1","preferredName":"Gastritis","longName":"2746385","preferredDefinition":"Inflammation of the lining of the stomach.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastritis","conceptCode":"C26780","definition":"Inflammation of the stomach.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C20DB99-72BF-0BA9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FC51-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Gastrinoma","valueDescription":"Malignant Gastrinoma","ValueMeaning":{"publicId":"4264815","version":"1","preferredName":"Malignant Gastrinoma","longName":"4264815","preferredDefinition":"A gastrin-producing neuroendocrine tumor.  It is characterized by inappropriate secretion of gastrin and associated with Zollinger Ellison syndrome.  It displays vascular invasion and metastasizes to other anatomic sites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Gastrinoma","conceptCode":"C65188","definition":"A gastrin-producing neuroendocrine tumor.  It is characterized by inappropriate secretion of gastrin and associated with Zollinger Ellison syndrome.  It displays vascular invasion and metastasizes to other anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42EF-FC5F-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FC78-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Gastric type adenocarcinoma","valueDescription":"Gastric Adenocarcinoma","ValueMeaning":{"publicId":"3206052","version":"1","preferredName":"Gastric Adenocarcinoma","longName":"3206052","preferredDefinition":"An adenocarcinoma arising from the stomach glandular epithelium. Gastric adenocarcinoma is primarily a disease of older individuals, most commonly develops after a long period of atrophic gastritis and is strongly associated with Helicobacter pylori infection. The lack of early symptoms often delays the diagnosis of gastric cancer. The majority of patients present with advanced tumors which have poor rates of curability. Microscopically, two important histologic types of gastric adenocarcinoma are recognized: the intestinal and diffuse type. The overall prognosis of gastric adenocarcinomas is poor, even in patients who receive a \"curative\" resection (adapted from Sternberg's Surgical Pathology, 3rd ed., 1999).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gastric Adenocarcinoma","conceptCode":"C4004","definition":"An adenocarcinoma arising from the stomach glandular epithelium. Gastric adenocarcinoma is primarily a disease of older individuals.  It most commonly develops after a long period of atrophic gastritis and is strongly associated with Helicobacter pylori infection. The lack of early symptoms often delays the diagnosis of gastric cancer. The majority of patients present with advanced tumors which have poor rates of curability. Microscopically, two important histologic types of gastric adenocarcinoma are recognized: the intestinal and diffuse type. The overall prognosis of gastric adenocarcinomas is poor, even in patients who receive a \"curative\" resection (adapted from Sternberg's Surgical Pathology, 3rd ed., 1999).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F03F2AF-4F8F-0E9A-E040-BB89AD436762","latestVersionIndicator":"Yes","beginDate":"2011-03-21","endDate":null,"createdBy":"BLABOLIJ","dateCreated":"2011-03-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FC8C-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Foveolar adenocarcinoma","valueDescription":"Foveolar Cell Adenocarcinoma","ValueMeaning":{"publicId":"4264817","version":"1","preferredName":"Foveolar Cell Adenocarcinoma","longName":"4264817","preferredDefinition":"An epithelial cell found in the glands of the gastric mucosa.: A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Foveolar Cell","conceptCode":"C32632","definition":"An epithelial cell found in the glands of the gastric mucosa.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42EF-FC9B-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FCB4-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Follicular lymphoma","valueDescription":"Follicular Lymphoma","ValueMeaning":{"publicId":"3088584","version":"1","preferredName":"Follicular Lymphoma","longName":"3088584","preferredDefinition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicular Lymphoma","conceptCode":"C3209","definition":"A neoplasm of follicle centre B cells which has at least a partial follicular pattern.  Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide.  Most patients have widespread disease at diagnosis.  Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present.  The vast majority of cases (70-95%) express the BCL-2 rearrangement [t(14;18)].  Histological grade correlates with prognosis.  Grades 1 and 2 follicular lymphomas are indolent and grade 3 is more aggressive (adapted from WHO, 2001).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86E3DD57-D19B-A26A-E040-BB89AD437117","latestVersionIndicator":"Yes","beginDate":"2010-05-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2010-05-18","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FCBE-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Follicle stimulating hormone","valueDescription":"Follicle Stimulating Hormone","ValueMeaning":{"publicId":"3293687","version":"1","preferredName":"Follicle Stimulating Hormone","longName":"3293687","preferredDefinition":"The determination of the amount of follicle stimulating hormone present in a sample.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicle Stimulating Hormone Measurement","conceptCode":"C74783","definition":"The determination of the amount of follicle stimulating hormone present in a sample.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF074E37-E624-1C17-E040-BB89AD431694","latestVersionIndicator":"Yes","beginDate":"2011-10-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-11","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FCD3-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Fibrosis","valueDescription":"Fibrosis","ValueMeaning":{"publicId":"4264818","version":"1","preferredName":"Fibrosis","longName":"4264818","preferredDefinition":"The formation of fibrous tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fibrosis","conceptCode":"C3044","definition":"The formation of fibrous tissue.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42EF-FCDE-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"COOPERM","dateModified":"2020-10-16","changeDescription":"10.16.2020 Updated definition to match current NCIt. mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FCF7-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Fibroblastic","valueDescription":"Fibroblast","ValueMeaning":{"publicId":"2983834","version":"1","preferredName":"Fibroblast","longName":"2983834","preferredDefinition":"A connective tissue cell that makes and secretes collagen proteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fibroblast","conceptCode":"C12482","definition":"A connective tissue cell that makes and secretes collagen proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7CE468AA-9B6B-3308-E040-BB89AD43649C","latestVersionIndicator":"Yes","beginDate":"2010-01-11","endDate":null,"createdBy":"WHITES","dateCreated":"2010-01-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FD0B-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Fibroadenoma","valueDescription":"Fibroadenoma","ValueMeaning":{"publicId":"2566468","version":"1","preferredName":"Fibroadenoma","longName":"2566468","preferredDefinition":"This is the most common benign breast lesion.  It usually occurs in premenopausal women.  Diagnostic exams and procedures include: clinical exam, imaging (mammography and ultra sound), and tissue biopsy (fine-needle aspiration or core biopsy). -2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Fibroadenoma","conceptCode":"C3744","definition":"A benign tumor of the breast characterized by the presence of stromal and epithelial elements. It presents as a painless, solitary, slow growing, firm, and mobile mass. It is the most common benign breast lesion. It usually occurs in women of childbearing age. The majority of fibroadenomas do not recur after complete excision. A slightly increased risk of developing cancer within fibroadenomas or in the breast tissue of patients previously treated for fibroadenomas has been reported.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D0B1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-08-11","endDate":null,"createdBy":"PWEST","dateCreated":"2003-08-11","modifiedBy":"REEVESD","dateModified":"2010-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FD16-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Estrogen receptor positive","valueDescription":"Estrogen Receptor Positive","ValueMeaning":{"publicId":"4264820","version":"1","preferredName":"Estrogen Receptor Positive","longName":"4264820","preferredDefinition":"Describes cells that have a receptor protein that binds the hormone estrogen. Cancer cells that are estrogen receptor positive may need estrogen to grow, and may stop growing or die when treated with substances that block the binding and actions of estrogen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Estrogen Receptor Positive","conceptCode":"C15492","definition":"An indication that estrogen receptor alpha expression has been detected in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42EF-FD23-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FD3C-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Epithelioid","valueDescription":"Epithelioid Cell","ValueMeaning":{"publicId":"4264822","version":"1","preferredName":"Epithelioid Cell","longName":"4264822","preferredDefinition":"Characteristic cells of granulomatous hypersensitivity. They appear as large, flattened cells with increased endoplasmic reticulum. They are believed to be activated macrophages that have differentiated as a result of prolonged antigenic stimulation. Further differentiation or fusion of epithelioid cells is thought to produce multinucleated giant cells. (MeSH)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epithelioid Cell","conceptCode":"C12559","definition":"A cell of mononuclear phagocyte system origin that resembles an epithelial cell and is involved in immune granuloma formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42EF-FD49-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FD62-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Epithelial","valueDescription":"Epithelial","ValueMeaning":{"publicId":"4264823","version":"1","preferredName":"Epithelial","longName":"4264823","preferredDefinition":"Refers to the cells that line the internal and external surfaces of the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epithelial","conceptCode":"C13315","definition":"A term that refers to the cells that make up the epithelial tissues.  They are found in the skin, and in the parenchyma, surface and lumen of internal organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42EF-FD6C-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FD85-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Endometrioid","valueDescription":"Endometrium","ValueMeaning":{"publicId":"3242713","version":"1","preferredName":"Endometrium","longName":"3242713","preferredDefinition":"The mucous membrane comprising the inner layer of the uterine wall; it consists of a simple columnar epithelium and a lamina propria that contains simple tubular uterine glands. The structure, thickness, and state of the endometrium undergo marked change with the menstrual cycle.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrium","conceptCode":"C12313","definition":"The mucous membrane comprising the inner layer of the uterine wall; it consists of a simple columnar epithelium and a lamina propria that contains simple tubular uterine glands. The structure, thickness, and state of the endometrium undergo marked change with the menstrual cycle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A524E309-8506-546F-E040-BB89AD436A0D","latestVersionIndicator":"Yes","beginDate":"2011-06-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Updated definition to most recent NCIt version. mc 2/15/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FD99-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Ependymoma","valueDescription":"Ependymoma","ValueMeaning":{"publicId":"2578706","version":"1","preferredName":"Ependymoma","longName":"2578706","preferredDefinition":"Ependymoma (WHO grade II) is the most common ependymal neoplasm. It is a slow growing tumor of children and young adults and is usually located intraventricularly.  It often causes clinical symptoms by blocking CSF pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes.(Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ependymoma","conceptCode":"C3017","definition":"A WHO grade 2, slow growing tumor of children and young adults, usually located intraventricularly. It is the most common ependymal neoplasm. It often causes clinical symptoms by blocking cerebrospinal fluid pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-007F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"REEVESD","dateModified":"2006-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FDA4-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Endometrioid carcinoma","valueDescription":"Endometrial Carcinoma","ValueMeaning":{"publicId":"2974467","version":"1","preferredName":"Endometrial Carcinoma","longName":"2974467","preferredDefinition":"A malignant tumor arising from the epithelium that lines the cavity of the uterine body.  The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases.  Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma.  Uterine bleeding is an initial clinical sign.  The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrial Carcinoma","conceptCode":"C7558","definition":"A malignant tumor arising from the epithelium that lines the cavity of the uterine body.  The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases.  Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma.  Uterine bleeding is an initial clinical sign.  The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BD8A964-F0F6-8A21-E040-BB89AD436C37","latestVersionIndicator":"Yes","beginDate":"2009-12-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FDB9-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Endometrioid adenocarcinoma","valueDescription":"Endometrioid Adenocarcinoma","ValueMeaning":{"publicId":"4264824","version":"1","preferredName":"Endometrioid Adenocarcinoma","longName":"4264824","preferredDefinition":"An adenocarcinoma characterized by the presence of malignant glandular epithelial cells resembling endometrial cells. It can arise from the uterine body, ovary, fallopian tube, cervix, vagina, and uterine ligament.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrioid Adenocarcinoma","conceptCode":"C3769","definition":"An adenocarcinoma characterized by the presence of malignant glandular epithelial cells resembling endometrial cells. It can arise from the uterine body, ovary, fallopian tube, cervix, vagina, and uterine ligament.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42EF-FDC4-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FDDD-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Endometrial polyp","valueDescription":"Endometrial Polyp","ValueMeaning":{"publicId":"4264826","version":"1","preferredName":"Endometrial Polyp","longName":"4264826","preferredDefinition":"A benign nodular lesion protruding above the surface of the endometrium.  It is composed of a fibrous stroma that contains thick-walled blood vessels and dilated endometrial glands.  Polypectomy is the treatment of choice.  Only few cases with recurrence have been reported.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrial Polyp","conceptCode":"C6433","definition":"A benign nodular lesion protruding above the surface of the endometrium. It is composed of a fibrous stroma that contains thick-walled blood vessels and dilated endometrial glands. Polypectomy is the treatment of choice. Only few cases with recurrence have been reported.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42EF-FDEA-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FE03-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Endometrial adenocarcinoma","valueDescription":"Endometrial Adenocarcinoma","ValueMeaning":{"publicId":"4264827","version":"1","preferredName":"Endometrial Adenocarcinoma","longName":"4264827","preferredDefinition":"Relating to or composed of endometrium.: A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrial","conceptCode":"C13322","definition":"Relating to or composed of endometrium.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42EF-FE10-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FE29-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Endocervical adenocarcinoma","valueDescription":"Endocervix Adenocarcinoma","ValueMeaning":{"publicId":"4264828","version":"1","preferredName":"Endocervix Adenocarcinoma","longName":"4264828","preferredDefinition":"The portion of the cervix which is lined by single columnar epithelium (mucosa).: A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endocervix","conceptCode":"C12309","definition":"The portion of the cervix which is lined by single columnar epithelium (mucosa).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42EF-FE36-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FE4F-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Embryonal","valueDescription":"Embryonic Tissue","ValueMeaning":{"publicId":"4264830","version":"1","preferredName":"Embryonic Tissue","longName":"4264830","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Embryonic Tissue","conceptCode":"C12950","definition":"Tissue that is formed during the embryonic stage of life of an organism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42EF-FE5C-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FE75-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Embryonal carcinoma","valueDescription":"Embryonal carcinoma","ValueMeaning":{"publicId":"2567194","version":"1","preferredName":"Embryonal carcinoma","longName":"2567194","preferredDefinition":"A non-seminomatous malignant germ cell tumor characterized by the presence of large germ cells with abundant cytoplasm resembling epithelial cells, geographic necrosis, high mitotic activity, and pseudoglandular and pseudopapillary structures formation. It can arise from the testis, ovary, and extragonadal sites (central nervous system and mediastinum).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Embryonal Carcinoma","conceptCode":"C3752","definition":"A non-seminomatous malignant germ cell tumor characterized by the presence of large germ cells with abundant cytoplasm resembling epithelial cells, geographic necrosis, high mitotic activity, and pseudoglandular and pseudopapillary structures formation. It can arise from the testis, ovary, and extragonadal sites (central nervous system and mediastinum).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D387-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"COOPERM","dateModified":"2012-11-09","changeDescription":"Added missing system generated definition. mc 11/9/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FE7F-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Dysgerminoma","valueDescription":"Dysgerminoma","ValueMeaning":{"publicId":"2574078","version":"1","preferredName":"Dysgerminoma","longName":"2574078","preferredDefinition":"Dysgerminoma","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dysgerminoma","conceptCode":"C2996","definition":"A malignant germ cell tumor characterized by the presence of a monotonous primitive germ cell population.  The neoplastic cells form aggregates and have an abundant pale cytoplasm and uniform nuclei.  The aggregates of the germ cells are separated by fibrous septa which contain inflammatory cells, mostly T-lymphocytes.  It arises primarily in the ovaries, but can occur both primarily and secondarily at other sites, particularly the central nervous system.  It responds to chemotherapy and radiotherapy. Its prognosis is related to the tumor stage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EE6B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FE89-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Ductal carcinoma in situ","valueDescription":"Ductal Breast Carcinoma In Situ","ValueMeaning":{"publicId":"2581232","version":"1","preferredName":"Ductal Breast Carcinoma In Situ","longName":"2581232","preferredDefinition":"Ductal carcinoma in situ (DCIS) is a carcinoma entirely confined to the mammary ducts. There is no evidence of invasion of the basement membrane. Currently, DCIS is classified into three categories: High-grade DCIS, intermediate-grade DCIS and low-grade DCIS. In this classification the DCIS grade is defined by a combination of nuclear grade, architectural growth pattern and presence of necrosis. The size of the lesion as well as the grade and the clearance margins play a major role in dictating the most appropriate therapy for DCIS. --2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Ductal Carcinoma In Situ","conceptCode":"C2924","definition":"A breast carcinoma entirely confined to the mammary ducts. It is also known as DCIS. There is no evidence of invasion of the basement membrane. Currently, it is classified into three categories: High-grade DCIS, intermediate-grade DCIS and low-grade DCIS. In this classification the DCIS grade is defined by a combination of nuclear grade, architectural growth pattern and presence of necrosis. The size of the lesion as well as the grade and the clearance margins play a major role in dictating the most appropriate therapy for DCIS.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A5D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"CURTIST","dateModified":"2006-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FE94-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Ductal carcinoma","valueDescription":"Ductal Breast Carcinoma","ValueMeaning":{"publicId":"2838039","version":"1","preferredName":"Ductal Breast Carcinoma","longName":"2838039","preferredDefinition":"A carcinoma arising from the ducts.  While ductal carcinomas can arise at other sites, this term is universally used to refer to carcinomas of the breast.  Ductal carcinomas account for about two thirds of all breast cancers.  Two types of ductal carcinomas have been described: Ductal carcinoma in situ (DCIS) and invasive ductal carcinoma, not otherwise specified.  The latter often spreads to the axillary lymph nodes and other anatomic sites.  The two forms of ductal carcinoma often coexist.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Ductal Carcinoma","conceptCode":"C4017","definition":"A breast carcinoma arising from the ducts.  While ductal carcinomas can arise at other sites, this term is universally used to refer to carcinomas of the breast. Ductal carcinomas account for about two thirds of all breast cancers. Two types of ductal carcinomas have been described: ductal carcinoma in situ (DCIS) and invasive breast carcinoma of no special type. The latter often spreads to the axillary lymph nodes and other anatomic sites. The two forms of ductal carcinoma often coexist.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62837FF7-84E7-6F46-E040-BB89AD433964","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FEA9-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Diffuse large B-cell lymphoma","valueDescription":"Diffuse Large B-Cell Lymphoma","ValueMeaning":{"publicId":"2838040","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma","longName":"2838040","preferredDefinition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse Large B-Cell Lymphoma","conceptCode":"C8851","definition":"A non-Hodgkin lymphoma characterized by a diffuse proliferation of predominantly large neoplastic B lymphocytes.  It is the most frequently seen type of non-Hodgkin lymphoma, representing 30%-40% of the cases.  Morphologic variants include centroblastic lymphoma, immunoblastic lymphoma, and anaplastic lymphoma.  Subtypes/entities include T-cell/histiocyte rich large B-cell lymphoma, primary diffuse large B-cell lymphoma of the central nervous system, plasmablastic lymphoma, primary cutaneous diffuse large B-cell lymphoma, leg type, and ALK-positive large B-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62837FF7-850A-6F46-E040-BB89AD433964","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"SOKKERL","dateModified":"2018-10-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FEBE-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Diffuse adenocarcinoma","valueDescription":"Diffuse Adenocarcinoma","ValueMeaning":{"publicId":"4264831","version":"1","preferredName":"Diffuse Adenocarcinoma","longName":"4264831","preferredDefinition":"widely spread; not localized or confined.: A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diffuse","conceptCode":"C14175","definition":"Widely spread; not localized or confined.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42EF-FECC-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FEE5-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Desmoplastic","valueDescription":"Desmoplastic","ValueMeaning":{"publicId":"4264832","version":"1","preferredName":"Desmoplastic","longName":"4264832","preferredDefinition":"This term refers to the growth of fibrous or connective tissue. Some tumors elicit a desmoplastic reaction, the pervasive growth of dense fibrous tissue around the tumor. Scar tissue (adhesion) within the abdomen after abdominal surgery is another type of desmoplastic reaction. (MedicineNet.com)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Desmoplastic","conceptCode":"C41603","definition":"This term refers to the growth of fibrous or connective tissue. Some tumors elicit a desmoplastic reaction, the pervasive growth of dense fibrous tissue around the tumor. Scar tissue (adhesion) within the abdomen after abdominal surgery is another type of desmoplastic reaction. (MedicineNet.com)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42EF-FEF1-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FF0A-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Cystic tumor","valueDescription":"Cystic Neoplasm","ValueMeaning":{"publicId":"4264834","version":"1","preferredName":"Cystic Neoplasm","longName":"4264834","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cystic Neoplasm","conceptCode":"C6784","definition":"A benign or malignant neoplasm that contains a single or multiple cystic spaces.  Examples include cystadenoma, mucinous cystadenocarcinoma, and serous cystadenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42EF-FF17-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FF30-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Cystadenocarcinoma","valueDescription":"Cystadenocarcinoma","ValueMeaning":{"publicId":"2831119","version":"1","preferredName":"Cystadenocarcinoma","longName":"2831119","preferredDefinition":"A malignant cystic epithelial neoplasm arising from the glandular epithelium.  The malignant epithelial cells invade the stroma.  The cystic spaces contain serous or mucinous fluid.  Representative examples include ovarian and pancreatic cystadenocarcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cystadenocarcinoma","conceptCode":"C2971","definition":"A malignant cystic epithelial neoplasm arising from the glandular epithelium.  The malignant epithelial cells invade the stroma.  The cystic spaces contain serous or mucinous fluid.  Representative examples include ovarian and pancreatic cystadenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"61F598EF-7D2C-BDE9-E040-BB89AD43552F","latestVersionIndicator":"Yes","beginDate":"2009-02-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-02-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FF3A-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Crohn Disease","valueDescription":"Crohn Disease","ValueMeaning":{"publicId":"2577525","version":"1","preferredName":"Crohn Disease","longName":"2577525","preferredDefinition":"A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn's disease most commonly involves the terminal ileum; the colon is the second most common site of involvement. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Crohn Disease","conceptCode":"C2965","definition":"A gastrointestinal disorder characterized by chronic inflammation involving all layers of the intestinal wall, noncaseating granulomas affecting the intestinal wall and regional lymph nodes, and transmural fibrosis. Crohn disease most commonly involves the terminal ileum; the colon is the second most common site of involvement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FBE2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-01-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-01-28","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FF45-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Conventional chondrosarcoma","valueDescription":"Conventional Chondrosarcoma","ValueMeaning":{"publicId":"4264836","version":"1","preferredName":"Conventional Chondrosarcoma","longName":"4264836","preferredDefinition":"A chondrosarcoma arising from the central portion of bone.  It is characterized by a lobulated growth pattern.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Central Chondrosarcoma","conceptCode":"C7155","definition":"A chondrosarcoma arising from the central portion of bone without a benign precursor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42EF-FF53-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FF6C-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Compound nevus","valueDescription":"Compound Nevus","ValueMeaning":{"publicId":"3251481","version":"1","preferredName":"Compound Nevus","longName":"3251481","preferredDefinition":"A nevus composed of neoplastic melanocytes that infiltrate both the epidermis and the dermis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Compound Nevus","conceptCode":"C3901","definition":"A nevus composed of neoplastic melanocytes that infiltrate both the epidermis and the dermis.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A765DE36-355C-FA28-E040-BB89AD435559","latestVersionIndicator":"Yes","beginDate":"2011-07-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FF80-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Clear cell renal cell carcinoma","valueDescription":"Clear Cell Renal Cell Carcinoma","ValueMeaning":{"publicId":"3248533","version":"1","preferredName":"Clear Cell Renal Cell Carcinoma","longName":"3248533","preferredDefinition":"A malignant epithelial neoplasm of the kidney characterized by the presence of lipid-containing clear cells within a vascular network.  The tumor may metastasize to unusual sites and late metastasis is common.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clear Cell Renal Cell Carcinoma","conceptCode":"C4033","definition":"A malignant epithelial neoplasm of the kidney characterized by the presence of lipid-containing clear cells within a vascular network.  The tumor may metastasize to unusual sites and late metastasis is common.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6BBE041-B9CF-9503-E040-BB89AD435A00","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"COOPERM","dateModified":"2011-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FF95-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Chronic pancreatitis","valueDescription":"Chronic Pancreatitis","ValueMeaning":{"publicId":"3210965","version":"1","preferredName":"Chronic Pancreatitis","longName":"3210965","preferredDefinition":"A chronic inflammatory process causing damage and fibrosis of the pancreatic parenchyma. Signs and symptoms include abdominal pain, malabsorption and diabetes mellitus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Pancreatitis","conceptCode":"C84637","definition":"A chronic inflammatory process causing damage and fibrosis of the pancreatic parenchyma. Signs and symptoms include abdominal pain, malabsorption and diabetes mellitus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BAE6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FFB5-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Chronic myelomonocytic leukemia","valueDescription":"Chronic Myelomonocytic Leukemia","ValueMeaning":{"publicId":"2771865","version":"1","preferredName":"Chronic Myelomonocytic Leukemia","longName":"2771865","preferredDefinition":"A myelodysplastic/myeloproliferative disease which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20% blasts in the bone marrow or blood, and myelodysplasia.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myelomonocytic Leukemia","conceptCode":"C3178","definition":"A myelodysplastic/myeloproliferative neoplasm which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20 percent blasts in the bone marrow and blood, myelodysplasia, and absence of PDGFRA or PDGFRB rearrangement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"54342348-5E2F-4602-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-08-11","modifiedBy":"SOKKERL","dateModified":"2022-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FFCA-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Chronic lymphocytic leukemia","valueDescription":"Chronic Lymphocytic Leukemia","ValueMeaning":{"publicId":"4264837","version":"1","preferredName":"Chronic Lymphocytic Leukemia","longName":"4264837","preferredDefinition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Lymphocytic Leukemia","conceptCode":"C3163","definition":"The most common type of chronic lymphoid leukemia.  It comprises 90% of chronic lymphoid leukemias in the United States.  Morphologically, the neoplastic cells are small, round B-lymphocytes.  This type of leukemia is not considered to be curable with available therapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42EF-FFD5-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FFEE-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Chronic eosinophilic leukemia","valueDescription":"Chronic Eosinophilic Leukemia, Not Otherwise Specified","ValueMeaning":{"publicId":"4130283","version":"1","preferredName":"Chronic Eosinophilic Leukemia, Not Otherwise Specified","longName":"4130283","preferredDefinition":"A rare myeloproliferative neoplasm characterized by a clonal proliferation of eosinophilic precursors resulting in persistently increased numbers of eosinophils in the blood, marrow and peripheral tissues.  Since acute eosinophilic leukemia is at best exceedingly rare, the term eosinophilic leukemia is normally used as a synonym for chronic eosinophilic leukemia.  In cases in which it is impossible to prove clonality and there is no increase in blast cells, the diagnosis of \"idiopathic hypereosinophilic syndrome\" is preferred.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Eosinophilic Leukemia, Not Otherwise Specified","conceptCode":"C4563","definition":"A rare myeloproliferative neoplasm characterized by a clonal proliferation of eosinophilic precursors resulting in persistently increased numbers of eosinophils in the blood, marrow and peripheral tissues.  Since acute eosinophilic leukemia is at best exceedingly rare, the term eosinophilic leukemia is normally used as a synonym for chronic eosinophilic leukemia.  In cases in which it is impossible to prove clonality and there is no increase in blast cells, the diagnosis of \"idiopathic hypereosinophilic syndrome\" is preferred.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F18569AC-01D3-4E6D-E040-BB89AD437CF4","latestVersionIndicator":"Yes","beginDate":"2014-02-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-0002-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Chromophobe renal cell carcinoma","valueDescription":"Chromophobe Renal Cell Carcinoma","ValueMeaning":{"publicId":"3248534","version":"1","preferredName":"Chromophobe Renal Cell Carcinoma","longName":"3248534","preferredDefinition":"A type of carcinoma that comprises a minority of renal cell carcinomas.  It is characterized by loss of chromosomes 1 and Y.  Based on the cytoplasmic characteristics of the neoplastic cells, this type of carcinoma is classified as classic (typical) or eosinophilic.  It has a much better prognosis than other renal cell carcinomas.  -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chromophobe Renal Cell Carcinoma","conceptCode":"C4146","definition":"A type of carcinoma that comprises a minority of renal cell carcinomas.  It is characterized by loss of chromosomes 1 and Y.  Based on the cytoplasmic characteristics of the neoplastic cells, this type of carcinoma is classified as classic (typical), eosinophilic, or oncocytic.  It has a much better prognosis than other renal cell carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6BBE041-B9F2-9503-E040-BB89AD435A00","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"COOPERM","dateModified":"2011-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-0017-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Choroid plexus carcinoma","valueDescription":"Choroid plexus carcinoma","ValueMeaning":{"publicId":"2578711","version":"1","preferredName":"Choroid plexus carcinoma","longName":"2578711","preferredDefinition":"Choroid Plexus Carcinoma (WHO grade III) is a malignant Choroid Plexus Tumor which shows anaplastic features and usually invades neighboring brain structures. CSF metastases are frequent. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choroid Plexus Carcinoma","conceptCode":"C4715","definition":"A malignant neoplasm arising from the choroid plexus.  It shows anaplastic features and usually invades neighboring brain structures. Cerebrospinal fluid metastases are frequent. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0084-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-0022-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Chondroblastic","valueDescription":"Chondroblastoma","ValueMeaning":{"publicId":"4264839","version":"1","preferredName":"Chondroblastoma","longName":"4264839","preferredDefinition":"A benign, lytic neoplasm usually arising from the cartilage in epiphysis and metaphysis of bone.  It is a well circumscribed tumor characterized by the presence of chondroblasts, osteoclast-like giant cells, myxoid stroma formation, calcification, and mitotic activity. In aggressive cases, there is rearrangement of the 8q21 chromosome band.  The tumor occurs most frequently in children and young adults.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chondroblastoma","conceptCode":"C2945","definition":"A benign, chondroid-producing, well-circumscribed, lytic neoplasm usually arising from the epiphysis of long bones.  It is characterized by the presence of chondroblasts, osteoclast-like giant cells, chondroid formation, calcification, and mitotic activity. In aggressive cases, there is rearrangement of the 8q21 chromosome band.  It occurs most frequently in children and young adults and rarely metastasizes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42F0-002F-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-0048-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Central neurocytoma","valueDescription":"Central neurocytoma","ValueMeaning":{"publicId":"2578719","version":"1","preferredName":"Central neurocytoma","longName":"2578719","preferredDefinition":"Central Neurocytoma is an intraventricular neuronal neoplasm composed of uniform round cells with neuronal differentiation. It is typically located in the lateral ventricles in the region of the foramen of Monro.  It generally affects young adults and has a favorable prognosis. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Neurocytoma","conceptCode":"C3791","definition":"An intraventricular neuronal neoplasm composed of uniform round cells with neuronal differentiation. It is typically located in the lateral ventricles in the region of the foramen of Monro. It generally affects young adults and has a favorable prognosis. (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-008C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"SOKKERL","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-0052-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Carcinoma in situ","valueDescription":"Carcinoma in Situ","ValueMeaning":{"publicId":"2567176","version":"1","preferredName":"Carcinoma in Situ","longName":"2567176","preferredDefinition":"A malignant epithelial neoplasm which is confined to the epithelial layer without evidence of further tissue invasion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carcinoma In Situ","conceptCode":"C2917","definition":"A malignant epithelial neoplasm which is confined to the epithelial layer without evidence of further tissue invasion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D375-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-005D-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Burkitt lymphoma","valueDescription":"Burkitt Lymphoma","ValueMeaning":{"publicId":"4173731","version":"1","preferredName":"Burkitt Lymphoma","longName":"4173731","preferredDefinition":"A highly aggressive lymphoma composed of monomorphic medium-sized B-cells with basophilic cytoplasm and numerous mitotic figures.  It is often associated with the presence of Epstein-Barr virus (EBV) and is commonly seen in AIDS patients.  Three morphologic variants are recognized: classical Burkitt lymphoma, Burkitt lymphoma with plasmacytoid differentiation, and atypical Burkitt/Burkitt-like lymphoma.  All cases express the MYC translocation [t(8;14)]. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Burkitt Lymphoma","conceptCode":"C2912","definition":"A highly aggressive lymphoma composed of monomorphic medium-sized B-cells with basophilic cytoplasm and numerous mitotic figures.  It is often associated with the presence of Epstein-Barr virus (EBV) and is commonly seen in AIDS patients.  Three morphologic variants are recognized: classical Burkitt lymphoma, Burkitt lymphoma with plasmacytoid differentiation, and atypical Burkitt/Burkitt-like lymphoma.  All cases express the MYC translocation [t(8;14)]. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F33D05F6-4928-3FBE-E040-BB89AD433F7A","latestVersionIndicator":"Yes","beginDate":"2014-02-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-0068-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Brenner tumor","valueDescription":"Brenner Tumor","ValueMeaning":{"publicId":"3248226","version":"1","preferredName":"Brenner Tumor","longName":"3248226","preferredDefinition":"A usually benign tumor composed of solid and cystic nests of epithelial cells resembling transitional epithelium; it is surrounded by an abundant stromal component that is dense and fibroblastic in nature.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brenner Tumor","conceptCode":"C39954","definition":"A tumor composed of solid and cystic nests of neoplastic urothelial-type cells in an abundant stromal component that is dense and fibroblastic in nature. It arises from the ovary and very rarely the paratesticular structures. It includes benign Brenner tumor, borderline Brenner tumor, and malignant Brenner tumor.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6B537E2-820B-5E57-E040-BB89AD4339B4","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-007D-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Bowen disease","valueDescription":"Bowen Disease of the Skin","ValueMeaning":{"publicId":"3248228","version":"1","preferredName":"Bowen Disease of the Skin","longName":"3248228","preferredDefinition":"A form of squamous cell carcinoma in situ.  It is a distinct clinicopathological entity and arises from the skin or the mucocutaneous junction.  It affects predominantly white males in their 6-8th decades of life.  Exposed and non-exposed skin sites are equally affected.  UV damage and ingestion of inorganic arsenic may play a role in the development of the disease.  On the skin surface, it presents as a single or multiple erythematous, scaly, keratotic patches or plaques.  The clinical entity of erythroplasia of Queyrat is regarded as Bowen disease of the penis and it presents as an asymptomatic, red, circumscribed plaque.  Morphologically, Bowen disease is characterized by the presence of hyperkeratosis, parakeratosis, dyskeratosis, and acanthosis.  The keratotic squamous cells are atypical and display hyperchromatism and abnormal mitotic figures.  The dermoepidermal basement membrane is intact.  Complete surgical removal of the lesion may be curative.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bowen Disease of the Skin","conceptCode":"C62571","definition":"A form of squamous cell carcinoma in situ. It is a distinct clinicopathological entity and arises from the skin or the mucocutaneous junction. It affects predominantly white males in their 6-8th decades of life. Exposed and non-exposed skin sites are equally affected. UV damage and ingestion of inorganic arsenic may play a role in the development of the disease. On the skin surface, it presents as a single or multiple erythematous, scaly, keratotic patches or plaques. The clinical entity of erythroplasia of Queyrat is regarded as Bowen disease of the penis and it presents as an asymptomatic, red, circumscribed plaque. Morphologically, Bowen disease is characterized by the presence of hyperkeratosis, parakeratosis, dyskeratosis, and acanthosis. The keratotic squamous cells are atypical and display hyperchromatism and abnormal mitotic figures. The dermoepidermal basement membrane is intact. Complete surgical removal of the lesion may be curative.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6B537E2-8231-5E57-E040-BB89AD4339B4","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-0092-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Hamartoma","valueDescription":"Hamartoma","ValueMeaning":{"publicId":"3249799","version":"1","preferredName":"Hamartoma","longName":"3249799","preferredDefinition":"A benign and excessive tumor-like growth of mature cells and normal tissues which grow in a disorganized pattern.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hamartoma","conceptCode":"C3075","definition":"A benign and excessive tumor-like growth of mature cells and normal tissues which grow in a disorganized pattern.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6DC37F6-D134-75B6-E040-BB89AD430517","latestVersionIndicator":"Yes","beginDate":"2011-06-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FB7F-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Hairy cell leukemia","valueDescription":"Hairy Cell Leukemia","ValueMeaning":{"publicId":"2838575","version":"1","preferredName":"Hairy Cell Leukemia","longName":"2838575","preferredDefinition":"A rare neoplasm of small B-lymphocytes with \"hairy\" projections in bone marrow, spleen and peripheral blood.  Most patients are middle-aged to elderly adults and present with splenomegaly and pancytopenia. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hairy Cell Leukemia","conceptCode":"C7402","definition":"A neoplasm of small B-lymphocytes with \"hairy\" projections in bone marrow, spleen, and peripheral blood.  Most patients present with splenomegaly and pancytopenia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-5837-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"GDEEN","dateModified":"2023-06-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FB94-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Hemangiopericytic","valueDescription":"Hemangiopericytic Neoplasm","ValueMeaning":{"publicId":"4264812","version":"1","preferredName":"Hemangiopericytic Neoplasm","longName":"4264812","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hemangiopericytic Neoplasm","conceptCode":"C7076","definition":"A term that refers to vascular neoplasms with a prominent hemangiopericytic growth pattern.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42EF-FBA2-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FBBB-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Granulosa cell tumor","valueDescription":"Granulosa Cell Tumor","ValueMeaning":{"publicId":"2567190","version":"1","preferredName":"Granulosa Cell Tumor","longName":"2567190","preferredDefinition":"A slow-growing, malignant tumor, characterize by the presence of granulosa-like cells and Call-Exner bodies, that is almost always found in the ovary. In rare cases, it has also been found in the testicle.  There are two types of granulosa cell tumor that can be distinguished under the microscope: the adult and the juvenile.  The testicular juvenile granulosa cell tumors are perhaps the most common congenital testicular neoplasms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Granulosa Cell Tumor","conceptCode":"C3070","definition":"A slow-growing sex cord-stromal tumor characterized by the presence of granulosa-like cells and Call-Exner bodies. It is almost always found in the ovary and rarely in the testis. There are two types of granulosa cell tumors: the adult and the juvenile.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D383-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FBC5-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Growth hormone","valueDescription":"Growth Hormone","ValueMeaning":{"publicId":"3553473","version":"1","preferredName":"Growth Hormone","longName":"3553473","preferredDefinition":"A peptide hormone secreted by the anterior lobe of the pituitary gland and regulates several physiologic processes, including growth and metabolism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Somatotropin","conceptCode":"C2288","definition":"Somatotropin (217 aa, ~25 kDa) is encoded by the human GH1 gene. This protein is involved in the regulation of many physiologic processes, including the growth of organs and tissues and the metabolism of amino acids and proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C6C7AAAE-5269-A72E-E040-BB89AD437479","latestVersionIndicator":"Yes","beginDate":"2012-08-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FBDA-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Gliosarcoma","valueDescription":"Gliosarcoma","ValueMeaning":{"publicId":"2578705","version":"1","preferredName":"Gliosarcoma","longName":"2578705","preferredDefinition":"A rare histological variant of glioblastoma (WHO grade IV) characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation (WHO).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gliosarcoma","conceptCode":"C3796","definition":"A rare histological variant of glioblastoma (WHO grade IV) characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation (WHO).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-007E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-04-23","modifiedBy":"COOPERM","dateModified":"2017-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42EF-FBE5-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Human epidermal growth factor receptor positive","valueDescription":"Human Epidermal Growth Factor Receptor Positive Finding","ValueMeaning":{"publicId":"4264911","version":"1","preferredName":"Human Epidermal Growth Factor Receptor Positive Finding","longName":"4264911","preferredDefinition":"An observation confirming something, such as the presence of a disease, condition, or microorganism.: The protein found on the surface of some cells and to which epidermal growth factor binds, causing the cells to divide. It is found at abnormally high levels on the surface of many types of cancer cells, so these cells may divide excessively in the presence of epidermal growth factor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Positive Finding","conceptCode":"C38758","definition":"A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Epidermal Growth Factor Receptor","conceptCode":"C17068","definition":"Epidermal growth factor receptor (1210 aa, ~134 kDa) is encoded by the human EGFR gene. This protein plays a role in cell-cell adhesion, cell migration, cell proliferation and signal transduction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67F3F28-FD2F-6FE9-E040-BB89AD433764","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67F3F28-FD48-6FE9-E040-BB89AD433764","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Hodgkin lymphoma","valueDescription":"Hodgkin Lymphoma","ValueMeaning":{"publicId":"4264912","version":"1","preferredName":"Hodgkin Lymphoma","longName":"4264912","preferredDefinition":"A lymphoma, previously known as Hodgkin's disease, characterized by the presence of Reed-Sternberg cells.  There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma.  Hodgkin lymphoma has a bimodal age distribution, and involves primarily lymph nodes.  Current therapy for Hodgkin lymphoma has resulted in an excellent outcome and cure for the majority of patients.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hodgkin Lymphoma","conceptCode":"C9357","definition":"A lymphoma characterized by the presence of relatively few malignant cells called Reed-Sternberg cells and mononuclear Hodgkin cells that are admixed with nonneoplastic inflammatory cells. The malignant cells have a distinctive immunophenotype; they are positive for CD30 and CD15 and negative for CD3, CD20, and CD45.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67F3F28-FD52-6FE9-E040-BB89AD433764","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"GDEEN","dateModified":"2023-06-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67F3F28-FD6B-6FE9-E040-BB89AD433764","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Hepatocellular carcinoma","valueDescription":"Hepatocellular Carcinoma","ValueMeaning":{"publicId":"2573454","version":"1","preferredName":"Hepatocellular Carcinoma","longName":"2573454","preferredDefinition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatocellular Carcinoma","conceptCode":"C3099","definition":"A malignant tumor that arises from hepatocytes. Hepatocellular carcinoma is relatively rare in the United States but very common in all African countries south of the Sahara and in Southeast Asia. Most cases are seen in patients over the age of 50 years, but this tumor can also occur in younger individuals and even in children. Hepatocellular carcinoma is more common in males than females and is associated with hepatitis B, hepatitis C, chronic alcohol abuse and cirrhosis. Serum elevation of alpha-fetoprotein occurs in a large percentage of patients with hepatocellular carcinoma. Grossly, hepatocellular carcinoma may present as a single mass, as multiple nodules, or as diffuse liver involvement. Microscopically, there is a wide range of differentiation from tumor to tumor (well differentiated to poorly differentiated tumors). Hepatocellular carcinomas quickly metastasize to regional lymph nodes and lung. The overall median survival of untreated liver cell carcinoma is about 4 months. The most effective treatment of hepatocellular carcinoma is complete resection of the tumor. Lately, an increasing number of tumors have been treated with liver transplantation.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EBFB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-15","modifiedBy":"CHILLIJ","dateModified":"2007-03-27","changeDescription":"03/27/2007 - Updated with NCI Thesaurus definition (abbreviated version.)","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67F3F28-FD7F-6FE9-E040-BB89AD433764","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Hepatoblastoma","valueDescription":"Hepatoblastoma","ValueMeaning":{"publicId":"4264913","version":"1","preferredName":"Hepatoblastoma","longName":"4264913","preferredDefinition":"A malignant liver neoplasm that occurs almost exclusively in infants, although isolated cases in older children and adults have been reported. Grossly, hepatoblastoma is solid, well circumscribed, and more often solitary than multiple. Microscopically, most of the tumors are composed exclusively of immature hepatocytic elements. About a fourth of hepatoblastomas contain a stromal component that may be undifferentiated or develop into bone or cartilage. The treatment of choice for hepatoblastoma is surgical excision with adjuvant therapy. Liver transplantation is being increasingly used as well.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatoblastoma","conceptCode":"C3728","definition":"A malignant embryonal neoplasm that arises from the liver. It occurs almost exclusively in infants, although isolated cases in older children and adults have been reported. Microscopically,  it consists of either epithelial or epithelial and mesenchymal components.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67F3F28-FD89-6FE9-E040-BB89AD433764","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67F3F28-FDA2-6FE9-E040-BB89AD433764","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Clear cell carcinoma","valueDescription":"Clear Cell Carcinoma","ValueMeaning":{"publicId":"3704625","version":"1","preferredName":"Clear Cell Carcinoma","longName":"3704625","preferredDefinition":"A cell with empty-appearing cytoplasm when viewed with a light microscope.: A malignant tumor arising from epithelial cells.  Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas.  Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis.  Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites.  Lung carcinoma, skin carcinoma, breast carcinoma, and prostate carcinoma are the most frequently seen carcinomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clear Cell","conceptCode":"C12478","definition":"A cell with empty-appearing cytoplasm when viewed with a light microscope.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D902E31D-3C28-5153-E040-BB89AD437E3A","latestVersionIndicator":"Yes","beginDate":"2013-03-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-03-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67F3F28-FDB6-6FE9-E040-BB89AD433764","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Lentigo maligna","valueDescription":"Lentigo Maligna Melanoma","ValueMeaning":{"publicId":"2569595","version":"1","preferredName":"Lentigo Maligna Melanoma","longName":"2569595","preferredDefinition":"(A melanoma of the skin characterized by single cell infiltration of the papillary dermis by atypical melanocytes, in a background of lentigo maligna changes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lentigo Maligna Melanoma","conceptCode":"C9151","definition":"A melanoma of the skin characterized by single cell infiltration of the papillary dermis by atypical melanocytes, in a background of lentigo maligna changes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DCE8-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-09","endDate":null,"createdBy":"CROWLEYR","dateCreated":"2004-05-13","modifiedBy":"DWARZEL","dateModified":"2006-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEA17-6048-3E0B-E040-BB89AD4363B5","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Large cell neuroendocrine","valueDescription":"Large Cell Neuroendocrine Carcinoma","ValueMeaning":{"publicId":"2838592","version":"1","preferredName":"Large Cell Neuroendocrine Carcinoma","longName":"2838592","preferredDefinition":"A usually aggressive carcinoma composed of large malignant cells which display neuroendocrine characteristics. It is characterized by the presence of high mitotic activity and necrotic changes. The vast majority of cases are positive for neuron-specific enolase. Representative examples include lung, breast, cervical, and thymic neuroendocrine carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Large Cell Neuroendocrine Carcinoma","conceptCode":"C6875","definition":"An aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation. It is composed of malignant large cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A5F1C9-F794-B082-E040-BB89AD436154","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2018-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEA17-605D-3E0B-E040-BB89AD4363B5","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Large cell carcinoma","valueDescription":"Large Cell Carcinoma","ValueMeaning":{"publicId":"4264919","version":"1","preferredName":"Large Cell Carcinoma","longName":"4264919","preferredDefinition":"A malignant epithelial neoplasm composed of large, atypical cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Large Cell Carcinoma","conceptCode":"C3780","definition":"A malignant epithelial neoplasm composed of large, atypical cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67FEA17-6068-3E0B-E040-BB89AD4363B5","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEA17-6081-3E0B-E040-BB89AD4363B5","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Keratosis","valueDescription":"Keratosis","ValueMeaning":{"publicId":"3252128","version":"1","preferredName":"Keratosis","longName":"3252128","preferredDefinition":"Any horny growth such as a wart or callus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Keratosis","conceptCode":"C34747","definition":"Excessive growth of keratin on the skin.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A781D14A-E806-8A44-E040-BB89AD4310FD","latestVersionIndicator":"Yes","beginDate":"2011-07-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEA17-6095-3E0B-E040-BB89AD4363B5","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Keratoacanthoma","valueDescription":"Keratoacanthoma","ValueMeaning":{"publicId":"3211199","version":"1","preferredName":"Keratoacanthoma","longName":"3211199","preferredDefinition":"A dome-shaped, rapidly growing skin lesion composed of well differentiated squamous cells.  It represents a proliferation of the infundibular epithelium of the hair follicle and its morphologic distinction from a well differentiated carcinoma may be difficult or impossible.  Keratoacanthomas affect males more frequently than females and the majority tend to regress spontaneously.  It has been suggested that keratoacanthoma represents a distinct subtype of squamous cell carcinoma of the skin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Keratoacanthoma","conceptCode":"C3146","definition":"A dome-shaped, rapidly growing skin lesion composed of well differentiated squamous cells. It usually occurs on sun-exposed areas of the body, most often the head, neck, and limbs. It is considered a variant of well-differentiated squamous cell carcinoma with distinct clinical behavior. Keratoacanthomas affect males more frequently than females and the majority tend to regress spontaneously.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DBCF-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEA17-60A0-3E0B-E040-BB89AD4363B5","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Keloid","valueDescription":"Keloid","ValueMeaning":{"publicId":"3250491","version":"1","preferredName":"Keloid","longName":"3250491","preferredDefinition":"A thick, irregular scar caused by excessive tissue growth at the site of an incision or wound.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Keloid","conceptCode":"C3145","definition":"An irregularly shaped, elevated mark on the skin caused by deposits of excessive amounts of collagen during wound healing. It extends beyond the original boundaries of the wound and may enlarge progressively.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6F215E6-C60B-B293-E040-BB89AD432EF3","latestVersionIndicator":"Yes","beginDate":"2011-06-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEA17-60B5-3E0B-E040-BB89AD4363B5","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Juvenile myelomonocytic leukemia","valueDescription":"Juvenile Myelomonocytic Leukemia","ValueMeaning":{"publicId":"2838584","version":"1","preferredName":"Juvenile Myelomonocytic Leukemia","longName":"2838584","preferredDefinition":"A myelodysplastic/myeloproliferative disease of childhood that is characterized by proliferation principally of the granulocytic and monocytic lineages.  Myelomonocytic proliferation is seen in the bone marrow and the blood.  The leukemic cells may infiltrate any tissue, however liver, spleen, lymph nodes, skin, and respiratory tract are the most common sites of involvement.  The prognosis is usually poor.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Juvenile Myelomonocytic Leukemia","conceptCode":"C9233","definition":"A clonal myeloid disorder of childhood previously classified as myelodysplastic/myeloproliferative neoplasm. It is characterized by the presence of monocytic proliferation in peripheral blood, less than 20% blasts in bone marrow and peripheral blood, splenomegaly, and the absence of BCR-ABL1 fusion. Almost all patients carry mutations of the RAS pathway.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A51A25-5942-CA49-E040-BB89AD435D3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"KUMMEROA","dateModified":"2023-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEA17-60CA-3E0B-E040-BB89AD4363B5","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Inverted papilloma","valueDescription":"Inverted Papilloma","ValueMeaning":{"publicId":"3251799","version":"1","preferredName":"Inverted Papilloma","longName":"3251799","preferredDefinition":"A type of tumor in which surface epithelial cells grow downward into the underlying supportive tissue. It may occur in the nose and/or sinuses or in the urinary tract (bladder, renal pelvis, ureter, urethra). When it occurs in the nose or sinuses, it may cause symptoms similar to those caused by sinusitis, such as nasal congestion. When it occurs in the urinary tract, it may cause blood in the urine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inverted Papilloma","conceptCode":"C3793","definition":"An endophytic benign papillary epithelial neoplasm that results from the invagination and proliferation of epithelial cells in the underlying stroma.  Representative examples are the inverted urothelial papilloma that arises from the urinary tract and inverted Schneiderian papilloma that arises from the nasal cavity or paranasal sinuses.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A76B8D07-9505-4C3A-E040-BB89AD433F54","latestVersionIndicator":"Yes","beginDate":"2011-07-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-06","modifiedBy":"COOPERM","dateModified":"2011-09-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEA17-60DF-3E0B-E040-BB89AD4363B5","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Intraepithelial neoplasia","valueDescription":"Intraepithelial Neoplasia","ValueMeaning":{"publicId":"3250497","version":"1","preferredName":"Intraepithelial Neoplasia","longName":"3250497","preferredDefinition":"A precancerous neoplastic process that affects the squamous, glandular, or transitional cell epithelium without evidence of invasion. According to the degree of nuclear atypia, number of mitotic figures, and presence of architectural distortion, it is classified as low grade (mild dysplasia) or high grade (moderate or severe dysplasia).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intraepithelial Neoplasia","conceptCode":"C8366","definition":"A precancerous neoplastic process that affects the squamous, glandular, or transitional cell epithelium without evidence of invasion. According to the degree of nuclear atypia, number of mitotic figures, and presence of architectural distortion, it is classified as low grade (mild dysplasia) or high grade (moderate or severe dysplasia).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6F215E6-C692-B293-E040-BB89AD432EF3","latestVersionIndicator":"Yes","beginDate":"2011-06-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-30","modifiedBy":"COOPERM","dateModified":"2011-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEA17-60F4-3E0B-E040-BB89AD4363B5","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Islet Cell","valueDescription":"Islet Cell","ValueMeaning":{"publicId":"3211573","version":"1","preferredName":"Islet Cell","longName":"3211573","preferredDefinition":"A pancreatic cell that produces and secretes hormones such as insulin and glucagon.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Islet Cell","conceptCode":"C32885","definition":"A pancreatic cell that produces and secretes hormones such as insulin and glucagon.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F53261F-2FC4-B1C2-E040-BB89AD43490D","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEA17-60FF-3E0B-E040-BB89AD4363B5","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Juvenile polyp","valueDescription":"Juvenile Polyp","ValueMeaning":{"publicId":"3251853","version":"1","preferredName":"Juvenile Polyp","longName":"3251853","preferredDefinition":"A non-neoplastic hamartomatous polyp that arises from the stomach and intestinal tract.  It is characterized by the presence of tortuous and cystically dilated glands, edematous changes, and inflammation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Juvenile Polyp","conceptCode":"C3826","definition":"A non-neoplastic hamartomatous polyp that arises from the stomach and intestinal tract.  It is characterized by the presence of tortuous and cystically dilated glands, edematous changes, and inflammation.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A771271A-FFAF-B6CD-E040-BB89AD436FA1","latestVersionIndicator":"Yes","beginDate":"2011-07-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-06","modifiedBy":"COOPERM","dateModified":"2011-09-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEA17-6114-3E0B-E040-BB89AD4363B5","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Intradermal","valueDescription":"Intradermal","ValueMeaning":{"publicId":"2562291","version":"1","preferredName":"Intradermal","longName":"2562291","preferredDefinition":"Within the skin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intradermal","conceptCode":"C28213","definition":"Within the skin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C060-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-08-08","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-08-08","modifiedBy":"ZHANGWE","dateModified":"2021-05-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEA17-6129-3E0B-E040-BB89AD4363B5","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Intestinal adenocarcinoma","valueDescription":"Intestinal Adenocarcinoma","ValueMeaning":{"publicId":"4264920","version":"1","preferredName":"Intestinal Adenocarcinoma","longName":"4264920","preferredDefinition":"Of, or related to, or referring to the intestines.: A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intestinal","conceptCode":"C25266","definition":"Of, or related to, or referring to the intestines.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67FEA17-6137-3E0B-E040-BB89AD4363B5","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEA17-6150-3E0B-E040-BB89AD4363B5","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Insulinoma","valueDescription":"Pancreatic Insulinoma","ValueMeaning":{"publicId":"3249057","version":"1","preferredName":"Pancreatic Insulinoma","longName":"3249057","preferredDefinition":"An insulin-producing neuroendocrine tumor arising from the beta cells of the pancreas.  Patients exhibit symptoms related to hypoglycemia due to inappropriate secretion of insulin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Insulinoma","conceptCode":"C95598","definition":"An insulin-producing neuroendocrine tumor arising from the beta cells of the pancreas. Patients exhibit symptoms related to hypoglycemia due to inappropriate secretion of insulin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6CA5E9E-18C4-D7DA-E040-BB89AD432E47","latestVersionIndicator":"Yes","beginDate":"2011-06-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEA17-6164-3E0B-E040-BB89AD4363B5","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Inflammation","valueDescription":"Inflammation","ValueMeaning":{"publicId":"2581231","version":"1","preferredName":"Inflammation","longName":"2581231","preferredDefinition":"A localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inflammation","conceptCode":"C3137","definition":"A finding of a localized protective response resulting from injury or destruction of tissues. Inflammation serves to destroy, dilute, or wall off both the injurious agent and the injured tissue. In the acute phase, inflammation is characterized by the signs of pain, heat, redness, swelling, and loss of function. Histologically, inflammation involves a complex series of events, including dilatation of arterioles, capillaries, and venules, with increased permeability and blood flow; exudation of fluids, including plasma proteins; and leukocyte migration into the site of inflammation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A5C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-13","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-17","modifiedBy":"COOPERM","dateModified":"2019-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEA17-616F-3E0B-E040-BB89AD4363B5","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Progesterone receptor positive","valueDescription":"Progesterone Receptor Positive Finding","ValueMeaning":{"publicId":"4264934","version":"1","preferredName":"Progesterone Receptor Positive Finding","longName":"4264934","preferredDefinition":"An observation confirming something, such as the presence of a disease, condition, or microorganism.: Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Positive Finding","conceptCode":"C38758","definition":"A finding of abnormality following an examination or observation confirming something, such as the presence of a disease, condition, or microorganism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Progesterone Receptor","conceptCode":"C17075","definition":"Progesterone receptor (933 aa, ~99 kDa) is encoded by the human PGR gene. This protein is involved in the regulation of transcription.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-369A-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-36B3-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Primary sclerosing cholangitis","valueDescription":"Primary Sclerosing Cholangitis","ValueMeaning":{"publicId":"3210800","version":"1","preferredName":"Primary Sclerosing Cholangitis","longName":"3210800","preferredDefinition":"A chronic, autoimmune inflammatory liver disorder characterized by narrowing and scarring of the lumen of the bile ducts. It is often seen in patients with ulcerative colitis. Signs and symptoms include jaundice, fatigue, and malabsorption. It may lead to cirrhosis and liver failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Sclerosing Cholangitis","conceptCode":"C4828","definition":"A chronic, autoimmune inflammatory liver disorder characterized by narrowing and scarring of the lumen of the bile ducts. It is often seen in patients with ulcerative colitis. Signs and symptoms include jaundice, fatigue, and malabsorption. It may lead to cirrhosis and liver failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-A1CC-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-36C7-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Primary myelofibrosis","valueDescription":"Primary Myelofibrosis","ValueMeaning":{"publicId":"4130282","version":"1","preferredName":"Primary Myelofibrosis","longName":"4130282","preferredDefinition":"A chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis.  The cause is unknown.  The median survival time is 3-5 years from diagnosis. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Myelofibrosis","conceptCode":"C2862","definition":"A chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F18569AC-01B0-4E6D-E040-BB89AD437CF4","latestVersionIndicator":"Yes","beginDate":"2014-02-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-02-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-36DC-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Primary effusion lymphoma","valueDescription":"Primary Effusion Lymphoma","ValueMeaning":{"publicId":"2838711","version":"1","preferredName":"Primary Effusion Lymphoma","longName":"2838711","preferredDefinition":"An aggressive non-Hodgkin B-cell lymphoma composed of large cells, presenting as a serous effusion without detectable tumor masses.  It is universally associated with human herpes virus 8 (HHV-8)/Kaposi sarcoma herpes virus (KSHV) [HHV-8/KSHV].  It mostly occurs in the setting of immunodeficiency; most cases have been reported in HIV positive patients.  The most common sites of involvement are the pleural, pericardial, and peritoneal cavities.  The prognosis is extremely unfavorable.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary Effusion Lymphoma","conceptCode":"C6915","definition":"A large B-cell lymphoma usually presenting as a serous effusion without detectable tumor masses. It is universally associated with human herpes virus 8 (HHV8), also called Kaposi sarcoma-associated herpesvirus.  It mostly occurs in the setting of immunodeficiency. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. Rare HHV8-positive lymphomas indistinguishable from primary effusion lymphomas (PEL) present as solid tumor masses, and have been termed extracavitary PEL. The prognosis is extremely unfavorable. (WHO 2017)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A7EC44-0A6F-AA83-E040-BB89AD437747","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-36E7-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Primary central nervous system lymphoma","valueDescription":"Primary Central Nervous System Lymphoma","ValueMeaning":{"publicId":"4264935","version":"1","preferredName":"Primary Central Nervous System Lymphoma","longName":"4264935","preferredDefinition":"Occurring first in time or sequence; original; of greatest rank or importance or value.: Cancer that forms in the lymph tissue of the brain, spinal cord, meninges (outer covering of the brain), or eye (called ocular lymphoma).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Primary","conceptCode":"C25251","definition":"Occurring first in time or sequence; original; of greatest rank or importance or value.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Central Nervous System Lymphoma","conceptCode":"C9301","definition":"A non-Hodgkin or Hodgkin lymphoma that arises in the brain or spinal cord as a primary lesion. There is no evidence of lymphoma outside the central nervous system at the time of diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-36F5-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-370E-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Potocki-Shaffer syndrome","valueDescription":"Potocki-Shaffer Syndrome","ValueMeaning":{"publicId":"4264937","version":"1","preferredName":"Potocki-Shaffer Syndrome","longName":"4264937","preferredDefinition":"A very rare genetic syndrome caused by deletions on the proximal short arm of chromosome 11.  It is characterized by the presence of multiple exostoses and enlarged parietal foramina.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Potocki-Shaffer Syndrome","conceptCode":"C75456","definition":"A very rare genetic syndrome caused by deletions on the proximal short arm of chromosome 11.  It is characterized by the presence of multiple exostoses and enlarged parietal foramina.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-371B-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3734-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Post transplant lymphoproliferative disorder","valueDescription":"Post-Transplant Lymphoproliferative Disorder","ValueMeaning":{"publicId":"3251848","version":"1","preferredName":"Post-Transplant Lymphoproliferative Disorder","longName":"3251848","preferredDefinition":"Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft.  PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Post-Transplant Lymphoproliferative Disorder","conceptCode":"C4727","definition":"Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A771271A-FF2C-B6CD-E040-BB89AD436FA1","latestVersionIndicator":"Yes","beginDate":"2011-07-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3748-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Poorly differentiated","valueDescription":"Poorly Differentiated","ValueMeaning":{"publicId":"3685459","version":"1","preferredName":"Poorly Differentiated","longName":"3685459","preferredDefinition":"Describes tumor cells that generally have lost most of the appearance of normal cells. They tend to grow and spread.","context":"PMI","contextVersion":"1","Concepts":[{"longName":"Poorly Differentiated","conceptCode":"C14167","definition":"Describes tumor cells that generally have lost most of the appearance of normal cells. They tend to grow and spread.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"0"}],"origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"D58D9008-3A3B-3F09-E040-BB89AD4368A5","latestVersionIndicator":"Yes","beginDate":"2022-08-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-02-12","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":"8/5/2022: created for PMI EC form. SL","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3753-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Polycythemia vera","valueDescription":"Polycythemia Vera","ValueMeaning":{"publicId":"2559822","version":"1","preferredName":"Polycythemia Vera","longName":"2559822","preferredDefinition":"A chronic myeloproliferative disorder characterized by an increased red blood cell production.  Excessive proliferation of the myeloid lineage is observed as well.  The major symptoms are related to hypertension or to vascular abnormalities caused by the increased red cell mass.  The cause is unknown.  With currently available treatment, the median survival exceeds 10 years.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Polycythemia Vera","conceptCode":"C3336","definition":"A chronic myeloproliferative neoplasm characterized by an increased red blood cell production. The bone marrow is hypercellular due to a panmyelotic proliferation typically characterized by pleomorphic megakaryocytes. The major symptoms are related to hypertension, splenomegaly or to episodes of thrombosis and/or hemorrhage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B6BB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-375E-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Pneumocytoma (sclerosing hemangioma)","valueDescription":"Lung Sclerosing Hemangioma","ValueMeaning":{"publicId":"4264939","version":"1","preferredName":"Lung Sclerosing Hemangioma","longName":"4264939","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sclerosing Pneumocytoma","conceptCode":"C5656","definition":"A benign tumor that arises from the lung.  It is characterized by the presence of sclerotic, papillary, solid, and hemorrhagic patterns and hyperplastic type II pneumocytes.  Cholesterol clefts, hemosiderin deposition, chronic inflammation, and calcifications may be present.  In the majority of cases, it is a solitary and peripheral tumor.  Patients are usually asymptomatic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-376C-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3785-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Pleural fluid","valueDescription":"Pleural Fluid","ValueMeaning":{"publicId":"3111297","version":"1","preferredName":"Pleural Fluid","longName":"3111297v1.00","preferredDefinition":"The fluid that is ordinarily present in the pleural space. It allows for normal movement of the lungs during respiration.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pleural Fluid","conceptCode":"C77613","definition":"The fluid that is ordinarily present in the pleural space. It allows for normal movement of the lungs during respiration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"894FFBD5-AD40-5061-E040-BB89AD435F93","latestVersionIndicator":"Yes","beginDate":"2010-06-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-18","modifiedBy":"GDEEN","dateModified":"2023-08-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3799-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Low grade cartilaginous tumor","valueDescription":"Low Grade Cartilaginous Neoplasm","ValueMeaning":{"publicId":"4264918","version":"1","preferredName":"Low Grade Cartilaginous Neoplasm","longName":"4264918","preferredDefinition":"Used to describe tumor samples that exhibit well to moderately well differentiated cells. They are generally expected to be slow growing and less aggressive.: A type of connective tissue composed of chondrocytes and an extracellular matrix, composed of collagen, elastin, and ground substance. There are three types of cartilage; namely elastic, hyaline, and fibrocartilage.: A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Low Grade","conceptCode":"C14161","definition":"Used to describe tumor samples that exhibit well to moderately well differentiated cells. They are generally expected to be slow growing and less aggressive.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cartilaginous Tissue","conceptCode":"C32268","definition":"A type of connective tissue composed of chondrocytes and an extracellular matrix, composed of collagen, elastin, and ground substance. There are three types of cartilage; namely elastic, hyaline, and fibrocartilage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67FEA17-5FFB-3E0B-E040-BB89AD4363B5","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEA17-6014-3E0B-E040-BB89AD4363B5","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Lobular carcinoma in situ","valueDescription":"Lobular Breast Carcinoma In Situ","ValueMeaning":{"publicId":"2581227","version":"1","preferredName":"Lobular Breast Carcinoma In Situ","longName":"2581227","preferredDefinition":"Lobular carcinoma in situ is characterized by a proliferation of monomorphic cells completely filling the lumina. The overall lobular architecture is preserved. LCIS is frequently multifocal (90% in some series) and bilateral. LCIS seldom becomes invasive, however there is an increased risk of infiltrating ductal adenocarcinoma.  --2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Lobular Carcinoma In Situ","conceptCode":"C4018","definition":"A non-invasive adenocarcinoma of the breast characterized by a proliferation of monomorphic cells completely filling the lumina.  The overall lobular architecture is preserved.  It is frequently multifocal (90% in some series) and bilateral.  It seldom becomes invasive; however there is an increased risk of infiltrating ductal adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0A58-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-13","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"CURTIST","dateModified":"2006-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEA17-601E-3E0B-E040-BB89AD4363B5","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Lobular carcinoma","valueDescription":"Lobular Breast Carcinoma","ValueMeaning":{"publicId":"2957350","version":"1","preferredName":"Lobular Breast Carcinoma","longName":"2957350","preferredDefinition":"An adenocarcinoma of the breast arising from the lobules.  This is a relatively uncommon carcinoma, represents approximately 10% of the breast adenocarcinomas and is often bilateral or multifocal.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Lobular Carcinoma","conceptCode":"C3771","definition":"An adenocarcinoma of the breast arising from the lobules.  This is a relatively uncommon carcinoma, represents approximately 10% of the breast adenocarcinomas and is often bilateral or multifocal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"770B3885-67E3-5BD6-E040-BB89AD4371E9","latestVersionIndicator":"Yes","beginDate":"2009-10-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-10-28","modifiedBy":"ONEDATA","dateModified":"2009-10-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEA17-6033-3E0B-E040-BB89AD4363B5","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"in situ neoplasm","valueDescription":"In Situ Neoplasm","ValueMeaning":{"publicId":"4264915","version":"1","preferredName":"In Situ Neoplasm","longName":"4264915","preferredDefinition":"in the natural or normal place, confined to the site of origin without invasion of neighboring tissues.: A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"In Situ","conceptCode":"C14160","definition":"In the natural or normal place, confined to the site of origin without invasion of neighboring tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67F74C7-A182-5B64-E040-BB89AD434237","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67F74C7-A19B-5B64-E040-BB89AD434237","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Hyperplastic polyp","valueDescription":"Hyperplastic Polyp","ValueMeaning":{"publicId":"3251826","version":"1","preferredName":"Hyperplastic Polyp","longName":"3251826","preferredDefinition":"A polyp found mainly in the stomach and colon.  Microscopically, it is characterized by elongated, serrated crypts lined by proliferative epithelium.  Hyperplastic polyps are traditionally considered non-neoplastic, but ras mutation is common, clonality has been demonstrated and biochemical abnormalities and epidemiological associations that occur in colorectal adenomas and carcinomas have been found (WHO Tumors of the Digestive System, 2000).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hyperplastic Polyp","conceptCode":"C4083","definition":"A polyp found mainly in the stomach and colon.  Microscopically, it is characterized by elongated, serrated crypts lined by proliferative epithelium.  Hyperplastic polyps are traditionally considered non-neoplastic, but ras mutation is common, clonality has been demonstrated and biochemical abnormalities and epidemiological associations that occur in colorectal adenomas and carcinomas have been found (WHO Tumors of the Digestive System, 2000).","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A76E3677-AD54-F84A-E040-BB89AD435C45","latestVersionIndicator":"Yes","beginDate":"2011-07-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67F74C7-A1AF-5B64-E040-BB89AD434237","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"In situ melanotic neoplasm","valueDescription":"In Situ Melanotic Neoplasm","ValueMeaning":{"publicId":"4264914","version":"1","preferredName":"In Situ Melanotic Neoplasm","longName":"4264914","preferredDefinition":"in the natural or normal place, confined to the site of origin without invasion of neighboring tissues.: A neoplasm composed of melanocytes that usually appears as a dark spot on the skin.: (TOO-mer) An abnormal mass of tissue that results from excessive cell division. Tumors perform no useful body function. They may be benign (not cancerous) or malignant (cancerous).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"In Situ","conceptCode":"C14160","definition":"In the natural or normal place, confined to the site of origin without invasion of neighboring tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Melanocytic Nevus","conceptCode":"C7570","definition":"A neoplasm composed of melanocytes that usually appears as a dark spot on the skin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"CL053268","definition":"(TOO-mer) An abnormal mass of tissue that results from excessive cell division. Tumors perform no useful body function. They may be benign (not cancerous) or malignant (cancerous).","evsSource":"NCI_META_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67F74C7-A15C-5B64-E040-BB89AD434237","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67F74C7-A175-5B64-E040-BB89AD434237","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Hyperplasia","valueDescription":"Hyperplasia","ValueMeaning":{"publicId":"2574092","version":"1","preferredName":"Hyperplasia","longName":"2574092","preferredDefinition":"An abnormal increase in the number of cells in an organ or a tissue with consequent enlargement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hyperplasia","conceptCode":"C3113","definition":"An abnormal increase in the number of cells in an organ or a tissue with consequent enlargement.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EE79-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67F74C7-A1B9-5B64-E040-BB89AD434237","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Hypereosinophilic syndrome","valueDescription":"Hypereosinophilic Syndrome","ValueMeaning":{"publicId":"4264916","version":"1","preferredName":"Hypereosinophilic Syndrome","longName":"4264916","preferredDefinition":"A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction.  This term has often been applied to cases of chronic eosinophilic leukemia.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Idiopathic Hypereosinophilic Syndrome","conceptCode":"C27038","definition":"A syndrome characterized by persistent eosinophilia, for which no underlying cause can be found, and which is associated with signs of organ involvement and dysfunction.  This term has often been applied to cases of chronic eosinophilic leukemia.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67F74C7-A1C6-5B64-E040-BB89AD434237","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67F74C7-A1DF-5B64-E040-BB89AD434237","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Solitary fibrous tumor","valueDescription":"Single Fibrocytic Neoplasm","ValueMeaning":{"publicId":"4264992","version":"1","preferredName":"Single Fibrocytic Neoplasm","longName":"4264992","preferredDefinition":"Not accompanied by another or others; exclusive of anyone or anything else.: A benign or malignant connective and soft tissue neoplasm. It is characterized by the presence of neoplastic fibroblastic cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Single","conceptCode":"C48440","definition":"Not accompanied by another or others; exclusive of anyone or anything else.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Fibroblastic Neoplasm","conceptCode":"C7075","definition":"A benign, intermediate, or malignant mesenchymal neoplasm characterized by the presence of neoplastic fibroblasts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3F4B-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3F64-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Solitary cyst","valueDescription":"Single Cyst","ValueMeaning":{"publicId":"4264993","version":"1","preferredName":"Single Cyst","longName":"4264993","preferredDefinition":"Not accompanied by another or others; exclusive of anyone or anything else.: A sac-like closed membranous structure that may be empty or contain fluid or amorphous material.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Single","conceptCode":"C48440","definition":"Not accompanied by another or others; exclusive of anyone or anything else.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cyst","conceptCode":"C2978","definition":"A sac-like closed membranous structure that may be empty or contain fluid or amorphous material.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3F71-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3F8A-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Solid tumor","valueDescription":"Solid Tumor","ValueMeaning":{"publicId":"4264994","version":"1","preferredName":"Solid Tumor","longName":"4264994","preferredDefinition":"An abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign (not cancer), or malignant (cancer). Different types of solid tumors are named for the type of cells that form them. Examples of solid tumors are sarcomas, carcinomas, and lymphomas. Leukemias (cancers of the blood) generally do not form solid tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Solid Neoplasm","conceptCode":"C9292","definition":"A benign or malignant neoplasm arising from tissues that do not include fluid areas.  Representative examples include epithelial neoplasms (e.g. lung carcinoma, prostate carcinoma, breast carcinoma, colon carcinoma), and neoplasms arising from the soft tissues and bones (e.g. leiomyosarcoma, liposarcoma, chondrosarcoma, osteosarcoma).  Neoplasms originating from the blood or bone marrow (leukemias and myeloproliferative disorders) are not considered solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3F94-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3FAD-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Solid pseudopapillary carcinoma","valueDescription":"Solid Pseudopapillary Carcinoma of the Pancreas","ValueMeaning":{"publicId":"4264996","version":"1","preferredName":"Solid Pseudopapillary Carcinoma of the Pancreas","longName":"4264996","preferredDefinition":"A malignant neoplasm arising from the exocrine pancreas. It occurs predominantly in young women. It is characterized by the presence of extensive necrosis and hemorrhage and is composed of polyhedral cells forming solid and pseudopapillary patterns. There is morphologic evidence of perineural invasion, vascular invasion, or extensive invasion into the surrounding tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Solid Pseudopapillary Carcinoma of the Pancreas","conceptCode":"C5728","definition":"A malignant neoplasm arising from the exocrine pancreas. It occurs predominantly in young women. It is characterized by the presence of extensive necrosis and hemorrhage and is composed of polyhedral cells forming solid and pseudopapillary patterns. There is morphologic evidence of perineural invasion, vascular invasion, or extensive invasion into the surrounding tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3FBA-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3FD3-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Small lymphocytic lymphoma","valueDescription":"Small Lymphocytic Lymphoma","ValueMeaning":{"publicId":"3251329","version":"1","preferredName":"Small Lymphocytic Lymphoma","longName":"3251329","preferredDefinition":"An indolent non-Hodgkin's lymphoma composed of monomorphic small, round B-lymphocytes in the lymph nodes.  When the lymphoid process involves predominantly the bone marrow and the peripheral blood it is called chronic lymphocytic leukemia. (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Small Lymphocytic Lymphoma","conceptCode":"C7540","definition":"A non-Hodgkin lymphoma composed of monomorphic small, round B-lymphocytes in the lymph nodes.  When the lymphoid process predominantly involves the bone marrow and the peripheral blood it is called chronic lymphocytic leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A758F49E-9BA2-73F4-E040-BB89AD430DFE","latestVersionIndicator":"Yes","beginDate":"2011-07-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-05","modifiedBy":"COOPERM","dateModified":"2011-09-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3FE7-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Small cell carcinoma","valueDescription":"Pancreatic Small Cell Neuroendocrine Carcinoma","ValueMeaning":{"publicId":"2838839","version":"1","preferredName":"Pancreatic Small Cell Neuroendocrine Carcinoma","longName":"2838839","preferredDefinition":"An aggressive, high-grade and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the pancreas.  It is characterized by the presence of malignant small cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pancreatic Small Cell Neuroendocrine Carcinoma","conceptCode":"C95583","definition":"An aggressive, high-grade and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the pancreas. It is characterized by the presence of malignant small cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A9743A-23D9-8C94-E040-BB89AD4308C2","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"HARTLEYG","dateModified":"2017-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3FFC-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Signet ring adenocarcinoma","valueDescription":"Signet Ring Adenocarcinoma Cell","ValueMeaning":{"publicId":"4264997","version":"1","preferredName":"Signet Ring Adenocarcinoma Cell","longName":"4264997","preferredDefinition":"A malignant glandular cell containing cytoplasmic mucin. The presence of mucin pushes the nucleus of the cell to the periphery, assuming a configuration resembling a signet ring.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Signet Ring Adenocarcinoma Cell","conceptCode":"C36777","definition":"A malignant glandular cell containing cytoplasmic mucin. The presence of mucin pushes the nucleus of the cell to the periphery, assuming a configuration resembling a signet ring.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-4007-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-4020-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Sezary syndrome","valueDescription":"Sezary Syndrome","ValueMeaning":{"publicId":"2560040","version":"1","preferredName":"Sezary Syndrome","longName":"2560040","preferredDefinition":"A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood.  Sezary syndrome is an aggressive disease. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sezary Syndrome","conceptCode":"C3366","definition":"A generalized peripheral (mature) T-cell neoplasm characterized by the presence of erythroderma, lymphadenopathy, and neoplastic, cerebriform T-lymphocytes in the blood.  Sezary syndrome is an aggressive disease. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B795-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-402A-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Serrated adenoma","valueDescription":"Traditional Serrated Adenoma","ValueMeaning":{"publicId":"3247847","version":"1","preferredName":"Traditional Serrated Adenoma","longName":"3247847","preferredDefinition":"An adenoma that arises from the large intestine and the appendix.  It is characterized by prominent serration of the glands and the presence of generalized low-grade dysplasia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Traditional Serrated Adenoma","conceptCode":"C38458","definition":"An adenoma that arises from the large intestine and the appendix.  It is characterized by prominent serration of the glands.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A67A743F-5DB1-D6C3-E040-BB89AD436761","latestVersionIndicator":"Yes","beginDate":"2011-06-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-403F-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Serous micropapillary carcinoma","valueDescription":"Micropapillary Serous Carcinoma","ValueMeaning":{"publicId":"4264999","version":"1","preferredName":"Micropapillary Serous Carcinoma","longName":"4264999","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Micropapillary Serous Carcinoma","conceptCode":"C6882","definition":"An adenocarcinoma usually arising from the ovary. It is characterized by the presence of complex micropapillary structures covered by round and cuboidal cells with a high nuclear to cytoplasmic ratio.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-404D-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-4066-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Serous adenocarcinofibroma","valueDescription":"Ovarian Serous Adenocarcinofibroma","ValueMeaning":{"publicId":"4265001","version":"1","preferredName":"Ovarian Serous Adenocarcinofibroma","longName":"4265001","preferredDefinition":"A malignant neoplasm of the ovary with an invasive epithelial component and a fibrotic stroma. The epithelial component is characterized by the presence of malignant epithelial cells of serous type, forming glandular, papillary, and solid patterns.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ovarian Serous Adenocarcinofibroma","conceptCode":"C67092","definition":"A malignant neoplasm of the ovary with an invasive epithelial component and a fibrotic stroma. The epithelial component is characterized by the presence of malignant epithelial cells of serous type, forming glandular, papillary, and solid patterns.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-4073-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-408C-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Serous carcinoma","valueDescription":"Serous Carcinoma","ValueMeaning":{"publicId":"4265002","version":"1","preferredName":"Serous Carcinoma","longName":"4265002","preferredDefinition":"Of or producing or containing serum.: A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Serous","conceptCode":"C14168","definition":"Of or producing or containing serum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-4099-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-40B2-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Serous cystadenocarcinoma","valueDescription":"Serous Cystadenocarcinoma","ValueMeaning":{"publicId":"3438800","version":"1","preferredName":"Serous Cystadenocarcinoma","longName":"3438800","preferredDefinition":"A malignant serous cystic neoplasm usually involving the ovary or the pancreas. It is characterized by the presence of invasive malignant glandular epithelial cells which often form papillary structures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Serous Cystadenocarcinoma","conceptCode":"C3778","definition":"A malignant serous cystic neoplasm usually involving the ovary or the pancreas. It is characterized by the presence of invasive malignant glandular epithelial cells which often form papillary structures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE0A5415-E62F-6FDD-E040-BB89AD4348BB","latestVersionIndicator":"Yes","beginDate":"2012-04-19","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-04-19","modifiedBy":"ONEDATA","dateModified":"2012-04-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-40C6-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Serous adenocarcinoma","valueDescription":"Serous Adenocarcinoma","ValueMeaning":{"publicId":"3183465","version":"1","preferredName":"Serous Adenocarcinoma","longName":"3183465","preferredDefinition":"Definition not available.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Serous Adenocarcinoma","conceptCode":"C40101","definition":"An adenocarcinoma that is characterized by the presence of papillary patterns and cellular budding. Psammoma bodies may be present.  Representative examples include cervical serous adenocarcinoma, endometrial serous adenocarcinoma, ovarian serous adenocarcinoma, and primary peritoneal serous adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"99D549A4-47D1-E906-E040-BB89AD430D41","latestVersionIndicator":"Yes","beginDate":"2011-01-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-01-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-40DB-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Sarcomatoid carcinoma","valueDescription":"Sarcomatoid Carcinoma","ValueMeaning":{"publicId":"2838764","version":"1","preferredName":"Sarcomatoid Carcinoma","longName":"2838764","preferredDefinition":"Cancer that arises in cells that appear spindle-shaped when viewed under a microscope. These cancers can occur in various places in the body, including the skin, lungs, kidney, breast, gastrointestinal tract, bone, and muscle.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sarcomatoid Carcinoma","conceptCode":"C27004","definition":"A malignant epithelial neoplasm characterized by the presence of spindle cells and anaplastic morphologic features.  Giant cells and a sarcomatous component may also be present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A85C92-12DF-B23A-E040-BB89AD431D54","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-40F0-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Renal cell carcinoma","valueDescription":"Renal Cell Carcinoma","ValueMeaning":{"publicId":"2581668","version":"1","preferredName":"Renal Cell Carcinoma","longName":"2581668","preferredDefinition":"Cancer that develops in the lining of the renal tubules, which filter the blood and produce urine.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Renal Cell Carcinoma","conceptCode":"C9385","definition":"A carcinoma arising from the renal parenchyma.  There is a strong correlation between cigarette smoking and the development of renal cell carcinoma.  The clinical presentation includes : hematuria, flank pain and a palpable lumbar mass.  A high percentage of renal cell carcinomas are diagnosed when an ultrasound is performed for other purposes.  Radical nephrectomy is the standard intervention procedure.  Renal cell carcinoma is generally considered to be resistant to radiation treatment and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C11-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-09","endDate":null,"createdBy":"SCHMANDL","dateCreated":"2006-11-09","modifiedBy":"ONEDATA","dateModified":"2006-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-4104-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Radial growth phase","valueDescription":"Radial Growth Phase","ValueMeaning":{"publicId":"4265004","version":"1","preferredName":"Radial Growth Phase","longName":"4265004v1.00","preferredDefinition":"A morphologic architectural pattern in which the tumor cells spread horizontally.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radial Growth Phase","conceptCode":"C35897","definition":"A morphologic architectural pattern in which the tumor cells spread horizontally.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-4111-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"KUMMEROA","dateModified":"2023-08-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-412A-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Psammomatous","valueDescription":"Psammomatous Meningioma","ValueMeaning":{"publicId":"3251375","version":"1","preferredName":"Psammomatous Meningioma","longName":"3251375","preferredDefinition":"A WHO grade I meningioma characterized by the presence of psammoma bodies that predominate over the meningeal cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Psammomatous Meningioma","conceptCode":"C4331","definition":"A WHO grade I meningioma characterized by the presence of psammoma bodies that predominate over the meningeal cells.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A758F49E-A2C4-73F4-E040-BB89AD430DFE","latestVersionIndicator":"Yes","beginDate":"2011-07-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-413E-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Prolactin","valueDescription":"Prolactin","ValueMeaning":{"publicId":"3564200","version":"1","preferredName":"Prolactin","longName":"3564200","preferredDefinition":"Human prolactin (227 aa, 26 kDa precursor) is encoded by the human prolactin (PIT1) gene. This secreted lactogenic glycoprotein is expressed in both anterior pituitary lactotropes and the decidual endometrium. It acts primarily on the mammary gland and, in synergy with estrogen, induces progesterone release by corpus luteum cells to render the uterine mucosa suitable for implantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prolactin","conceptCode":"C778","definition":"Prolactin (227 aa, ~26 kDa) is encoded by the human PRL gene. This protein is involved in the promotion of lactation in the mammary gland.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7E04FAB-8E11-E4C9-E040-BB89AD435CF1","latestVersionIndicator":"Yes","beginDate":"2012-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-22","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-4153-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Seminoma","valueDescription":"Seminoma","ValueMeaning":{"publicId":"2575033","version":"1","preferredName":"Seminoma","longName":"2575033","preferredDefinition":"A radiosensitive malignant germ cell tumor found in the testis (especially undescended), and extragonadal sites (anterior mediastinum and pineal gland).  It is characterized by the presence of uniform cells with clear or dense cytoplasm which contains glycogen, and by a large nucleus which contains one or more nucleoli.  The neoplastic germ cells form aggregates separated by fibrous septa.  The fibrous septa contain chronic inflammatory cells, mainly lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Seminoma","conceptCode":"C9309","definition":"A radiosensitive malignant germ cell tumor found in the testis (especially undescended), and extragonadal sites (anterior mediastinum and pineal gland).  It is characterized by the presence of uniform cells with clear or dense cytoplasm which contains glycogen, and by a large nucleus which contains one or more nucleoli.  The neoplastic germ cells form aggregates separated by fibrous septa.  The fibrous septa contain chronic inflammatory cells, mainly lymphocytes.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F226-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-05-23","modifiedBy":"COOPERM","dateModified":"2016-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-415E-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Serous","valueDescription":"Serous","ValueMeaning":{"publicId":"2575176","version":"1","preferredName":"Serous","longName":"2575176","preferredDefinition":"Of or producing or containing serum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Serous","conceptCode":"C14168","definition":"Of or producing or containing serum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F2B5-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-05-24","modifiedBy":"COOPERM","dateModified":"2016-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-4169-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Serrated","valueDescription":"Serrated Glandular Architecture","ValueMeaning":{"publicId":"4265005","version":"1","preferredName":"Serrated Glandular Architecture","longName":"4265005","preferredDefinition":"The common saw-tooth architectural pattern observed within hyperplastic polyps.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Serrated Glandular Architecture","conceptCode":"C42599","definition":"The common saw-tooth architectural pattern observed within hyperplastic polyps.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-4176-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-418F-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Acute lymphoblastic leukemia","valueDescription":"Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"4263934","version":"1","preferredName":"Acute Lymphoblastic Leukemia","longName":"4263934","preferredDefinition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood.  It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Lymphoblastic Leukemia","conceptCode":"C3167","definition":"Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood. It includes the acute B lymphoblastic leukemia and acute T lymphoblastic leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63D55FF-343E-F699-E040-BB89AD433A6C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2023-03-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F63D55FF-3457-F699-E040-BB89AD433A6C","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"ONEDATA","dateModified":"2014-04-04","deletedIndicator":"No"},{"value":"Actinic keratosis","valueDescription":"Actinic (Solar) Keratosis","ValueMeaning":{"publicId":"4263935","version":"1","preferredName":"Actinic (Solar) Keratosis","longName":"4263935","preferredDefinition":"A precancerous lesion of the skin composed of atypical keratinocytes.  It is characterized by the presence of thick, scaly patches of skin.  Several histologic variants have been described, including atrophic, acantholytic, and hyperkeratotic variants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Actinic Keratosis","conceptCode":"C3148","definition":"A precancerous lesion of the skin composed of atypical keratinocytes. It is characterized by the presence of thick, scaly patches of skin. Several histologic variants have been described, including atrophic, acantholytic, and hyperkeratotic variants.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63D55FF-3461-F699-E040-BB89AD433A6C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F63D55FF-347A-F699-E040-BB89AD433A6C","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"ONEDATA","dateModified":"2014-04-04","deletedIndicator":"No"},{"value":"Acral lentiginous","valueDescription":"Acral Lentiginous Melanoma","ValueMeaning":{"publicId":"4263936","version":"1","preferredName":"Acral Lentiginous Melanoma","longName":"4263936","preferredDefinition":"A form of melanoma occurring most often on the plantar, palmar, subungual, and periungual skin.  It presents as a pigmented macular lesion with irregular borders.  Morphologically, it consists of atypical spindled and dendritic melanocytes.  The epidermis is often hyperplastic and there is pagetoid infiltration of the epidermis by anaplastic cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acral Lentiginous Melanoma","conceptCode":"C4022","definition":"A form of melanoma occurring most often on the plantar, palmar, subungual, and periungual skin.  It presents as a pigmented macular lesion with irregular borders.  Morphologically, it consists of atypical spindled and dendritic melanocytes.  The epidermis is often hyperplastic and there is pagetoid infiltration of the epidermis by anaplastic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63D55FF-3484-F699-E040-BB89AD433A6C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F63D55FF-349D-F699-E040-BB89AD433A6C","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"ONEDATA","dateModified":"2014-04-04","deletedIndicator":"No"},{"value":"Acinar adenocarcinoma","valueDescription":"Acinar Cell Adenocarcinoma","ValueMeaning":{"publicId":"4263937","version":"1","preferredName":"Acinar Cell Adenocarcinoma","longName":"4263937","preferredDefinition":"A secreting cell that lines an acinus (i.e. a small sac or sac-like structure).  A representative example is the acinar cell located in the pancreas that produces pancreatic enzymes and juices.: A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acinar Cell","conceptCode":"C13077","definition":"A secreting cell that lines an acinus (i.e. a small sac or sac-like structure).  A representative example is the acinar cell located in the pancreas that produces pancreatic enzymes and juices.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63D55FF-34AA-F699-E040-BB89AD433A6C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F63D55FF-34C3-F699-E040-BB89AD433A6C","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"ONEDATA","dateModified":"2014-04-04","deletedIndicator":"No"},{"value":"Acinar carcinoma","valueDescription":"Acinar Cell Carcinoma","ValueMeaning":{"publicId":"2558157","version":"1","preferredName":"Acinar Cell Carcinoma","longName":"2558157","preferredDefinition":"A malignant glandular epithelial neoplasm consisting of secretory cells forming acinar patterns. Representative examples include the acinar cell carcinoma of the pancreas and the acinar adenocarcinoma of the prostate gland.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acinar Cell Carcinoma","conceptCode":"C3768","definition":"A malignant glandular epithelial neoplasm consisting of secretory cells forming acinar patterns. Representative examples include the acinar cell carcinoma of the pancreas and the acinar adenocarcinoma of the prostate gland.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B03A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F63D55FF-34D7-F699-E040-BB89AD433A6C","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"ONEDATA","dateModified":"2014-04-04","deletedIndicator":"No"},{"value":"Acantholytic squamous cell","valueDescription":"Acantholytic Squamous Cell Skin Carcinoma","ValueMeaning":{"publicId":"4263939","version":"1","preferredName":"Acantholytic Squamous Cell Skin Carcinoma","longName":"4263939v1.00","preferredDefinition":"A histologic variant of squamous cell carcinoma that arises from the skin. It is characterized by loosening of the intercellular bridges between the malignant cells which results in acantholysis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin Acantholytic Squamous Cell Carcinoma","conceptCode":"C4460","definition":"A histologic variant of squamous cell carcinoma that arises from the skin. It is characterized by loosening of the intercellular bridges between the malignant cells which results in acantholysis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63D55FF-34E4-F699-E040-BB89AD433A6C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"CLOHNES","dateModified":"2023-06-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F63D55FF-34FD-F699-E040-BB89AD433A6C","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"ONEDATA","dateModified":"2014-04-04","deletedIndicator":"No"},{"value":"Anaplastic carcinoma","valueDescription":"Anaplastic carcinoma","ValueMeaning":{"publicId":"2575056","version":"1","preferredName":"Anaplastic carcinoma","longName":"2575056","preferredDefinition":"A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular, squamous, or transitional cell differentiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Undifferentiated Carcinoma","conceptCode":"C3692","definition":"A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular, squamous, or transitional cell differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F23D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-05-24","modifiedBy":"REEVESD","dateModified":"2014-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F63D55FF-3511-F699-E040-BB89AD433A6C","beginDate":"2014-03-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"ONEDATA","dateModified":"2014-04-04","deletedIndicator":"No"},{"value":"Acinic cell carcinoma","valueDescription":"Acinic Cell Carcinoma of Parotid","ValueMeaning":{"publicId":"4360174","version":"1","preferredName":"Acinic Cell Carcinoma of Parotid","longName":"4360174","preferredDefinition":"A carcinoma of the salivary gland characterized by serous acinar cell differentiation.  The vast majority of cases occur in the parotid gland.  It usually presents as a slowly enlarging mass.  A minority of patients experience pain.  It may recur or metastasize.  Multiple recurrences and metastasis to cervical lymph nodes are usually associated with a poor prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Salivary Gland Acinic Cell Carcinoma","conceptCode":"C8013","definition":"A carcinoma of the salivary gland characterized by serous acinar cell differentiation.  The vast majority of cases occur in the parotid gland.  It usually presents as a slowly enlarging mass.  A minority of patients experience pain.  It may recur or metastasize.  Multiple recurrences and metastasis to cervical lymph nodes are usually associated with a poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC2FC033-B40D-91B6-E040-BB89AD434EAD","latestVersionIndicator":"Yes","beginDate":"2014-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FC2FC033-B426-91B6-E040-BB89AD434EAD","beginDate":"2014-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-06-19","modifiedBy":"ONEDATA","dateModified":"2014-06-19","deletedIndicator":"No"},{"value":"Adrenocorticotropic hormone alpha subunit","valueDescription":"Adrenocorticotropic Hormone Subunit Alpha ","ValueMeaning":{"publicId":"4360172","version":"1","preferredName":"Adrenocorticotropic Hormone Subunit Alpha ","longName":"4360172","preferredDefinition":"A single unit of a multimeric object.: The 1st letter of the Greek alphabet.: A measurement of the adrenocorticotropic hormone in a biological specimen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Subunit","conceptCode":"C48788","definition":"A single unit of a multimeric object.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Alpha","conceptCode":"C86942","definition":"The 1st letter of the Greek alphabet.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Adrenocorticotropic Hormone Measurement","conceptCode":"C74780","definition":"The determination of the amount of adrenocorticotropic hormone present in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC2FC033-B3E7-91B6-E040-BB89AD434EAD","latestVersionIndicator":"Yes","beginDate":"2014-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FC2FC033-B400-91B6-E040-BB89AD434EAD","beginDate":"2014-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-06-19","modifiedBy":"ONEDATA","dateModified":"2014-06-19","deletedIndicator":"No"},{"value":"Essential thrombocythemia","valueDescription":"Essential Thrombocythemia","ValueMeaning":{"publicId":"2838061","version":"1","preferredName":"Essential Thrombocythemia","longName":"2838061","preferredDefinition":"A chronic myeloproliferative disorder that involves primarily the megakaryocytic lineage and it is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage.  The cause is unknown.  Median survival times of 10-15 years are commonly reported.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Essential Thrombocythemia","conceptCode":"C3407","definition":"A chronic myeloproliferative neoplasm that involves primarily the megakaryocytic lineage. It is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage. (WHO, 2008)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62843923-FF56-E9AE-E040-BB89AD435A7B","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6B324DB-B2C1-270F-E040-BB89AD436D58","beginDate":"2014-04-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-10","modifiedBy":"ONEDATA","dateModified":"2014-04-10","deletedIndicator":"No"},{"value":"Borderline tumor","valueDescription":"Borderline Lesion","ValueMeaning":{"publicId":"4264841","version":"1","preferredName":"Borderline Lesion","longName":"4264841","preferredDefinition":"A lesion characterized by the presence of atypical or low-grade neoplastic cells, which may or may not exhibit stromal microinvasion and cannot be qualified as completely malignant.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Borderline Lesion","conceptCode":"C36116","definition":"A lesion characterized by the presence of atypical or low-grade neoplastic cells, which may or may not exhibit stromal microinvasion and cannot be qualified as completely malignant.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42F0-00A0-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-00B9-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Blue nevus","valueDescription":"Blue Nevus","ValueMeaning":{"publicId":"4264843","version":"1","preferredName":"Blue Nevus","longName":"4264843","preferredDefinition":"An intradermal nevus characterized by the presence of benign pigmented dendritic spindle-shaped melanocytes. It most frequently occurs in the skin of the distal upper extremities, followed by the lower extremities, scalp, face, and buttocks. It usually presents as a single blue or blue-black papular lesion less than 1cm in diameter. Simple excision is usually curative.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blue Nevus","conceptCode":"C3803","definition":"An intradermal nevus characterized by the presence of benign pigmented dendritic spindle-shaped melanocytes. It most frequently occurs in the skin of the distal upper extremities, followed by the lower extremities, scalp, face, and buttocks. It usually presents as a single blue or blue-black papular lesion less than 1cm in diameter. Simple excision is usually curative.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42F0-00C6-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-00DF-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Biphasic mesothelioma","valueDescription":"Biphasic Mesothelioma","ValueMeaning":{"publicId":"3686380","version":"1","preferredName":"Biphasic Mesothelioma","longName":"3686380","preferredDefinition":"A malignant neoplasm arising from mesothelial cells in the pleura. It is characterized by the presence of neoplastic epithelioid cells and sarcomatoid features.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biphasic Mesothelioma","conceptCode":"C4282","definition":"A malignant mesothelioma characterized by the presence of epithelioid and sarcomatoid components, with each component representing at least 10% of the tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5C713B1-B577-DF11-E040-BB89AD436E24","latestVersionIndicator":"Yes","beginDate":"2013-02-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-00E9-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Bilateral Wilms tumor","valueDescription":"Bilateral Wilms Tumor","ValueMeaning":{"publicId":"4264844","version":"1","preferredName":"Bilateral Wilms Tumor","longName":"4264844","preferredDefinition":"Affecting both sides of the body, or a matched pair of organs.: An embryonal neoplasm characterized by the presence of epithelial, mesenchymal, and blastema components. The vast majority of cases arise from the kidney. A small number of cases with morphologic features resembling Wilms tumor of the kidney have been reported arising from the ovary and the cervix.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bilateral","conceptCode":"C13332","definition":"Affecting both sides of the body or a matched pair of organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Wilms Tumor","conceptCode":"C3267","definition":"An embryonal neoplasm characterized by the presence of epithelial, mesenchymal, and blastema components. The vast majority of cases arise from the kidney. A small number of cases with morphologic features resembling Wilms tumor of the kidney have been reported arising from the ovary and the cervix.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42F0-00F7-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-0110-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Basal cell carcinoma","valueDescription":"Skin Basal Cell Carcinoma","ValueMeaning":{"publicId":"2961462","version":"1","preferredName":"Skin Basal Cell Carcinoma","longName":"2961462","preferredDefinition":"The most frequently seen skin cancer. It arises from basal cells of the epidermis and pilosebaceous units. Clinically it is divided into the following types: nodular, ulcerative, superficial, multicentric, erythematous, and sclerosing or morphea-like.. More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck and the remaining 15% on the trunk and extremities. Basal cell carcinoma usually grows in a slow and indolent fashion. However, if untreated, the tumor may invade the subcutaneous fat, skeletal muscle and bone. Distant metastases are rare. Excision, curettage and irradiation cure most basal cell carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Skin Basal Cell Carcinoma","conceptCode":"C2921","definition":"The most frequently seen skin cancer. It arises from basal cells of the epidermis and pilosebaceous units. Clinically it is divided into the following types: nodular, ulcerative, superficial, multicentric, erythematous, and sclerosing or morphea-like. More than 95% of these carcinomas occur in patients over 40. They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck and the remaining 15% on the trunk and extremities. Basal cell carcinoma usually grows in a slow and indolent fashion. However, if untreated, the tumor may invade the subcutaneous fat, skeletal muscle and bone. Distant metastases are rare. Excision, curettage and irradiation cure most basal cell carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78AB07DC-B5C7-F05E-E040-BB89AD43180B","latestVersionIndicator":"Yes","beginDate":"2009-11-18","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-11-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-011A-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Barrett Esophagus","valueDescription":"Barrett Esophagus","ValueMeaning":{"publicId":"3210773","version":"1","preferredName":"Barrett Esophagus","longName":"3210773","preferredDefinition":"Esophageal segment lined with columnar metaplastic epithelium which is flat or villiform.  Barrett's epithelium is characterized by two different types of cells: goblet cells and columnar cells.  The symptomatology of Barrett's esophagus is that of gastro-esophageal reflux.  It is the precursor of most esophageal adenocarcinomas.  (WHO, 2000) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Barrett Esophagus","conceptCode":"C2891","definition":"Esophageal lesion lined with columnar metaplastic epithelium which is flat or villiform. Barrett epithelium is characterized by two different types of cells: goblet cells and columnar cells. The symptomatology of Barrett esophagus is that of gastro-esophageal reflux. It is the precursor of most esophageal adenocarcinomas.  (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9D5E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-0125-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Barrett-associated adenocarcinoma","valueDescription":"Barrett Adenocarcinoma","ValueMeaning":{"publicId":"4264846","version":"1","preferredName":"Barrett Adenocarcinoma","longName":"4264846","preferredDefinition":"An adenocarcinoma arising from Barrett metaplastic epithelium in the esophagus.  There is evidence supporting the idea that the Barrett adenocarcinomas develop through a stepwise progression through intestinal metaplastic epithelium to epithelial dysplasia to malignancy.  Adenocarcinomas arising in the setting of Barrett esophagus are typically papillary and/or tubular.  In terms of grading, they are well or moderately differentiated adenocarcinomas. -- 2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Barrett Adenocarcinoma","conceptCode":"C7027","definition":"An adenocarcinoma arising from Barrett metaplastic epithelium in the esophagus.  There is evidence supporting the idea that the Barrett adenocarcinomas develop through a stepwise progression through intestinal metaplastic epithelium to epithelial dysplasia to malignancy.  Adenocarcinomas arising in the setting of Barrett esophagus are typically papillary and/or tubular.  In terms of grading, they are well or moderately differentiated adenocarcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42F0-0133-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-014C-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"B-lymphocytes","valueDescription":"B-Lymphocyte","ValueMeaning":{"publicId":"2581328","version":"1","preferredName":"B-Lymphocyte","longName":"2581328","preferredDefinition":"Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B-Lymphocyte","conceptCode":"C12474","definition":"Immunologically important lymphocyte that is not thymus-dependent, is either short-lived and naive or long-lived and of memory phenotype, and resembles the bursa-derived lymphocyte of birds in that it is responsible for the production of immunoglobulins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0ABD-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-10-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-10-24","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-0160-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"B-cell lymphoma","valueDescription":"B-Cell Non-Hodgkin Lymphoma","ValueMeaning":{"publicId":"4264847","version":"1","preferredName":"B-Cell Non-Hodgkin Lymphoma","longName":"4264847","preferredDefinition":"The most common type of non-Hodgkin lymphoma.  It includes the most frequently seen morphologic variants which are: diffuse large B-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma and marginal zone B-cell lymphoma. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B-Cell Non-Hodgkin Lymphoma","conceptCode":"C3457","definition":"The most common type of non-Hodgkin lymphoma.  It includes the most frequently seen morphologic variants which are: diffuse large B-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma and marginal zone B-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42F0-016B-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-0184-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Atypical","valueDescription":"Atypia","ValueMeaning":{"publicId":"3238717","version":"1","preferredName":"Atypia","longName":"3238717","preferredDefinition":"The condition of being irregular or not conforming to type.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atypia","conceptCode":"C9478","definition":"The condition of being irregular or not conforming to type.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A41FA3DD-9660-2446-E040-BB89AD43483C","latestVersionIndicator":"Yes","beginDate":"2011-05-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-05-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-0198-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Anaplastic renal cell carcinoma","valueDescription":"Renal Cell Carcinoma Anaplastic Lesion","ValueMeaning":{"publicId":"4264849","version":"1","preferredName":"Renal Cell Carcinoma Anaplastic Lesion","longName":"4264849","preferredDefinition":"The most common type of kidney cancer. It begins in the lining of the renal tubules in the kidney. The renal tubules filter the blood and produce urine.: No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Renal Cell Carcinoma","conceptCode":"C9385","definition":"A carcinoma arising from the renal parenchyma.  There is a strong correlation between cigarette smoking and the development of renal cell carcinoma.  The clinical presentation includes : hematuria, flank pain and a palpable lumbar mass.  A high percentage of renal cell carcinomas are diagnosed when an ultrasound is performed for other purposes.  Radical nephrectomy is the standard intervention procedure.  Renal cell carcinoma is generally considered to be resistant to radiation treatment and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Anaplastic Lesion","conceptCode":"C36113","definition":"A morphologic finding indicating the presence of a malignant cellular infiltrate characterized by the presence of large pleomorphic cells, necrosis, and high mitotic activity in a tissue sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42F0-01A7-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-01C0-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Anaplastic large cell lymphoma","valueDescription":"Anaplastic Large Cell Lymphoma","ValueMeaning":{"publicId":"2558222","version":"1","preferredName":"Anaplastic Large Cell Lymphoma","longName":"2558222","preferredDefinition":"A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells.  Majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein.  The most frequently seen genetic alteration is a t(2;5) translocation.  Majority of patients present with advanced disease.  The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic Large Cell Lymphoma","conceptCode":"C3720","definition":"A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells. The majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein. The most frequently seen genetic alteration is a t(2;5) translocation. Majority of patients present with advanced disease. The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B07B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-01CA-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Wart","valueDescription":"Verrucous Lesion","ValueMeaning":{"publicId":"4264850","version":"1","preferredName":"Verrucous Lesion","longName":"4264850","preferredDefinition":"A papillomavirus related epithelial overgrowth. It can be located anywhere on the body though when it involves the perineal region it is generally referred to as condyloma acuminata.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Verrucous Lesion","conceptCode":"C5028","definition":"A papillomavirus related epithelial overgrowth. It can be located anywhere on the body though when it involves the perineal region it is generally referred to as condyloma acuminatum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42F0-01D5-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-01ED-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Well differentiated","valueDescription":"Well Differentiated","ValueMeaning":{"publicId":"3685458","version":"1","preferredName":"Well Differentiated","longName":"3685458v1.00","preferredDefinition":"Describes tumor cells that generally retain the appearance of normal cells and tend to grow and spread at a slower rate than undifferentiated or poorly differentiated tumor cells.","context":"PMI","contextVersion":"1","Concepts":[{"longName":"Well Differentiated","conceptCode":"C14171","definition":"Describes tumor cells that generally retain the appearance of normal cells and tend to grow and spread at a slower rate than undifferentiated or poorly differentiated tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"D58D9008-3A18-3F09-E040-BB89AD4368A5","latestVersionIndicator":"Yes","beginDate":"2022-08-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-02-12","modifiedBy":"MMADDINENI","dateModified":"2023-07-26","changeDescription":null,"administrativeNotes":"8/5/2022: created for PMI EC form. SL","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-01F8-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Yolk sac tumor","valueDescription":"Yolk Sac Tumor","ValueMeaning":{"publicId":"4264851","version":"1","preferredName":"Yolk Sac Tumor","longName":"4264851","preferredDefinition":"A non-seminomatous malignant germ cell tumor composed of primitive germ cells.  It is the most common malignant germ cell tumor in the pediatric population. It occurs in the infant testis, ovary, sacrococcygeal region, vagina, uterus, prostate, abdomen, liver, retroperitoneum, thorax, and pineal/third ventricle. The tumor mimics the yolk sac of the embryo and produces alpha-fetoprotein (AFP). Treatment includes: surgical resection, radiation, and chemotherapy. This tumor is very responsive to chemotherapy regimens that include cisplatinum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yolk Sac Tumor","conceptCode":"C3011","definition":"A non-seminomatous malignant germ cell tumor composed of primitive germ cells.  It is the most common malignant germ cell tumor in the pediatric population. It occurs in the infant testis, ovary, sacrococcygeal region, vagina, uterus, prostate, abdomen, liver, retroperitoneum, thorax, and pineal/third ventricle. The tumor mimics the yolk sac of the embryo and produces alpha-fetoprotein (AFP). Treatment includes: surgical resection, radiation, and chemotherapy. This tumor is very responsive to chemotherapy regimens that include cisplatinum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42F0-0203-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-021B-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Ameloblastoma","valueDescription":"Ameloblastoma","ValueMeaning":{"publicId":"3210863","version":"1","preferredName":"Ameloblastoma","longName":"3210863","preferredDefinition":"The most common odontogenic tumor, arising from the epithelial component of the embryonic tooth and usually affecting the molar-ramus region of the mandible or maxilla.  Although most ameloblastomas are morphologically and clinically benign, they may cause extensive local destruction, recur, or metastasize.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ameloblastoma","conceptCode":"C4313","definition":"The most common odontogenic tumor, arising from the epithelial component of the embryonic tooth and usually affecting the molar-ramus region of the mandible or maxilla.  Although most ameloblastomas are morphologically and clinically benign, they may cause extensive local destruction, recur, or metastasize.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AC54-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-0226-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Amelanotic","valueDescription":"Amelanotic Melanoma","ValueMeaning":{"publicId":"3251354","version":"1","preferredName":"Amelanotic Melanoma","longName":"3251354","preferredDefinition":"A melanoma characterized by the complete absence of melanin pigment in the melanoma cells. It occurs more frequently on the face and it is often associated with desmoplastic reaction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amelanotic Melanoma","conceptCode":"C3802","definition":"A melanoma characterized by the complete absence of melanin pigment in the melanoma cells. It occurs more frequently on the face and it is often associated with desmoplastic reaction.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A758F49E-9EF5-73F4-E040-BB89AD430DFE","latestVersionIndicator":"Yes","beginDate":"2011-07-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-023B-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"AIDS-related lymphoma","valueDescription":"AIDS-Related Lymphoma","ValueMeaning":{"publicId":"3210852","version":"1","preferredName":"AIDS-Related Lymphoma","longName":"3210852","preferredDefinition":"An aggressive lymphoma that develops in HIV-positive patients.  There is a significant increase in the incidence of lymphomas associated with the AIDS epidemic in the last two decades.  These lymphomas are usually extranodal, most often express a B-cell phenotype and morphologically are classified as Burkitt, diffuse large B-cell, and Hodgkin lymphomas.  The prognosis is closely related to the severity of immunodeficiency.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AIDS-Related Lymphoma","conceptCode":"C3471","definition":"An aggressive lymphoma that develops in HIV-positive patients.  There is a significant increase in the incidence of lymphomas associated with the AIDS epidemic.  These lymphomas are usually extranodal, most often express a B-cell phenotype and morphologically are classified as Burkitt, diffuse large B-cell, and Hodgkin lymphomas.  The prognosis is closely related to the severity of immunodeficiency.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-AA9E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-0250-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Adult T-cell lymphoma/leukemia","valueDescription":"Adult T-Cell Leukemia/Lymphoma","ValueMeaning":{"publicId":"4264852","version":"1","preferredName":"Adult T-Cell Leukemia/Lymphoma","longName":"4264852","preferredDefinition":"A peripheral (mature) T-cell neoplasm caused by the human T-cell leukemia virus type 1 (HTLV-1).  Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adult T-Cell Leukemia/Lymphoma","conceptCode":"C3184","definition":"A peripheral (mature) T-cell neoplasm linked to the human T-cell leukemia virus type 1 (HTLV-1).  Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42F0-025B-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-0274-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Adrenocorticotropic hormone","valueDescription":"Adrenocorticotropic Hormone","ValueMeaning":{"publicId":"3253517","version":"1","preferredName":"Adrenocorticotropic Hormone","longName":"3253517","preferredDefinition":"A hormone secreted by the anterior portion of the pituitary gland and regulates hormone, primarily cortisol, secreted by the adrenal gland.(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Corticotropin","conceptCode":"C2282","definition":"Corticotropin (39 aa, ~5 kDa) is encoded by the human POMC gene. This protein plays a role in the stimulation of cortisol secretion by the adrenal gland.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A81C14B3-3BC7-E9D6-E040-BB89AD4369F4","latestVersionIndicator":"Yes","beginDate":"2011-07-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-07-15","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-0288-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Astrocytoma","valueDescription":"Astrocytoma, NOS","ValueMeaning":{"publicId":"2837827","version":"1","preferredName":"Astrocytoma, NOS","longName":"2837827","preferredDefinition":"A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Astrocytoma","conceptCode":"C60781","definition":"A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"628169CF-83A0-F4D3-E040-BB89AD433D78","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"REEVESD","dateModified":"2014-07-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-0293-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Blastoma","valueDescription":"Blastoma","ValueMeaning":{"publicId":"2574993","version":"1","preferredName":"Blastoma","longName":"2574993","preferredDefinition":"A malignant neoplasm composed of undifferentiated cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blastoma","conceptCode":"C8997","definition":"A rare embryonal neoplasm affecting children. It is associated with DICER1 gene mutation. This category includes pituitary gland blastoma and pleuropulmonary blastoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F1FE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-05-23","modifiedBy":"COOPERM","dateModified":"2016-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-029E-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Carcinoma","valueDescription":"Carcinoma","ValueMeaning":{"publicId":"2935533","version":"1","preferredName":"Carcinoma","longName":"2935533","preferredDefinition":"A malignant tumor arising from epithelial cells.  Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas.  Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis.  Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites.  Lung carcinoma, skin carcinoma, breast carcinoma, and prostate carcinoma are the most frequently seen carcinomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71F88553-C4BB-17CC-E040-BB89AD43398B","latestVersionIndicator":"Yes","beginDate":"2009-08-25","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-08-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-02A9-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Carcinosarcoma","valueDescription":"Carcinosarcoma","ValueMeaning":{"publicId":"3248559","version":"1","preferredName":"Carcinosarcoma","longName":"3248559","preferredDefinition":"A malignant tumor composed of a mixture of carcinomatous and sarcomatous elements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carcinosarcoma","conceptCode":"C34448","definition":"A malignant tumor composed of a mixture of carcinomatous and sarcomatous elements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6BBE041-BD1E-9503-E040-BB89AD435A00","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-02B3-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Chondroma","valueDescription":"Chondroma","ValueMeaning":{"publicId":"2572937","version":"1","preferredName":"Chondroma","longName":"2572937","preferredDefinition":"A benign well circumscribed neoplasm of hyaline cartilage arising from bone or soft tissue. It is characterized by the presence of chondrocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chondroma","conceptCode":"C53459","definition":"A benign well circumscribed neoplasm of hyaline cartilage arising from bone or soft tissue. It is characterized by the presence of chondrocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E9F6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-02-03","modifiedBy":"COOPERM","dateModified":"2016-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-02BE-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Choriocarcinoma","valueDescription":"Choriocarcinoma","ValueMeaning":{"publicId":"2837860","version":"1","preferredName":"Choriocarcinoma","longName":"2837860","preferredDefinition":"An aggressive malignant tumor arising from trophoblastic cells.  The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells.  Approximately half of the cases develop from a complete hydatidiform mole.  A minority of cases arise in the testis or the ovaries.  There is often marked elevation of human chorionic gonadotropin (hCG) in the blood.  Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Choriocarcinoma","conceptCode":"C2948","definition":"An aggressive malignant tumor arising from trophoblastic cells. The vast majority of cases arise in the uterus and represent gestational choriocarcinomas that derive from placental trophoblastic cells. Approximately half of the cases develop from a complete hydatidiform mole. A minority of cases arise in the testis or the ovaries. There is often marked elevation of human chorionic gonadotropin (hCG) in the blood. Choriocarcinomas disseminate rapidly through the hematogenous route; the lungs are most frequently affected.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6281C75A-491B-A127-E040-BB89AD431A41","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"ONEDATA","dateModified":"2009-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67A42F0-02C9-5F77-E040-BB89AD433177","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Pleural effusion","valueDescription":"Pleural Effusion","ValueMeaning":{"publicId":"4264940","version":"1","preferredName":"Pleural Effusion","longName":"4264940","preferredDefinition":"Increased amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough, and chest pain. It is usually caused by lung infections, congestive heart failure, pleural and lung tumors, connective tissue disorders, and trauma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pleural Effusion","conceptCode":"C3331","definition":"Increased amounts of fluid within the pleural cavity. Symptoms include shortness of breath, cough, and chest pain. It is usually caused by lung infections, congestive heart failure, pleural and lung tumors, connective tissue disorders, and trauma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-37A4-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"KUMMEROA","dateModified":"2022-07-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-37BD-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Pleomorphic carcinoma","valueDescription":"Pleomorphic Carcinoma","ValueMeaning":{"publicId":"3669464","version":"1","preferredName":"Pleomorphic Carcinoma","longName":"3669464","preferredDefinition":"A usually aggressive malignant epithelial neoplasm composed of cells with significant cytologic atypia and nuclear pleomorphism.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pleomorphic Carcinoma","conceptCode":"C4094","definition":"A usually aggressive malignant epithelial neoplasm composed of cells with significant cytologic atypia and nuclear pleomorphism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D4858C70-78F1-328A-E040-BB89AD433B84","latestVersionIndicator":"Yes","beginDate":"2013-01-30","endDate":null,"createdBy":"MAESKEB","dateCreated":"2013-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-37C7-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Pleomorphic","valueDescription":"Pleomorphic","ValueMeaning":{"publicId":"3113268","version":"1","preferredName":"Pleomorphic","longName":"3113268","preferredDefinition":"Occurring in various distinct forms.  In terms of cells, having variation in the size and shape of cells or their nuclei.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pleomorphic","conceptCode":"C28109","definition":"Occurring in various distinct forms.  In terms of cells, having variation in the size and shape of cells or their nuclei.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"899A6C2D-CCA4-EBDD-E040-BB89AD432D12","latestVersionIndicator":"Yes","beginDate":"2010-06-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-37D1-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Plasmacytoma","valueDescription":"Plasmacytoma","ValueMeaning":{"publicId":"3210724","version":"1","preferredName":"Plasmacytoma","longName":"3210724","preferredDefinition":"A malignant (clonal) proliferation of plasma cells that are cytologically and immunophenotypically identical to those of plasma cell myeloma, but manifest a localized osseous or extraosseous growth pattern. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasmacytoma","conceptCode":"C9349","definition":"A malignant neoplasm characterized by the presence of a monoclonal population of plasma cells forming a tumor mass.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-94B6-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-37DC-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Plasma cell myeloma","valueDescription":"Plasma Cell Myeloma","ValueMeaning":{"publicId":"2559811","version":"1","preferredName":"Plasma Cell Myeloma","longName":"2559811","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B6B0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-37E7-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Pineoblastoma","valueDescription":"Pineoblastoma","ValueMeaning":{"publicId":"3251836","version":"1","preferredName":"Pineoblastoma","longName":"3251836","preferredDefinition":"Pineoblastoma (WHO grade IV) is a highly malignant, primitive embryonal neoplasm, which occurs more commonly in children. It is composed of patternless sheets of densely packed small cells with round-to-irregular nuclei and scant cytoplasm, similar to medulloblastoma and related primitive neuroectodermal tumors. A frequent complication is metastasis via cerebrospinal fluid pathways, which is often associated with a fatal outcome. (Adapted from WHO.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pineoblastoma","conceptCode":"C9344","definition":"A poorly differentiated malignant embryonal neoplasm arising from the pineal region.  It usually occurs in children and it is characterized by the presence of small immature neuroepithelial cells.  It may follow an aggressive clinical course.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A76E3677-AE5C-F84A-E040-BB89AD435C45","latestVersionIndicator":"Yes","beginDate":"2011-07-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-06","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-37F2-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Pilomatricoma","valueDescription":"Pilomatricoma","ValueMeaning":{"publicId":"3211364","version":"1","preferredName":"Pilomatricoma","longName":"3211364","preferredDefinition":"A benign adnexal neoplasm arising from hair-bearing skin surfaces, usually the head and neck and upper extremities. It usually presents as a solitary, slow-growing nodular mass. Morphologically, it displays differentiation towards the matrix and inner sheath of the normal hair follicle and the hair cortex. Complete surgical excision is usually curative. Occasionally, it may recur.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pilomatricoma","conceptCode":"C7368","definition":"A benign adnexal neoplasm arising from hair-bearing skin surfaces, usually the head and neck and upper extremities. It usually presents as a solitary, slow-growing nodular mass. Morphologically, it displays differentiation towards the matrix and inner sheath of the normal hair follicle and the hair cortex. Complete surgical excision is usually curative. Occasionally, it may recur.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-F37D-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-37FD-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Phyllodes tumor","valueDescription":"Phyllodes Tumor","ValueMeaning":{"publicId":"3293674","version":"1","preferredName":"Phyllodes Tumor","longName":"3293674","preferredDefinition":"A benign, borderline, or malignant fibroepithelial neoplasm arising from the breast and rarely the prostate gland.  It may recur following resection.  The recurrence rates are higher for borderline and malignant phyllodes tumors.  In borderline and malignant phyllodes tumors metastases to distant anatomic sites can occur.  The incidence of metastases is higher in malignant phyllodes tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Phyllodes Tumor","conceptCode":"C2977","definition":"A benign, borderline, or malignant fibroepithelial neoplasm arising from the breast and rarely the prostate gland.  It may recur following resection.  The recurrence rates are higher for borderline and malignant phyllodes tumors.  In borderline and malignant phyllodes tumors metastases to distant anatomic sites can occur.  The incidence of metastases is higher in malignant phyllodes tumors.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF074E37-E51B-1C17-E040-BB89AD431694","latestVersionIndicator":"Yes","beginDate":"2011-10-11","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3808-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Peutz-Jeghers polyp","valueDescription":"Peutz-Jeghers Polyp","ValueMeaning":{"publicId":"4264942","version":"1","preferredName":"Peutz-Jeghers Polyp","longName":"4264942","preferredDefinition":"A hamartomatous polyp that occurs in the stomach, small and large intestines, and rarely within the esophagus, nasopharynx and the urinary tract.  The Peutz-Jeghers polyps are grossly lobulated and dark.  Microscopically, they have a central core of smooth muscle covered by mucosa.  The smooth muscle shows tree-like branching.  The question of whether or not the Peutz-Jeghers polyp is precancerous is a matter of controversy.  The loss of heterozygosity on chromosome 19p (where the responsible gene LKB1 is located) suggests that the increased risk of malignancy may be due to malignant transformation from hamartoma to adenocarcinoma. --2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peutz-Jeghers Polyp","conceptCode":"C4733","definition":"A hamartomatous polyp that occurs in the stomach, small and large intestines, and rarely within the esophagus, nasopharynx and the urinary tract.  The Peutz-Jeghers polyps are grossly lobulated and dark.  Microscopically, they have a central core of smooth muscle covered by mucosa.  The smooth muscle shows tree-like branching.  The question of whether or not the Peutz-Jeghers polyp is precancerous is a matter of controversy.  The loss of heterozygosity on chromosome 19p (where the responsible gene LKB1 is located) suggests that the increased risk of malignancy may be due to malignant transformation from hamartoma to adenocarcinoma. --2002","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3816-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-382F-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Peritoneal fluid","valueDescription":"Peritoneal Fluid","ValueMeaning":{"publicId":"3902632","version":"1","preferredName":"Peritoneal Fluid","longName":"3902632v1.00","preferredDefinition":"The small amount of fluid that is generated in the abdominal cavity to lubricate the peritoneum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peritoneal Fluid","conceptCode":"C77612","definition":"The small amount of fluid that is generated in the abdominal cavity to lubricate the peritoneum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E6AF2FDF-8386-A14F-E040-BB89AD433004","latestVersionIndicator":"Yes","beginDate":"2013-09-18","endDate":null,"createdBy":"WONGW","dateCreated":"2013-09-18","modifiedBy":"GDEEN","dateModified":"2023-08-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3839-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Peripheral T-cell lymphoma unspecified","valueDescription":"Peripheral T-Cell Lymphoma, Not Otherwise Specified","ValueMeaning":{"publicId":"4173735","version":"1","preferredName":"Peripheral T-Cell Lymphoma, Not Otherwise Specified","longName":"4173735","preferredDefinition":"Aggressive nodal or extranodal mature (peripheral) T-cell lymphomas that do not belong to the better defined entities of the remainder of mature T-cell lymphomas.  This category includes the following variants: lymphoepithelioid cell variant (Lennert's lymphoma), follicular variant, and T-zone variant.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peripheral T-Cell Lymphoma, Not Otherwise Specified","conceptCode":"C4340","definition":"A group of peripheral T-cell lymphomas that do not meet the criteria for any other category of specifically defined entities of peripheral T-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F33D84E5-7AD8-4906-E040-BB89AD434E8B","latestVersionIndicator":"Yes","beginDate":"2014-02-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-384E-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Periosteal","valueDescription":"Periosteum","ValueMeaning":{"publicId":"4264944","version":"1","preferredName":"Periosteum","longName":"4264944","preferredDefinition":"The outer membrane that surrounds a bone. It contains connective tissue, capillaries, nerves, and a number of types of cell, including osteoclasts. The periosteum plays an important role in bone repair and growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Periosteum","conceptCode":"C13184","definition":"The outer membrane that surrounds a bone. It contains connective tissue, capillaries, nerves, and a number of types of cell, including osteoclasts. The periosteum plays an important role in bone repair and growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-385C-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3875-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Pericardial fluid","valueDescription":"Pericardial Effusion","ValueMeaning":{"publicId":"3227905","version":"1","preferredName":"Pericardial Effusion","longName":"3227905","preferredDefinition":"Fluid collection within the pericardial sac, usually due to inflammation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pericardial Effusion","conceptCode":"C3319","definition":"Fluid collection within the pericardial sac, usually due to inflammation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0E811F0-F3AC-3136-E040-BB89AD430E1B","latestVersionIndicator":"Yes","beginDate":"2011-04-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3889-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Papillomatosis","valueDescription":"Papillomatosis","ValueMeaning":{"publicId":"4264946","version":"1","preferredName":"Papillomatosis","longName":"4264946","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papillomatosis","conceptCode":"C3713","definition":"Glandular or squamous cell neoplastic proliferations characterized by the formation of multiple papillary structures diffusely involving a specific anatomic site.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3897-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-38B0-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Papilloma","valueDescription":"Papilloma","ValueMeaning":{"publicId":"3251768","version":"1","preferredName":"Papilloma","longName":"3251768","preferredDefinition":"A benign epithelial neoplasm that projects above the surrounding epithelial surface and consists of villous or arborescent outgrowths of fibrovascular stroma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papilloma","conceptCode":"C7440","definition":"A benign epithelial neoplasm that projects above the surrounding epithelial surface and consists of villous or arborescent outgrowths of fibrovascular stroma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A76B0E8E-B2B7-247A-E040-BB89AD4332AA","latestVersionIndicator":"Yes","beginDate":"2011-07-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-38BA-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Papillary serous adenocarcinoma","valueDescription":"Papillary Serous Adenocarcinoma","ValueMeaning":{"publicId":"4264947","version":"1","preferredName":"Papillary Serous Adenocarcinoma","longName":"4264947","preferredDefinition":"of or relating to or resembling papilla.: Definition not available.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papillary","conceptCode":"C14166","definition":"Of or relating to or resembling papilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Serous Adenocarcinoma","conceptCode":"C40101","definition":"An adenocarcinoma that is characterized by the presence of papillary patterns and cellular budding. Psammoma bodies may be present.  Representative examples include cervical serous adenocarcinoma, endometrial serous adenocarcinoma, ovarian serous adenocarcinoma, and primary peritoneal serous adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-38C8-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-38E1-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Papillary thyroid carcinoma","valueDescription":"Thyroid Gland Papillary Carcinoma","ValueMeaning":{"publicId":"4264948","version":"1","preferredName":"Thyroid Gland Papillary Carcinoma","longName":"4264948","preferredDefinition":"A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland.  It is linked to radiation exposure and is the most common malignant thyroid lesion, comprising 75% to 80% of all thyroid cancers in iodine sufficient countries.  Diagnostic procedures include: thyroid function tests, thyroid radioisotope scanning, thyroid ultrasound, and fine needle biopsy.  Microscopically, the diagnosis is based on the distinct characteristics of the malignant cells, which include enlargement, oval shape, elongation, and overlapping of the nuclei.  The nuclei also display clearing or have a ground glass appearance.  Depending on the size and spread of the disease, surgical options include lobectomy, and partial or complete thyroidectomy.  Adjuvant treatment options include: radioiodine therapy, TSH suppression and external radiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Papillary Carcinoma","conceptCode":"C4035","definition":"A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland.  Radiation exposure is a risk factor and it is the most common malignant thyroid lesion, comprising 75% to 80% of all thyroid cancers in iodine sufficient countries.  Diagnostic procedures include thyroid ultrasound and fine needle biopsy.  Microscopically, the diagnosis is based on the distinct characteristics of the malignant cells, which include enlargement, oval shape, elongation, and overlapping of the nuclei.  The nuclei also display clearing or have a ground glass appearance.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-38ED-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3906-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Papillary serous cystadenocarcinoma","valueDescription":"Papillary Serous Cystadenocarcinoma","ValueMeaning":{"publicId":"3248541","version":"1","preferredName":"Papillary Serous Cystadenocarcinoma","longName":"3248541","preferredDefinition":"A malignant cystic serous epithelial neoplasm characterized by the presence of malignant glandular epithelial cells forming papillary structures. Stromal invasion is present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papillary Serous Cystadenocarcinoma","conceptCode":"C8377","definition":"A malignant cystic serous epithelial neoplasm characterized by the presence of malignant glandular epithelial cells forming papillary structures. Stromal invasion is present.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6BBE041-BA9C-9503-E040-BB89AD435A00","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-391A-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Papillary renal cell carcinoma","valueDescription":"Papillary Renal Cell Carcinoma","ValueMeaning":{"publicId":"2581626","version":"1","preferredName":"Papillary Renal Cell Carcinoma","longName":"2581626","preferredDefinition":"Also known as chromophil carcinoma, it represents a minority of renal cell carcinomas.  It can be hereditary or sporadic.  The sporadic papillary renal cell carcinoma is characterized by trisomy of chromosomes 7, 16, and 17, and loss of chromosome Y.  The peak incidence is in the sixth and seven decades.  It is classified as type 1 or 2, based on the cytoplasmic volume and the thickness of the lining neoplastic cells. The prognosis is more favorable than for conventional (clear cell) renal cell carcinoma. -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papillary Renal Cell Carcinoma","conceptCode":"C6975","definition":"Also known as chromophil carcinoma, it represents a minority of renal cell carcinomas.  It can be hereditary or sporadic.  The sporadic papillary renal cell carcinoma is characterized by trisomy of chromosomes 7, 16, and 17, and loss of chromosome Y.  The peak incidence is in the sixth and seven decades.  It is classified as type 1 or 2, based on the cytoplasmic volume and the thickness of the lining neoplastic cells. The prognosis is more favorable than for conventional (clear cell) renal cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0BE7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-07","endDate":null,"createdBy":"SCHMANDL","dateCreated":"2006-11-07","modifiedBy":"ONEDATA","dateModified":"2006-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3925-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Papillary mesothelioma","valueDescription":"Papillary Mesothelioma","ValueMeaning":{"publicId":"4264949","version":"1","preferredName":"Papillary Mesothelioma","longName":"4264949","preferredDefinition":"of or relating to or resembling papilla.: A usually malignant and aggressive neoplasm of the mesothelium which is often associated with exposure to asbestos.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papillary","conceptCode":"C14166","definition":"Of or relating to or resembling papilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Mesothelioma","conceptCode":"C3234","definition":"A usually malignant and aggressive neoplasm of the mesothelium which is often associated with exposure to asbestos.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3932-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-394B-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Papillary carcinoma","valueDescription":"Papillary Carcinoma","ValueMeaning":{"publicId":"4264950","version":"1","preferredName":"Papillary Carcinoma","longName":"4264950","preferredDefinition":"A malignant epithelial neoplasm characterized by a papillary growth pattern. A papillary carcinoma may be composed of glandular cells (papillary adenocarcinoma), squamous cells (papillary squamous cell carcinoma), or transitional cells (papillary transitional cell carcinoma). Bladder carcinoma is a representative example of papillary transitional cell carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papillary Carcinoma","conceptCode":"C2927","definition":"A malignant epithelial neoplasm characterized by a papillary growth pattern. A papillary carcinoma may be composed of glandular cells (papillary adenocarcinoma), squamous cells (papillary squamous cell carcinoma), or transitional cells (papillary transitional cell carcinoma). Bladder carcinoma is a representative example of papillary transitional cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3955-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-396E-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Papillary adenocarcinoma","valueDescription":"Papillary Adenocarcinoma","ValueMeaning":{"publicId":"3251702","version":"1","preferredName":"Papillary Adenocarcinoma","longName":"3251702","preferredDefinition":"A morphologic variant of adenocarcinoma. It is characterized by the presence of a papillary growth pattern. Representative examples include thyroid gland papillary carcinoma, invasive papillary breast carcinoma, and ovarian serous surface papillary adenocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Papillary Adenocarcinoma","conceptCode":"C2853","definition":"A morphologic variant of adenocarcinoma. It is characterized by the presence of a papillary growth pattern. Representative examples include thyroid gland papillary carcinoma, invasive papillary breast carcinoma, and ovarian serous surface papillary adenocarcinoma.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7696A98-D53F-85AE-E040-BB89AD433885","latestVersionIndicator":"Yes","beginDate":"2011-07-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3982-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Osteoclast-like giant cell carcinoma","valueDescription":"Osteoclast-Like Giant Cell","ValueMeaning":{"publicId":"4264952","version":"1","preferredName":"Osteoclast-Like Giant Cell","longName":"4264952","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Osteoclast-Like Giant Cell","conceptCode":"C36827","definition":"A large, multinucleated cell that expresses osteoclast-specific markers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-398F-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-39A8-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Osteoblastic","valueDescription":"Osteoblast","ValueMeaning":{"publicId":"3962428","version":"1","preferredName":"Osteoblast","longName":"3962428","preferredDefinition":"Cells which secrete an extracellular matrix into which hydroxyapaetite crystals are deposited to form bone.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Osteoblast","conceptCode":"C12568","definition":"Cells which secrete an extracellular matrix into which hydroxyapaetite crystals are deposited to form bone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EC02FD3E-BF33-CD22-E040-BB89AD4305C1","latestVersionIndicator":"Yes","beginDate":"2013-11-25","endDate":null,"createdBy":"COLBERTM","dateCreated":"2013-11-25","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-39BC-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Oligodendroglioma","valueDescription":"Oligodendroglioma","ValueMeaning":{"publicId":"2838655","version":"1","preferredName":"Oligodendroglioma","longName":"2838655","preferredDefinition":"A well-differentiated (WHO grade II), diffusely infiltrating neuroglial tumor, typically located in the cerebral hemispheres.  It is composed predominantly of cells which morphologically resemble oligodendroglia. The neoplastic cells have rounded homogeneous nuclei and, on paraffin sections, a swollen, clear cytoplasm ('honeycomb' appearance). (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oligodendroglioma","conceptCode":"C3288","definition":"A well-differentiated (WHO grade 2), diffusely infiltrating neuroglial tumor, typically located in the cerebral hemispheres.  It is composed predominantly of cells which morphologically resemble oligodendroglia. The neoplastic cells have rounded homogeneous nuclei and, on paraffin sections, a swollen, clear cytoplasm ('honeycomb' appearance). (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A770F5-59CD-03F5-E040-BB89AD435AD2","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-03-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-39C7-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Oligoastrocytoma","valueDescription":"Oligoastrocytoma","ValueMeaning":{"publicId":"2838647","version":"1","preferredName":"Oligoastrocytoma","longName":"2838647","preferredDefinition":"A WHO grade II tumor composed of a conspicuous mixture of two distinct neoplastic cell types morphologically resembling the tumor cells in oligodendroglioma and diffuse astrocytoma. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oligoastrocytoma","conceptCode":"C4050","definition":"A WHO grade 2 tumor composed of a conspicuous mixture of two distinct neoplastic cell types morphologically resembling the tumor cells in oligodendroglioma and diffuse astrocytoma. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A740CA-95EA-2FE1-E040-BB89AD4311CA","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-39D2-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Esophagitis","valueDescription":"Esophagitis","ValueMeaning":{"publicId":"2746383","version":"1","preferredName":"Esophagitis","longName":"2746383","preferredDefinition":"Inflammation, acute or chronic, of the esophagus caused by bacteria, chemicals, or trauma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Esophagitis","conceptCode":"C9224","definition":"An acute or chronic inflammatory process affecting the esophageal wall.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C20DB99-724E-0BA9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-39DD-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Normal","valueDescription":"Normal","ValueMeaning":{"publicId":"2567281","version":"1","preferredName":"Normal","longName":"2567281","preferredDefinition":"Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Normal","conceptCode":"C14165","definition":"Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D3DE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-39E8-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Non-small cell lung carcinoma","valueDescription":"Non-Small Cell Lung Carcinoma","ValueMeaning":{"publicId":"2581628","version":"1","preferredName":"Non-Small Cell Lung Carcinoma","longName":"2581628","preferredDefinition":"A group of at least three distinct histological types of lung cancer, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.  Non-small cell lung carcinomas have a poor response to conventional chemotherapy.  --2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lung Non-Small Cell Carcinoma","conceptCode":"C2926","definition":"A group of at least three distinct histological types of lung cancer, including non-small cell squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Non-small cell lung carcinomas have a poor response to conventional chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0BE9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-07","endDate":null,"createdBy":"SCHMANDL","dateCreated":"2006-11-07","modifiedBy":"ONEDATA","dateModified":"2006-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-39FC-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Non-small cell carcinoma","valueDescription":"Non-Small Cell Carcinoma","ValueMeaning":{"publicId":"2837836","version":"1","preferredName":"Non-Small Cell Carcinoma","longName":"2837836","preferredDefinition":"A malignant epithelial neoplasm characterized by the absence of neoplastic small epithelial cells. A representative example is the lung non-small cell carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Small Cell Carcinoma","conceptCode":"C65151","definition":"A malignant epithelial neoplasm characterized by the absence of neoplastic small epithelial cells. A representative example is the lung non-small cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6281C75A-488E-A127-E040-BB89AD431A41","latestVersionIndicator":"Yes","beginDate":"2009-02-09","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3A10-E912-E040-BB89AD433874","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Non-seminoma","valueDescription":"Non-Seminomatous Lesion","ValueMeaning":{"publicId":"4264954","version":"1","preferredName":"Non-Seminomatous Lesion","longName":"4264954","preferredDefinition":"A group of testicular cancers that begin in the germ cells (cells that give rise to sperm). Nonseminomas are identified by the type of cell in which they begin and include embryonal carcinoma, teratoma, choriocarcinoma, and yolk sac carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Seminomatous Lesion","conceptCode":"C36127","definition":"A group of testicular cancers that begin in the germ cells (cells that give rise to sperm). Nonseminomas are identified by the type of cell in which they begin and include embryonal carcinoma, teratoma, choriocarcinoma, and yolk sac carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3A1E-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3A37-E912-E040-BB89AD433874","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Non-neoplastic","valueDescription":"Non-Neoplastic Disorder","ValueMeaning":{"publicId":"4264955","version":"1","preferredName":"Non-Neoplastic Disorder","longName":"4264955","preferredDefinition":"Any disorder other than abnormal tissue growth resulting from uncontrolled cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Neoplastic Disorder","conceptCode":"C53529","definition":"Any disorder other than abnormal tissue growth resulting from uncontrolled cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3A43-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3A5C-E912-E040-BB89AD433874","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Nodular","valueDescription":"Nodular Pattern","ValueMeaning":{"publicId":"3192590","version":"1","preferredName":"Nodular Pattern","longName":"3192590","preferredDefinition":"A morphologic architectural pattern characterized by the presence of proliferating non-neoplastic or neoplastic cells forming single or multiple nodules within a lesion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nodular Pattern","conceptCode":"C35899","definition":"A morphologic architectural pattern characterized by the presence of proliferating non-neoplastic or neoplastic cells forming single or multiple nodules within a lesion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9C915748-5969-DCD6-E040-BB89AD436AD0","latestVersionIndicator":"Yes","beginDate":"2011-02-18","endDate":null,"createdBy":"SORENSENS","dateCreated":"2011-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3A66-E912-E040-BB89AD433874","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Neuroendocrine carcinoma","valueDescription":"Neuroendocrine Carcinoma","ValueMeaning":{"publicId":"2559503","version":"1","preferredName":"Neuroendocrine Carcinoma","longName":"2559503","preferredDefinition":"A malignant neuroendocrine tumor composed of cells containing secretory granules that stain positive for NSE and chromogranin.  Tumor cells are often round and form clusters or trabecular sheets.  Representative examples are carcinoid tumor, small cell carcinoma, and Merkel cell carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuroendocrine Carcinoma","conceptCode":"C3773","definition":"A usually aggressive carcinoma composed of malignant cells exhibiting neuroendocrine differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B57C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3A71-E912-E040-BB89AD433874","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Neoplasm","valueDescription":"Neoplasm","ValueMeaning":{"publicId":"3071117","version":"1","preferredName":"Neoplasm","longName":"3071117","preferredDefinition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"84B019E9-7DC7-77A7-E040-BB89AD4330E0","latestVersionIndicator":"Yes","beginDate":"2010-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-04-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3A86-E912-E040-BB89AD433874","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Nasopharyngeal carcinoma","valueDescription":"Nasopharyngeal Carcinoma","ValueMeaning":{"publicId":"4264956","version":"1","preferredName":"Nasopharyngeal Carcinoma","longName":"4264956","preferredDefinition":"A carcinoma arising from the nasopharyngeal epithelium.  It includes the following types: keratinizing squamous cell carcinoma, nonkeratinizing carcinoma (differentiated and undifferentiated), basaloid squamous cell carcinoma, and papillary adenocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nasopharyngeal Carcinoma","conceptCode":"C3871","definition":"A carcinoma arising from the nasopharyngeal epithelium.  It includes the following types: keratinizing squamous cell carcinoma, nonkeratinizing carcinoma (differentiated and undifferentiated), basaloid squamous cell carcinoma, and papillary adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3A91-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3AAA-E912-E040-BB89AD433874","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Nasal polyp","valueDescription":"Nasal Cavity Polyp","ValueMeaning":{"publicId":"4264958","version":"1","preferredName":"Nasal Cavity Polyp","longName":"4264958","preferredDefinition":"A soft and painless polypoid mass that arises from the mucosa in the nasal cavity.  It is usually the result of an inflammatory process.  It may recur following surgical resection.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nasal Cavity Polyp","conceptCode":"C3256","definition":"A soft and painless polypoid mass that arises from the mucosa in the nasal cavity.  It is usually the result of an inflammatory process.  It may recur following surgical resection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3AB7-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3AD0-E912-E040-BB89AD433874","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Myxoid round cell","valueDescription":"Myxoid/Round Cell Liposarcoma","ValueMeaning":{"publicId":"4264959","version":"1","preferredName":"Myxoid/Round Cell Liposarcoma","longName":"4264959","preferredDefinition":"A liposarcoma characterized by the presence of round non-lipogenic mesenchymal cells and small signet ring lipoblasts within a myxoid stoma with a vascular-branching pattern, or the presence of solid sheets of primitive round cells without myxoid stroma. The tumor is usually well-circumscribed. The majority of cases arise from within the thigh muscles.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myxoid Liposarcoma","conceptCode":"C27781","definition":"A liposarcoma characterized by the presence of round non-lipogenic primitive mesenchymal cells and small signet ring lipoblasts within a myxoid stoma with a branching vascular pattern.  This category includes hypercellular lesions with round cell morphology, formerly known as round cell liposarcoma.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3ADA-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3AF3-E912-E040-BB89AD433874","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Myxoid","valueDescription":"Myxoid Changes Present","ValueMeaning":{"publicId":"4264960","version":"1","preferredName":"Myxoid Changes Present","longName":"4264960","preferredDefinition":"A morphologic finding indicating the presence of myxoid changes in a tissue sample.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myxoid Changes Present","conceptCode":"C39744","definition":"A morphologic finding indicating the presence of myxoid changes in a tissue sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3AFF-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3B18-E912-E040-BB89AD433874","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Myoepithelial","valueDescription":"Myoepithelial","ValueMeaning":{"publicId":"4264962","version":"1","preferredName":"Myoepithelial","longName":"4264962","preferredDefinition":"Derived from epithelial cells and destined to become a part of the muscular system; having the characteristics of both muscle and epithelium.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myoepithelial","conceptCode":"C14164","definition":"Derived from epithelial cells and destined to become a part of the muscular system; having the characteristics of both muscle and epithelium.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3B25-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3B3E-E912-E040-BB89AD433874","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Myeloproliferative neoplasm","valueDescription":"Myeloproliferative Neoplasm","ValueMeaning":{"publicId":"4264963","version":"1","preferredName":"Myeloproliferative Neoplasm","longName":"4264963","preferredDefinition":"A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3B48-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3B61-E912-E040-BB89AD433874","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Mucosa-associated lymphoid tissue lymphoma","valueDescription":"Mucosa-Associated Lymphoid Tissue Lymphoma","ValueMeaning":{"publicId":"4264964","version":"1","preferredName":"Mucosa-Associated Lymphoid Tissue Lymphoma","longName":"4264964","preferredDefinition":"Lymphoid tissue located beneath the mucosal epithelia of those mucosal surfaces that have contact with the external environment, such as the respiratory, digestive, and urinary systems. MALT consists of a collection of predominantly small lymphocytes, fewer larger, transformed lymphocytes, and plasma cells. It protects the body from pathogens that enter via the mucosa. MALT gives rise to a distinctive type of B-cell lymphoma that usually follows an indolent clinical course.: A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucosa-Associated Lymphoid Tissue","conceptCode":"C12910","definition":"Lymphoid tissue located beneath the mucosal epithelia of those mucosal surfaces that have contact with the external environment, such as the respiratory, digestive, and urinary systems. MALT consists of a collection of predominantly small lymphocytes, fewer larger, transformed lymphocytes, and plasma cells. It protects the body from pathogens that enter via the mucosa. MALT gives rise to a distinctive type of B-cell lymphoma that usually follows an indolent clinical course.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Lymphoma","conceptCode":"C3208","definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3B6E-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3B87-E912-E040-BB89AD433874","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Myelofibrosis","valueDescription":"Myelofibrosis","ValueMeaning":{"publicId":"4264965","version":"1","preferredName":"Myelofibrosis","longName":"4264965","preferredDefinition":"A partial or complete replacement of the bone marrow stroma by fibrous tissue.  It can be a primary bone marrow lesion as part of the chronic myeloproliferative disorders (chronic idiopathic myelofibrosis), a manifestation of acute myeloid leukemia (acute panmyelosis with myelofibrosis), or a secondary phenomenon due to bone marrow involvement by a metastatic tumor (e.g., metastatic breast carcinoma). --2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelofibrosis","conceptCode":"C3248","definition":"A partial or complete replacement of the bone marrow stroma by fibrous tissue.  It can be a primary bone marrow lesion as part of the chronic myeloproliferative disorders (chronic idiopathic myelofibrosis), a manifestation of acute myeloid leukemia (acute panmyelosis with myelofibrosis), or a secondary phenomenon due to bone marrow involvement by a metastatic tumor (e.g., metastatic breast carcinoma). --2003","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3B91-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3BAA-E912-E040-BB89AD433874","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Myelodysplastic syndrome","valueDescription":"Myelodysplastic Syndrome","ValueMeaning":{"publicId":"2570433","version":"1","preferredName":"Myelodysplastic Syndrome","longName":"2570433","preferredDefinition":"Myelodysplastic syndrome (MDS) is a clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.  The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia.  MDS may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E02E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3BB4-E912-E040-BB89AD433874","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Mycosis Fungoides","valueDescription":"Mycosis Fungoides","ValueMeaning":{"publicId":"4264966","version":"1","preferredName":"Mycosis Fungoides","longName":"4264966","preferredDefinition":"A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei.  Patients with limited disease generally have an excellent prognosis.  In the more advanced stages, the prognosis is poor. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mycosis Fungoides","conceptCode":"C3246","definition":"A peripheral (mature) T-cell lymphoma presenting in the skin with patches/plaques. It is characterized by epidermal and dermal infiltration of small to medium-sized T-cells with cerebriform nuclei.  Patients with limited disease generally have an excellent prognosis.  In the more advanced stages, the prognosis is poor. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3BBF-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3BD8-E912-E040-BB89AD433874","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Vulvar intraepithelial neoplasia Grade III","valueDescription":"Vulvar Intraepithelial Neoplasia Grade III","ValueMeaning":{"publicId":"4264967","version":"1","preferredName":"Vulvar Intraepithelial Neoplasia Grade III","longName":"4264967","preferredDefinition":"A morphologic qualifier indicating that a cancerous lesion is poorly differentiated.: High-grade intraepithelial neoplasia of the vulvar squamous epithelium.  There is no evidence of invasion.  This category includes vulvar intraepithelial neoplasia, usual type and vulvar intraepithelial neoplasia, differentiated type.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 3","conceptCode":"C28079","definition":"A morphologic qualifier indicating that a cancerous lesion is poorly differentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Vulvar Intraepithelial Neoplasia","conceptCode":"C4756","definition":"Intraepithelial neoplasia of the vulvar squamous epithelium. There is no evidence of invasion. It includes vulvar squamous intraepithelial lesion, HPV-associated and vulvar intraepithelial neoplasia, HPV-independent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3BEC-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3C05-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Vulvar intraepithelial neoplasia Grade I","valueDescription":"Vulvar Intraepithelial Neoplasia Grade I","ValueMeaning":{"publicId":"4264968","version":"1","preferredName":"Vulvar Intraepithelial Neoplasia Grade I","longName":"4264968","preferredDefinition":"A morphologic qualifier indicating that a cancerous lesion is well differentiated.: High-grade intraepithelial neoplasia of the vulvar squamous epithelium.  There is no evidence of invasion.  This category includes vulvar intraepithelial neoplasia, usual type and vulvar intraepithelial neoplasia, differentiated type.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 1","conceptCode":"C28077","definition":"A morphologic qualifier indicating that a cancerous lesion is well differentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Vulvar Intraepithelial Neoplasia","conceptCode":"C4756","definition":"Intraepithelial neoplasia of the vulvar squamous epithelium. There is no evidence of invasion. It includes vulvar squamous intraepithelial lesion, HPV-associated and vulvar intraepithelial neoplasia, HPV-independent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3C12-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3C2B-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Vipoma","valueDescription":"VIP-Producing Neuroendocrine Tumor","ValueMeaning":{"publicId":"4264969","version":"1","preferredName":"VIP-Producing Neuroendocrine Tumor","longName":"4264969","preferredDefinition":"An often clinically aggressive neuroendocrine tumor located in the pancreas or small intestine.  It is composed of cells containing vasoactive intestinal peptide.  It may cause intractable diarrhea and metabolic disturbances.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"VIP-Producing Neuroendocrine Tumor","conceptCode":"C26749","definition":"An often clinically aggressive neuroendocrine tumor located in the pancreas or small intestine.  It is composed of cells containing vasoactive intestinal peptide.  It may cause intractable diarrhea and metabolic disturbances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3C35-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3C4E-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Villous","valueDescription":"Villous","ValueMeaning":{"publicId":"4264970","version":"1","preferredName":"Villous","longName":"4264970","preferredDefinition":"Abounding in, or covered with, fine hairs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Villous","conceptCode":"C14170","definition":"Abounding in, or covered with, fine hairs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3C5A-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3C73-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Vertical growth phase","valueDescription":"Vertical Growth Phase","ValueMeaning":{"publicId":"4264972","version":"1","preferredName":"Vertical Growth Phase","longName":"4264972v1.00","preferredDefinition":"A morphologic architectural pattern in which the tumor cells spread vertically.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vertical Growth Phase","conceptCode":"C35898","definition":"A morphologic architectural pattern in which the tumor cells spread vertically.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3C80-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"KUMMEROA","dateModified":"2023-08-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3C99-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Unilateral Wilms tumor","valueDescription":"Unilateral Wilms Tumor","ValueMeaning":{"publicId":"4264974","version":"1","preferredName":"Unilateral Wilms Tumor","longName":"4264974","preferredDefinition":"Involving only one part or side.: An embryonal neoplasm characterized by the presence of epithelial, mesenchymal, and blastema components. The vast majority of cases arise from the kidney. A small number of cases with morphologic features resembling Wilms tumor of the kidney have been reported arising from the ovary and the cervix.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unilateral","conceptCode":"C68598","definition":"Involving only one part or side.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Wilms Tumor","conceptCode":"C3267","definition":"An embryonal neoplasm characterized by the presence of epithelial, mesenchymal, and blastema components. The vast majority of cases arise from the kidney. A small number of cases with morphologic features resembling Wilms tumor of the kidney have been reported arising from the ovary and the cervix.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3CA7-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3CC0-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Undifferentiated carcinoma","valueDescription":"Undifferentiated Carcinoma","ValueMeaning":{"publicId":"4264975","version":"1","preferredName":"Undifferentiated Carcinoma","longName":"4264975","preferredDefinition":"A term used to describe cells or tissues that do not have specialized (\"mature\") structures or functions. Undifferentiated cancer cells often grow and spread quickly.: A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Undifferentiated","conceptCode":"C14176","definition":"Describes tumor cells that generally have lost all of the appearance of normal cells. They tend to grow and spread quickly and aggressively.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3CCD-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3CE6-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Undifferentiated adenocarcinoma","valueDescription":"Undifferentiated Adenocarcinoma","ValueMeaning":{"publicId":"4264976","version":"1","preferredName":"Undifferentiated Adenocarcinoma","longName":"4264976","preferredDefinition":"A term used to describe cells or tissues that do not have specialized (\"mature\") structures or functions. Undifferentiated cancer cells often grow and spread quickly.: A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Undifferentiated","conceptCode":"C14176","definition":"Describes tumor cells that generally have lost all of the appearance of normal cells. They tend to grow and spread quickly and aggressively.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3CF3-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3D0C-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Ulcerative colitis","valueDescription":"Ulcerative Colitis","ValueMeaning":{"publicId":"4264977","version":"1","preferredName":"Ulcerative Colitis","longName":"4264977","preferredDefinition":"An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ulcerative Colitis","conceptCode":"C2952","definition":"An inflammatory bowel disease involving the mucosal surface of the large intestine and rectum. It may present with an acute or slow onset and follows an intermittent or continuous course. Signs and symptoms include abdominal pain, diarrhea, fever, weight loss, and intestinal hemorrhage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3D16-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3D2F-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Tubulovillous","valueDescription":"Tubulovillous Adenoma","ValueMeaning":{"publicId":"3247843","version":"1","preferredName":"Tubulovillous Adenoma","longName":"3247843","preferredDefinition":"An epithelial neoplasm morphologically characterized by the presence of a villous and a tubular architectural pattern. Most often it occurs in the large intestine, small intestine, and the stomach in which the neoplastic epithelial cells show dysplastic features.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tubulovillous Adenoma","conceptCode":"C4143","definition":"An adenoma arising from the glandular epithelium of the gastrointestinal tract. It is characterized by the presence of a tubular and a villous architectural pattern. Most often it occurs in the large intestine, small intestine, and the stomach. The neoplastic epithelial cells show dysplastic features.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A67A743F-5D65-D6C3-E040-BB89AD436761","latestVersionIndicator":"Yes","beginDate":"2011-06-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3D43-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Tubular adenocarcinoma","valueDescription":"Tubular Adenocarcinoma","ValueMeaning":{"publicId":"4264979","version":"1","preferredName":"Tubular Adenocarcinoma","longName":"4264979","preferredDefinition":"An infiltrating adenocarcinoma in which the malignant cells form tubular structures. Representative examples include the tubular breast carcinoma and the gastric tubular adenocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tubular Adenocarcinoma","conceptCode":"C65192","definition":"An infiltrating adenocarcinoma in which the malignant cells form tubular structures. Representative examples include the tubular breast carcinoma and the gastric tubular adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3D51-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3D6A-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Tubular","valueDescription":"Tubular","ValueMeaning":{"publicId":"4264980","version":"1","preferredName":"Tubular","longName":"4264980","preferredDefinition":"Shaped like a tube; of or pertaining to a tubule.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tubular","conceptCode":"C14169","definition":"Shaped like a tube; of or pertaining to a tubule.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3D74-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3D8D-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Trichoepithelioma","valueDescription":"Trichoblastoma","ValueMeaning":{"publicId":"4264982","version":"1","preferredName":"Trichoblastoma","longName":"4264982","preferredDefinition":"A benign hair follicle neoplasm with trichoblastic differentiation. It usually presents as a solitary papular lesion It most often presents on the head and neck area, but it may develop in any anatomic site containing hair follicles. Because of its benign nature, treatment usually is not required, provided that the diagnosis has been established with certainty.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trichoblastoma","conceptCode":"C27132","definition":"A benign hair follicle neoplasm with trichoblastic differentiation. It usually presents as a solitary papular lesion It most often presents on the head and neck area, but it may develop in any anatomic site containing hair follicles. Because of its benign nature, treatment usually is not required, provided that the diagnosis has been established with certainty.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3D9A-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3DB3-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Transitional meningioma","valueDescription":"Transitional Meningioma","ValueMeaning":{"publicId":"3251373","version":"1","preferredName":"Transitional Meningioma","longName":"3251373","preferredDefinition":"A WHO grade I meningioma characterized by the coexistence of meningothelial cells and fibrous architectural patterns.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transitional Meningioma","conceptCode":"C4333","definition":"A WHO grade I meningioma characterized by the coexistence of meningothelial cells and fibrous architectural patterns.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A758F49E-A29E-73F4-E040-BB89AD430DFE","latestVersionIndicator":"Yes","beginDate":"2011-07-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3DC7-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Transitional cell carcinoma","valueDescription":"Transitional Cell Carcinoma","ValueMeaning":{"publicId":"4264983","version":"1","preferredName":"Transitional Cell Carcinoma","longName":"4264983","preferredDefinition":"A malignant neoplasm arising from the transitional epithelium, usually affecting the urinary bladder, ureter, or renal pelvis. It may or may not have a papillary configuration. It is graded 1 to 3 or 4 according to the degree of cellular differentiation and architectural patterns. Grade 1 transitional cell carcinoma is histologically benign but it may recur. Transitional cell carcinomas may also affect the upper respiratory tract and the ovaries.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transitional Cell Carcinoma","conceptCode":"C2930","definition":"A malignant neoplasm arising from the transitional epithelium, usually affecting the urinary bladder, ureter, or renal pelvis. It may or may not have a papillary configuration. It is graded 1 to 3 or 4 according to the degree of cellular differentiation and architectural patterns. Grade 1 transitional cell carcinoma is histologically benign but it may recur. Transitional cell carcinomas may also affect the upper respiratory tract and the ovaries.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3DD2-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3DEB-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Thymus like differentiation","valueDescription":"T-Cell Differentiation in the Thymus","ValueMeaning":{"publicId":"4264985","version":"1","preferredName":"T-Cell Differentiation in the Thymus","longName":"4264985","preferredDefinition":"The progression of T cell precursors in the thymus through many stages of maturation.  These stages include regulated expression of the alpha and beta (or gamma and delta) chains of the T cell receptor, expression of both CD4 and CD8 molecules (double positive stage), down regulation to a single positive stage (CD4 or CD8), as well as allowing those thymocytes to die which are unable to bind to self MHC molecules (death by neglect), selecting those thymocytes with T Cell Receptors that are able to bind to self MHC molecules with moderate affinity (positive selection), and deleting those thymocytes having T Cell Receptors that bind with high affinity to self MHC (negative selection), before allowing mature T cells to emigrate to the periphery.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Cell Differentiation in the Thymus","conceptCode":"C19317","definition":"The progression of T cell precursors in the thymus through many stages of maturation.  These stages include regulated expression of the alpha and beta (or gamma and delta) chains of the T cell receptor, expression of both CD4 and CD8 molecules (double positive stage), down regulation to a single positive stage (CD4 or CD8), as well as allowing those thymocytes to die which are unable to bind to self MHC molecules (death by neglect), selecting those thymocytes with T Cell Receptors that are able to bind to self MHC molecules with moderate affinity (positive selection), and deleting those thymocytes having T Cell Receptors that bind with high affinity to self MHC (negative selection), before allowing mature T cells to emigrate to the periphery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3DF8-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3E11-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Therapy related","valueDescription":"Therapy-Related Neoplasm","ValueMeaning":{"publicId":"4264986","version":"1","preferredName":"Therapy-Related Neoplasm","longName":"4264986","preferredDefinition":"The development of a neoplasm in response to medical or surgical treatment, induced by the treatment itself.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Therapy-Related Neoplasm","conceptCode":"C3487","definition":"The development of a neoplasm in response to medical or surgical treatment, induced by the treatment itself.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3E1B-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3E34-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Teratoma","valueDescription":"Teratoma","ValueMeaning":{"publicId":"2566025","version":"1","preferredName":"Teratoma","longName":"2566025","preferredDefinition":"A non-seminomatous germ cell tumor characterized by the presence of various tissues which correspond to the different germinal layers (endoderm, mesoderm, and ectoderm). It occurs in the testis, ovary, and extragonadal sites including central nervous system, mediastinum, lung, and stomach. According to the level of differentiation of the tissues which comprise the tumor, teratomas are classified as mature or immature. Mature teratomas are composed of well differentiated, adult-type tissues. Immature teratomas are composed of immature, fetal-type tissues. Testicular teratomas in children follow a benign clinical course. Mature ovarian teratomas without a fetal-type component have an excellent outcome. The prognosis of immature ovarian teratomas is related to the grade and stage of the tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Teratoma","conceptCode":"C3403","definition":"A non-seminomatous germ cell tumor characterized by the presence of various tissues which correspond to the different germinal layers (endoderm, mesoderm, and ectoderm). It occurs in the testis, ovary, and extragonadal sites including central nervous system, mediastinum, lung, and stomach. According to the level of differentiation of the tissues which comprise the tumor, teratomas are classified as benign (grade 0 or 1), immature (grade 2), and malignant (grade 3). Grade 0 teratomas contain only mature elements; grade 1 teratomas have a limited degree of immaturity; grade 2 teratomas have a more extensive degree of immaturity; grade 3 teratomas are composed exclusively of immature tissues. The prognosis depends on patient age, tumor size and grade, and stage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CEF6-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-05-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-05-30","modifiedBy":"COOPERM","dateModified":"2012-11-09","changeDescription":"Added system generated definition for TCGA. mc 11/9/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3E3E-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"T-cell prolymphocytic leukemia","valueDescription":"T-Cell Prolymphocytic Leukemia","ValueMeaning":{"publicId":"2838858","version":"1","preferredName":"T-Cell Prolymphocytic Leukemia","longName":"2838858","preferredDefinition":"An aggressive T-cell leukemia, characterized by the proliferation of small to medium sized prolymphocytes with a mature T-cell phenotype, involving the blood, bone marrow, lymph nodes, liver, spleen, and skin.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Cell Prolymphocytic Leukemia","conceptCode":"C4752","definition":"An aggressive T-cell leukemia, characterized by the proliferation of small to medium sized prolymphocytes with a mature T-cell phenotype, involving the blood, bone marrow, lymph nodes, liver, spleen, and skin.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A98887-3A5F-9A11-E040-BB89AD434E3A","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3E53-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"T-cell leukemia","valueDescription":"Adult T-Cell Leukemia/Lymphoma","ValueMeaning":{"publicId":"4264852","version":"1","preferredName":"Adult T-Cell Leukemia/Lymphoma","longName":"4264852","preferredDefinition":"A peripheral (mature) T-cell neoplasm caused by the human T-cell leukemia virus type 1 (HTLV-1).  Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adult T-Cell Leukemia/Lymphoma","conceptCode":"C3184","definition":"A peripheral (mature) T-cell neoplasm linked to the human T-cell leukemia virus type 1 (HTLV-1).  Adult T-cell leukemia/lymphoma is endemic in several regions of the world, in particular Japan, the Caribbean, and parts of Central Africa.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67A42F0-025B-5F77-E040-BB89AD433177","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3E68-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"T-cell large granular lymphocytic leukemia","valueDescription":"T-Cell Chronic Lymphocytic Leukemia","ValueMeaning":{"publicId":"3338483","version":"1","preferredName":"T-Cell Chronic Lymphocytic Leukemia","longName":"3338483","preferredDefinition":"A slow-growing type of leukemia (blood cancer) in which too many lymphocytes are found in the bone marrow and/or blood.  The T-cell is specified as the defective cell line.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T-Cell Chronic Lymphocytic Leukemia","conceptCode":"C70649","definition":"A slow-growing type of leukemia (blood cancer) in which too many lymphocytes are found in the bone marrow and/or blood.  The T-cell is specified as the defective cell line.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4B1E777-0BEA-2D03-E040-BB89AD4355FC","latestVersionIndicator":"Yes","beginDate":"2011-12-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-12-22","modifiedBy":"ONEDATA","dateModified":"2011-12-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3E7C-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Superficial spreading","valueDescription":"Superficial Spreading Melanoma","ValueMeaning":{"publicId":"4264987","version":"1","preferredName":"Superficial Spreading Melanoma","longName":"4264987","preferredDefinition":"A type of melanoma that typically occurs in light-skinned individuals ranging in age from young adults to the elderly.  Risk factors include extensive sun exposure during childhood, a family history of melanoma, and the presence of dysplastic nevi.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Low-CSD Melanoma","conceptCode":"C9152","definition":"A type of melanoma that typically occurs in light-skinned individuals ranging in age from young adults to the elderly.  Risk factors include extensive sun exposure during childhood, a family history of melanoma, and the presence of dysplastic nevi.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3E87-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3EA0-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Storiform pleomorphic","valueDescription":"Storiform-Pleomorphic Malignant Fibrous Histiocytoma","ValueMeaning":{"publicId":"3179380","version":"1","preferredName":"Storiform-Pleomorphic Malignant Fibrous Histiocytoma","longName":"3179380","preferredDefinition":"A morphologic variant of malignant fibrous histiocytoma. It is well-circumscribed tumor characterized by the presence of bizarre giant cells, spindle cells, round histiocyte-like cells, stromal chronic inflammatory cells, and nuclear pleomorphism in a prominent storiform pattern.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Storiform-Pleomorphic Malignant Fibrous Histiocytoma","conceptCode":"C6495","definition":"A well-circumscribed sarcoma characterized by the presence of bizarre giant cells, spindle cells, round histiocyte-like cells, stromal chronic inflammatory cells, and nuclear pleomorphism in a prominent storiform pattern.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"98903582-4FB1-C5EF-E040-BB89AD431B68","latestVersionIndicator":"Yes","beginDate":"2010-12-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3EB4-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Squamous cell carcinoma","valueDescription":"Squamous Cell Carcinoma","ValueMeaning":{"publicId":"4264988","version":"1","preferredName":"Squamous Cell Carcinoma","longName":"4264988","preferredDefinition":"A carcinoma arising from squamous epithelial cells.  Morphologically, it is characterized by the proliferation of atypical, often pleomorphic squamous cells.  Squamous cell carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Well differentiated carcinomas are usually associated with keratin production and the presence of intercellular bridges between adjacent cells.  Representative examples are lung squamous cell carcinoma, skin squamous cell carcinoma, and cervical squamous cell carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Squamous Cell Carcinoma","conceptCode":"C2929","definition":"A carcinoma arising from squamous epithelial cells.  Morphologically, it is characterized by the proliferation of atypical, often pleomorphic squamous cells.  Squamous cell carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Well differentiated carcinomas are usually associated with keratin production and the presence of intercellular bridges between adjacent cells.  Representative examples are lung squamous cell carcinoma, skin squamous cell carcinoma, and cervical squamous cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3EBF-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3ED7-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Spitz","valueDescription":"Spitz Nevus","ValueMeaning":{"publicId":"4264990","version":"1","preferredName":"Spitz Nevus","longName":"4264990","preferredDefinition":"A benign, acquired or congenital, usually single skin lesion. It can occur on any area of the body, but most commonly occurs on the face of children and the thighs of young females. It is characterized by a proliferation of large spindle, oval, or large epithelioid melanocytes in the dermal-epidermal junction. The melanocytic proliferation subsequently extends into the dermis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Spitz Nevus","conceptCode":"C27007","definition":"A benign, acquired or congenital, usually single skin lesion. It can occur on any area of the body, but most commonly occurs on the face of children and the thighs of young females. It is characterized by a proliferation of large spindle, oval, or large epithelioid melanocytes in the dermal-epidermal junction. The melanocytic proliferation subsequently extends into the dermis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F681E9E5-3EE5-E912-E040-BB89AD433874","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3EFE-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Spindle cell carcinoma","valueDescription":"Sarcomatoid Carcinoma","ValueMeaning":{"publicId":"2838764","version":"1","preferredName":"Sarcomatoid Carcinoma","longName":"2838764","preferredDefinition":"Cancer that arises in cells that appear spindle-shaped when viewed under a microscope. These cancers can occur in various places in the body, including the skin, lungs, kidney, breast, gastrointestinal tract, bone, and muscle.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sarcomatoid Carcinoma","conceptCode":"C27004","definition":"A malignant epithelial neoplasm characterized by the presence of spindle cells and anaplastic morphologic features.  Giant cells and a sarcomatous component may also be present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A85C92-12DF-B23A-E040-BB89AD431D54","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3F12-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Spindle cell","valueDescription":"Spindle Cell Metaplasia","ValueMeaning":{"publicId":"3251407","version":"1","preferredName":"Spindle Cell Metaplasia","longName":"3251407","preferredDefinition":"A morphologic finding indicating the transformation of non-spindle cells to spindle-shaped cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Spindle Cell Metaplasia","conceptCode":"C54709","definition":"A morphologic finding indicating the transformation of non-spindle cells to spindle-shaped cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A758F49E-A5A5-73F4-E040-BB89AD430DFE","latestVersionIndicator":"Yes","beginDate":"2011-07-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-05","modifiedBy":"COOPERM","dateModified":"2011-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3F27-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Sonic hedgehog subtype","valueDescription":"Sonic Hedgehog Homolog","ValueMeaning":{"publicId":"3443063","version":"1","preferredName":"Sonic Hedgehog Homolog","longName":"3443063","preferredDefinition":"Expressed only during embryogenesis by human SHH Gene (Hedgehog Family), 462-aa 50-kDa (precursor) Sonic Hedgehog Homolog is the notochord inductive signal in ventral neural tube and somite patterning and the polarizing signal for anterior-posterior limb axis patterning. The C-terminal domain displays precursor processing autoproteolytic activity that generates the soluble signaling N-portion. With transferase activity, the C-portion covalently attaches cholesterol to the new N-product C-terminus, restricting it to the cell surface and regulating distribution of protein activity throughout the embryo. SHH binds to PTC receptor, releasing constitutive SMO repression and activating target gene transcription. Defects in SHH cause HPE3. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sonic Hedgehog Protein","conceptCode":"C29962","definition":"Sonic hedgehog protein (462 aa, ~50 kDa) is encoded by the human SHH gene. This protein plays a role in embryonic pattern formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BE966AC4-B310-AB82-E040-BB89AD435C86","latestVersionIndicator":"Yes","beginDate":"2012-04-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-26","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F681E9E5-3F3C-E912-E040-BB89AD433874","beginDate":"2014-04-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-08","modifiedBy":"ONEDATA","dateModified":"2014-04-08","deletedIndicator":"No"},{"value":"Anaplastic","valueDescription":"Anaplastic","ValueMeaning":{"publicId":"4360176","version":"1","preferredName":"Anaplastic","longName":"4360176","preferredDefinition":"A term used to describe cancer cells that divide rapidly and have little or no resemblance to normal cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anaplastic","conceptCode":"C14144","definition":"A term used to describe cancer cells that divide rapidly and have little or no resemblance to normal cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC2FF07C-5C01-E43C-E040-BB89AD4336C7","latestVersionIndicator":"Yes","beginDate":"2014-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FC2FF07C-5C1A-E43C-E040-BB89AD4336C7","beginDate":"2014-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-06-19","modifiedBy":"ONEDATA","dateModified":"2014-06-19","deletedIndicator":"No"},{"value":"Blast Phase","valueDescription":"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","ValueMeaning":{"publicId":"4360175","version":"1","preferredName":"Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","longName":"4360175","preferredDefinition":"An advanced phase of chronic myelogenous leukemia.  It is characterized by: 1.  the presence of blasts in the peripheral blood or bone marrow that are at least 20% of the peripheral blood white cells or of the nucleated cells in the bone marrow respectively, or 2. an extramedullary proliferation of blasts, and/or 3. when there are large aggregates and clusters of blasts in the bone marrow biopsy specimen (adapted from WHO, 2001).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C9110","definition":"An advanced phase of chronic myeloid leukemia.  It is characterized by: 1.  the presence of blasts in the peripheral blood or bone marrow that are at least 20% of the peripheral blood white cells or of the nucleated cells in the bone marrow respectively, or 2. an extramedullary proliferation of blasts, and/or 3. when there are large aggregates and clusters of blasts in the bone marrow biopsy specimen (adapted from WHO, 2001).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC2FF07C-5BDE-E43C-E040-BB89AD4336C7","latestVersionIndicator":"Yes","beginDate":"2014-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FC2FF07C-5BF7-E43C-E040-BB89AD4336C7","beginDate":"2014-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-06-19","modifiedBy":"ONEDATA","dateModified":"2014-06-19","deletedIndicator":"No"},{"value":"Aldosterone producing","valueDescription":"Aldosterone-Producing Adrenal Cortex Adenoma","ValueMeaning":{"publicId":"4360179","version":"1","preferredName":"Aldosterone-Producing Adrenal Cortex Adenoma","longName":"4360179","preferredDefinition":"An adenoma of the adrenal cortex that produces aldosterone.  It may be associated with Conn syndrome.  Clinical presentation includes hypertension, hypokalemia, and muscle weakness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aldosterone-Producing Adrenal Cortical Adenoma","conceptCode":"C48451","definition":"An adenoma of the adrenal cortex that produces aldosterone. It may be associated with Conn syndrome. Clinical presentation includes hypertension, hypokalemia, and muscle weakness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC2FF07C-5C4A-E43C-E040-BB89AD4336C7","latestVersionIndicator":"Yes","beginDate":"2014-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FC2FF07C-5C63-E43C-E040-BB89AD4336C7","beginDate":"2014-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-06-19","modifiedBy":"ONEDATA","dateModified":"2014-06-19","deletedIndicator":"No"},{"value":"Myalgic encephalomyelitis","valueDescription":"Myalgic Encephalomyelitis","ValueMeaning":{"publicId":"4264922","version":"1","preferredName":"Myalgic Encephalomyelitis","longName":"4264922","preferredDefinition":"Painful sensation originating from a muscle or group of muscles.: Inflammation of the brain and the spinal cord.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myalgia","conceptCode":"C27009","definition":"Painful sensation originating from a muscle or group of muscles.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Encephalomyelitis","conceptCode":"C34580","definition":"Inflammation of the brain and the spinal cord.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67FEF75-9F6B-6988-E040-BB89AD432041","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEF75-9F84-6988-E040-BB89AD432041","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Mucosal lentiginous","valueDescription":"Mucosal Lentiginous Melanoma","ValueMeaning":{"publicId":"2577108","version":"1","preferredName":"Mucosal Lentiginous Melanoma","longName":"2577108","preferredDefinition":"An acral lentiginous melanoma affecting mucosal surfaces.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucosal Lentiginous Melanoma","conceptCode":"C48622","definition":"An acral lentiginous melanoma affecting mucosal surfaces.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FA41-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-23","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-11-23","modifiedBy":"DWARZEL","dateModified":"2006-10-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEF75-9F98-6988-E040-BB89AD432041","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Mucoepidermoid carcinoma","valueDescription":"Mucoepidermoid Carcinoma","ValueMeaning":{"publicId":"3704622","version":"1","preferredName":"Mucoepidermoid Carcinoma","longName":"3704622","preferredDefinition":"A carcinoma morphologically characterized the presence of cuboidal mucous cells, goblet-like mucous cells, squamoid cells, cystic changes, and a fibrotic stromal formation. It can occur in several anatomic sites, including parotid gland, oral cavity, paranasal sinus, skin, breast, lung, larynx, and lacrimal ducts. It is classified as low or high grade.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucoepidermoid Carcinoma","conceptCode":"C3772","definition":"A carcinoma morphologically characterized the presence of cuboidal mucous cells, goblet-like mucous cells, squamoid cells, cystic changes, and a fibrotic stromal formation. It can occur in several anatomic sites, including parotid gland, oral cavity, paranasal sinus, skin, breast, lung, larynx, and lacrimal ducts. It is classified as low or high grade.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D902E31D-3B3E-5153-E040-BB89AD437E3A","latestVersionIndicator":"Yes","beginDate":"2013-03-28","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-03-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEF75-9FAD-6988-E040-BB89AD432041","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Mucinous carcinoma","valueDescription":"Mucinous Carcinoma","ValueMeaning":{"publicId":"3528691","version":"1","preferredName":"Mucinous Carcinoma","longName":"3528691","preferredDefinition":"containing or resembling mucin.: A malignant tumor arising from epithelial cells.  Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas.  Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis.  Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites.  Lung carcinoma, skin carcinoma, breast carcinoma, and prostate carcinoma are the most frequently seen carcinomas. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucinous","conceptCode":"C14163","definition":"Containing or resembling mucin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C50C722F-876C-9DCE-E040-BB89AD432F82","latestVersionIndicator":"Yes","beginDate":"2012-07-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEF75-9FC2-6988-E040-BB89AD432041","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Mucinous adenocarcinoma","valueDescription":"Mucinous Adenocarcinoma","ValueMeaning":{"publicId":"2838623","version":"1","preferredName":"Mucinous Adenocarcinoma","longName":"2838623","preferredDefinition":"An invasive adenocarcinoma composed of malignant glandular cells which contain intracytoplasmic mucin. Often, the infiltrating glandular structures are associated with mucoid stromal formation. It may arise from the large and small intestine, appendix, stomach, lung, ovary, breast, corpus uteri, cervix, vagina, and salivary gland.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucinous Adenocarcinoma","conceptCode":"C26712","definition":"An invasive adenocarcinoma composed of malignant glandular cells which contain intracytoplasmic mucin. Often, the infiltrating glandular structures are associated with mucoid stromal formation. It may arise from the large and small intestine, appendix, stomach, lung, ovary, breast, corpus uteri, cervix, vagina, and salivary gland.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6E019-596B-F2F6-E040-BB89AD4350E9","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"HARTLEYG","dateModified":"2017-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEF75-9FCC-6988-E040-BB89AD432041","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Mucinous","valueDescription":"Mucinous","ValueMeaning":{"publicId":"2838625","version":"1","preferredName":"Mucinous","longName":"2838625","preferredDefinition":"containing or resembling mucin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucinous","conceptCode":"C14163","definition":"Containing or resembling mucin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6E019-5991-F2F6-E040-BB89AD4350E9","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEF75-9FD7-6988-E040-BB89AD432041","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Mixed carcinoma","valueDescription":"Mixed Carcinoma","ValueMeaning":{"publicId":"4264923","version":"1","preferredName":"Mixed Carcinoma","longName":"4264923","preferredDefinition":"Involving or composed of different kinds.: A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed","conceptCode":"C25259","definition":"Involving or composed of different kinds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67FEF75-9FE5-6988-E040-BB89AD432041","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEF75-9FFE-6988-E040-BB89AD432041","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Mixed adenosquamous carcinoma","valueDescription":"Mixed (normal and tumor) Adenosquamous Carcinoma","ValueMeaning":{"publicId":"4264924","version":"1","preferredName":"Mixed (normal and tumor) Adenosquamous Carcinoma","longName":"4264924","preferredDefinition":"Mixed; being composed of a combination of normal and tumor cells.: A carcinoma composed of malignant glandular cells and malignant squamous cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed (Normal and Tumor)","conceptCode":"C26457","definition":"Mixed; being composed of a combination of normal and tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Adenosquamous Carcinoma","conceptCode":"C3727","definition":"An invasive carcinoma composed of malignant glandular cells and malignant squamous cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67FEF75-A00B-6988-E040-BB89AD432041","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEF75-A024-6988-E040-BB89AD432041","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Mixed","valueDescription":"Mixed (normal and tumor) histology","ValueMeaning":{"publicId":"4264925","version":"1","preferredName":"Mixed (normal and tumor) histology","longName":"4264925","preferredDefinition":"Mixed; being composed of a combination of normal and tumor cells.: The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed (Normal and Tumor)","conceptCode":"C26457","definition":"Mixed; being composed of a combination of normal and tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Histology","conceptCode":"C16681","definition":"The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67FEF75-A030-6988-E040-BB89AD432041","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEF75-A049-6988-E040-BB89AD432041","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Metaplastic carcinoma","valueDescription":"Metaplastic Carcinoma","ValueMeaning":{"publicId":"3248487","version":"1","preferredName":"Metaplastic Carcinoma","longName":"3248487","preferredDefinition":"A general term used to describe carcinomas arising from epithelial cells that have been transformed into another cells type (metaplastic epithelial cells). A representative example is the adenocarcinoma arising in Barrett esophagus. This term is also used to describe carcinomas in which the malignant epithelial cells show differentiation towards another cell type. A representative example of the latter is the metaplastic breast carcinoma in which the malignant glandular cells show squamous, spindle cell, or chondroid/osseous differentiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metaplastic Carcinoma","conceptCode":"C27949","definition":"A general term used to describe carcinomas arising from epithelial cells that have been transformed into another cells type (metaplastic epithelial cells). A representative example is the adenocarcinoma arising in Barrett esophagus. This term is also used to describe carcinomas in which the malignant epithelial cells show differentiation towards another cell type. A representative example of the latter is the metaplastic breast carcinoma in which the malignant glandular cells show squamous, spindle cell, or chondroid/osseous differentiation.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6B8531E-1718-F891-E040-BB89AD4324F8","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEF75-A05D-6988-E040-BB89AD432041","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Metaplasia","valueDescription":"Metaplasia","ValueMeaning":{"publicId":"2838903","version":"1","preferredName":"Metaplasia","longName":"2838903","preferredDefinition":"Transformation of a mature, normal cell or groups of mature cells to other forms of mature cells.  The capacity for malignant transformation of metaplastic cells is a subject of controversy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metaplasia","conceptCode":"C3236","definition":"Transformation of a mature, normal cell or groups of mature cells to other forms of mature cells.  The capacity for malignant transformation of metaplastic cells is a subject of controversy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62AB59ED-A521-4EBE-E040-BB89AD4348C8","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEF75-A067-6988-E040-BB89AD432041","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Merkel cell carcinoma","valueDescription":"Merkel Cell Carcinoma","ValueMeaning":{"publicId":"3210716","version":"1","preferredName":"Merkel Cell Carcinoma","longName":"3210716","preferredDefinition":"A rare malignant cutaneous tumor seen in elderly patients.  Its usual location is on the head, neck and extremities.  The tumor is composed of small round cells with scanty cytoplasm arranged in a trabecular pattern, or in ill-defined nodules or in a diffuse pattern.  The tumor cells contain cytoplasmic membrane-bound dense core granules resembling neurosecretory granules.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Merkel Cell Carcinoma","conceptCode":"C9231","definition":"A rare aggressive neuroendocrine carcinoma that usually arises from the skin. Rarely, it arises from extracutaneous sites, including the oral cavity, salivary glands, breast, vulva, and vaginal wall. The tumor is composed of small round cells with scanty cytoplasm. Merkel cell polyomavirus is implicated in the majority of cases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-935E-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEF75-A07C-6988-E040-BB89AD432041","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Meningothelial","valueDescription":"Meningothelial Cell Neoplasm","ValueMeaning":{"publicId":"4264927","version":"1","preferredName":"Meningothelial Cell Neoplasm","longName":"4264927","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Meningothelial Cell Neoplasm","conceptCode":"C6971","definition":"A neoplasm that arises from meningothelial cells. This category refers to meningiomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67FEF75-A08A-6988-E040-BB89AD432041","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEF75-A0A3-6988-E040-BB89AD432041","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Medullary carcinoma","valueDescription":"Thyroid Gland Medullary Carcinoma","ValueMeaning":{"publicId":"2861420","version":"1","preferredName":"Thyroid Gland Medullary Carcinoma","longName":"2861420","preferredDefinition":"A neuroendocrine carcinoma arising from the C-cells of the thyroid gland.  It is closely associated with multiple endocrine neoplasia syndromes.  Approximately 10% to 20% of medullary thyroid carcinomas are familial.  Patients usually present with a thyroid nodule that is painless and firm.  In the majority of cases nodal involvement is present at diagnosis.  Surgery is the preferred treatment for both primary lesions and recurrences.  This carcinoma is generally not very sensitive to radiation and almost unresponsive to chemotherapy.  - 2002","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Medullary Carcinoma","conceptCode":"C3879","definition":"A neuroendocrine carcinoma arising from the C-cells of the thyroid gland. It is closely associated with multiple endocrine neoplasia syndromes. Approximately 10% to 20% of medullary thyroid carcinomas are familial. Patients usually present with a thyroid nodule that is painless and firm. In the majority of cases nodal involvement is present at diagnosis. Surgery is the preferred treatment for both primary lesions and recurrences. This carcinoma is generally not very sensitive to radiation and almost unresponsive to chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"67B13250-5416-3FB8-E040-BB89AD43483F","latestVersionIndicator":"Yes","beginDate":"2009-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-04-16","modifiedBy":"ONEDATA","dateModified":"2009-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEF75-A0B7-6988-E040-BB89AD432041","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Mast cell neoplasm","valueDescription":"Mast Cell Neoplasm","ValueMeaning":{"publicId":"4264929","version":"1","preferredName":"Mast Cell Neoplasm","longName":"4264929","preferredDefinition":"A heterogeneous group of disorders characterized by the abnormal growth and accumulation of mast cells in one or more organ systems.  Recent data suggest that most variants of mast cell neoplasms are clonal disorders. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mast Cell Neoplasm","conceptCode":"C9295","definition":"A heterogeneous group of disorders characterized by the abnormal growth and accumulation of mast cells in one or more organ systems.  Recent data suggest that most variants of mast cell neoplasms are clonal disorders. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67FEF75-A0C5-6988-E040-BB89AD432041","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEF75-A0DE-6988-E040-BB89AD432041","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Marginal zone lymphoma","valueDescription":"Marginal Zone Lymphoma","ValueMeaning":{"publicId":"3251331","version":"1","preferredName":"Marginal Zone Lymphoma","longName":"3251331","preferredDefinition":"A usually indolent mature B-cell lymphoma, arising from the marginal zone of lymphoid tissues.  It is characterized by the presence of small to medium sized atypical lymphocytes.  It comprises three entities, according to the anatomic sites involved: extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, which affects extranodal sites (most often stomach, lung, skin, and ocular adnexa); nodal marginal zone B-cell lymphoma, which affects lymph nodes without evidence of extranodal disease; and splenic marginal zone B-cell lymphoma, which affects the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Marginal Zone Lymphoma","conceptCode":"C4341","definition":"A usually indolent mature B-cell lymphoma, arising from the marginal zone of lymphoid tissues.  It is characterized by the presence of small to medium sized atypical lymphocytes.  It comprises three entities, according to the anatomic sites involved: extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, which affects extranodal sites (most often stomach, lung, skin, and ocular adnexa); nodal marginal zone B-cell lymphoma, which affects lymph nodes without evidence of extranodal disease; and splenic marginal zone B-cell lymphoma, which affects the spleen and splenic hilar lymph nodes, bone marrow, and often the peripheral blood.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A758F49E-9C05-73F4-E040-BB89AD430DFE","latestVersionIndicator":"Yes","beginDate":"2011-07-05","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-05","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEF75-A0F2-6988-E040-BB89AD432041","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Mantle cell lymphoma","valueDescription":"Mantle Cell Lymphoma","ValueMeaning":{"publicId":"2838603","version":"1","preferredName":"Mantle Cell Lymphoma","longName":"2838603","preferredDefinition":"An aggressive, usually diffuse non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes).  Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement.  The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma.  The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mantle Cell Lymphoma","conceptCode":"C4337","definition":"A non-Hodgkin lymphoma composed of small to medium sized B-lymphocytes (centrocytes). Most patients present with advanced stage disease with lymphadenopathy, hepatosplenomegaly, and bone marrow involvement. The gastrointestinal tract is the most commonly affected extranodal site by this type of non-Hodgkin lymphoma. The vast majority of cases express the t(11;14)(q13;q32) resulting in the rearrangement of the BCL-1 gene and the overexpression of cyclin D1 mRNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A6485A-AE62-B656-E040-BB89AD437D5F","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"COOPERM","dateModified":"2017-10-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEF75-A0FD-6988-E040-BB89AD432041","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Malignant mesothelioma","valueDescription":"Malignant Mesothelioma","ValueMeaning":{"publicId":"4264931","version":"1","preferredName":"Malignant Mesothelioma","longName":"4264931","preferredDefinition":"A malignant neoplasm of the pleura or peritoneum, arising from mesothelial cells.  It is associated with exposure to asbestos.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Mesothelioma","conceptCode":"C4456","definition":"A malignant neoplasm that arises from mesothelial cells, usually in the pleura or peritoneum. It is associated with exposure to asbestos.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67FEF75-A10B-6988-E040-BB89AD432041","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEF75-A124-6988-E040-BB89AD432041","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Malignant mesodermal mixed tumor","valueDescription":"Malignant Mixed Mesodermal (Mullerian) Tumor","ValueMeaning":{"publicId":"4264932","version":"1","preferredName":"Malignant Mixed Mesodermal (Mullerian) Tumor","longName":"4264932","preferredDefinition":"An aggressive malignant tumor of the female reproductive system, affecting predominantly elderly menopausal women.  The endometrium and ovary are the most common sites of tumor origin.  Morphologically, it is a high grade tumor, composed of carcinomatous and sarcomatous elements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant Mixed Mesodermal (Mullerian) Tumor","conceptCode":"C8975","definition":"An aggressive malignant tumor of the female reproductive system, affecting predominantly elderly menopausal women.  The endometrium and ovary are the most common sites of tumor origin.  Morphologically, it is a high grade tumor, composed of carcinomatous and sarcomatous elements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67FEF75-A130-6988-E040-BB89AD432041","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEF75-A149-6988-E040-BB89AD432041","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Malignant adnexal tumor","valueDescription":"Malignant Adnexal Mass","ValueMeaning":{"publicId":"4264933","version":"1","preferredName":"Malignant Adnexal Mass","longName":"4264933","preferredDefinition":"Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host.: A lump in tissue near the uterus, usually in the ovary or fallopian tube. Adnexal masses include ovarian cysts, ectopic (tubal) pregnancies, and benign (not cancer) or malignant (cancer) tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Malignant","conceptCode":"C14143","definition":"Refers to abnormal cell activity manifested by decreased control over growth and function, causing tumor growth or spread into surrounding tissue and adverse effects to the host.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Adnexal Mass","conceptCode":"C35155","definition":"An abnormal growth in the ovary, fallopian tube, or surrounding connective tissue.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67FEF75-A156-6988-E040-BB89AD432041","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEF75-A16F-6988-E040-BB89AD432041","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Lymphatoid papulosis","valueDescription":"Lymphomatoid Papulosis","ValueMeaning":{"publicId":"2838593","version":"1","preferredName":"Lymphomatoid Papulosis","longName":"2838593","preferredDefinition":"This is a chronic, recurrent skin disease characterized by spontaneously regressing papules composed of an atypical CD30-positive T-cell population.  The disease is defined as an atypical lymphoproliferative process and usually has a benign course.  However, a minority of cases are clonal and can progress to frank lymphoma.  Low dose methotrexate and psoralen/UVA (PUVA) are the best available therapies.  (WHO, 2001) -- 2003","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphomatoid Papulosis","conceptCode":"C3721","definition":"A chronic, recurrent cutaneous disorder characterized by the presence of spontaneously regressing papules.  The papules are composed of an atypical lymphocytic infiltrate that contains anaplastic CD30-positive T-cells, which are found in type A and diffuse large cell type (type C) lymphomatoid papulosis.  In a small number of cases, of type B, the lymphocytic infiltrate is composed of small, cerebriform-like lymphocytes that are often negative for CD30.  The majority of cases follow a benign clinical course, but some cases are clonal and may progress to lymphoma.  Treatment options include low dose methotrexate and psoralen/UVA (PUVA).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62A5F1C9-F7CE-B082-E040-BB89AD436154","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEF75-A183-6988-E040-BB89AD432041","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Luteinizing hormone","valueDescription":"Luteinizing Hormone Measurement","ValueMeaning":{"publicId":"3293685","version":"1","preferredName":"Luteinizing Hormone Measurement","longName":"3293685","preferredDefinition":"The determination of the amount of luteinizing hormone present in a sample.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Luteinizing Hormone Measurement","conceptCode":"C74790","definition":"The determination of the amount of luteinizing hormone present in a sample.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AF074E37-E5FE-1C17-E040-BB89AD431694","latestVersionIndicator":"Yes","beginDate":"2011-10-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-11","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F67FEF75-A198-6988-E040-BB89AD432041","beginDate":"2014-04-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-07","modifiedBy":"ONEDATA","dateModified":"2014-04-07","deletedIndicator":"No"},{"value":"Adamantinomatous","valueDescription":"Adamantinoma","ValueMeaning":{"publicId":"4263971","version":"1","preferredName":"Adamantinoma","longName":"4263971","preferredDefinition":"A low grade malignant biphasic tumor characterized by a variety of morphologic patterns, most commonly epithelial cells surrounded by a relatively bland spindle-cell osteofibrous component. The tibia is the most commonly affected site. (WHO 2002)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adamantinoma","conceptCode":"C7644","definition":"A low grade malignant neoplasm arising from the long bones. The tibia is the most frequently affected bone site. Patients present with swelling which may or may not be associated with pain. Morphologically, it is characterized by a biphasic pattern consisting of an epithelial and an osteofibrous component. The vast majority of cases recur if they are not treated with radical surgery. In a minority of cases the tumor may metastasize to other anatomic sites including lymph nodes, lungs, liver, brain, and skeleton.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-10ED-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F63DCAA0-1106-5D4B-E040-BB89AD432C9C","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"ONEDATA","dateModified":"2014-04-04","deletedIndicator":"No"},{"value":"Acute myeloid leukemia","valueDescription":"Acute Myeloid Leukemia","ValueMeaning":{"publicId":"4263972","version":"1","preferredName":"Acute Myeloid Leukemia","longName":"4263972","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-1110-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2022-05-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F63DCAA0-1129-5D4B-E040-BB89AD432C9C","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"ONEDATA","dateModified":"2014-04-04","deletedIndicator":"No"},{"value":"Acute lymphoblastic T cell leukemia","valueDescription":"T Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"4263973","version":"1","preferredName":"T Acute Lymphoblastic Leukemia","longName":"4263973","preferredDefinition":"Acute lymphoblastic leukemia of T-cell origin.  It comprises about 15% of childhood cases and 25% of adult cases.  It is more common in males than females.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"T Acute Lymphoblastic Leukemia","conceptCode":"C3183","definition":"Acute lymphoblastic leukemia of T-cell origin.  It comprises about 15% of childhood cases and 25% of adult cases.  It is more common in males than females.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-1133-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F63DCAA0-114C-5D4B-E040-BB89AD432C9C","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"ONEDATA","dateModified":"2014-04-04","deletedIndicator":"No"},{"value":"Acute lymphoblastic B cell leukemia","valueDescription":"B Acute Lymphoblastic Leukemia","ValueMeaning":{"publicId":"4263974","version":"1","preferredName":"B Acute Lymphoblastic Leukemia","longName":"4263974","preferredDefinition":"The most frequent type of acute lymphoblastic leukemia.  Approximately 75% of cases occur in children under six years of age.  This is a good prognosis leukemia.  In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%.  Approximately 80% of children appear to be cured.  In the adult age group the complete remission rate is 60-85%.  (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"B Acute Lymphoblastic Leukemia","conceptCode":"C8644","definition":"The most frequent type of acute lymphoblastic leukemia.  Approximately 75% of cases occur in children under six years of age.  This is a good prognosis leukemia.  In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%.  Approximately 80% of children appear to be cured.  In the adult age group the complete remission rate is 60-85%.  (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-1156-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"KUMMEROA","dateModified":"2023-12-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F63DCAA0-116F-5D4B-E040-BB89AD432C9C","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"ONEDATA","dateModified":"2014-04-04","deletedIndicator":"No"},{"value":"Adenosquamous carcinoma","valueDescription":"Adenosquamous Carcinoma","ValueMeaning":{"publicId":"4264016","version":"1","preferredName":"Adenosquamous Carcinoma","longName":"4264016","preferredDefinition":"A carcinoma composed of malignant glandular cells and malignant squamous cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenosquamous Carcinoma","conceptCode":"C3727","definition":"An invasive carcinoma composed of malignant glandular cells and malignant squamous cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-11A0-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F63DCAA0-11B9-5D4B-E040-BB89AD432C9C","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"ONEDATA","dateModified":"2014-04-04","deletedIndicator":"No"},{"value":"Adenoid cystic carcinoma","valueDescription":"Adenoid Cystic Carcinoma","ValueMeaning":{"publicId":"4264017","version":"1","preferredName":"Adenoid Cystic Carcinoma","longName":"4264017","preferredDefinition":"A malignant tumor arising from the epithelial cells.  Microscopically, the neoplastic epithelial cells form cylindrical spatial configurations (cribriform or classic type of adenoid cystic carcinoma), cordlike structures (tubular type of adenoid cystic carcinoma), or solid structures (basaloid variant of adenoid cystic carcinoma).  Adenoid cystic carcinomas mostly occur in the salivary glands.  Other primary sites of involvement include the lacrimal gland, the larynx, and the lungs.  Adenoid cystic carcinomas spread along nerve sheaths, resulting in severe pain, and they tend to recur.  Lymph node metastases are unusual; hematogenous tumor spread is characteristic.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenoid Cystic Carcinoma","conceptCode":"C2970","definition":"A malignant tumor arising from the epithelial cells.  Microscopically, the neoplastic epithelial cells form cylindrical spatial configurations (cribriform or classic type of adenoid cystic carcinoma), cordlike structures (tubular type of adenoid cystic carcinoma), or solid structures (basaloid variant of adenoid cystic carcinoma).  Adenoid cystic carcinomas mostly occur in the salivary glands.  Other primary sites of involvement include the lacrimal gland, the larynx, and the lungs.  Adenoid cystic carcinomas spread along nerve sheaths, resulting in severe pain, and they tend to recur.  Lymph node metastases are unusual; hematogenous tumor spread is characteristic.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F63DCAA0-11C3-5D4B-E040-BB89AD432C9C","latestVersionIndicator":"Yes","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F63DCAA0-11DB-5D4B-E040-BB89AD432C9C","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"ONEDATA","dateModified":"2014-04-04","deletedIndicator":"No"},{"value":"Adenofibroma","valueDescription":"Adenofibroma","ValueMeaning":{"publicId":"3247886","version":"1","preferredName":"Adenofibroma","longName":"3247886","preferredDefinition":"A benign neoplasm characterized by the presence of connective tissue stroma and epithelial structures. It occurs in the ovary, fallopian tube, uterine corpus, and cervix. Cases of adenofibroma of the ovary with low grade malignant potential have also been reported.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Female Reproductive System Adenofibroma","conceptCode":"C8984","definition":"A benign or borderline neoplasm characterized by the presence of connective tissue stroma and epithelial structures. It occurs in the ovary, fallopian tube, uterine corpus, and cervix.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A67A743F-6100-D6C3-E040-BB89AD436761","latestVersionIndicator":"Yes","beginDate":"2011-06-24","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-24","modifiedBy":"COOPERM","dateModified":"2011-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F63DCAA0-11E6-5D4B-E040-BB89AD432C9C","beginDate":"2014-04-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-04","modifiedBy":"ONEDATA","dateModified":"2014-04-04","deletedIndicator":"No"},{"value":"Peripheral T cell lymphoma","valueDescription":"Peripheral T-Cell Lymphoma, Not Otherwise Specified","ValueMeaning":{"publicId":"4173735","version":"1","preferredName":"Peripheral T-Cell Lymphoma, Not Otherwise Specified","longName":"4173735","preferredDefinition":"Aggressive nodal or extranodal mature (peripheral) T-cell lymphomas that do not belong to the better defined entities of the remainder of mature T-cell lymphomas.  This category includes the following variants: lymphoepithelioid cell variant (Lennert's lymphoma), follicular variant, and T-zone variant.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peripheral T-Cell Lymphoma, Not Otherwise Specified","conceptCode":"C4340","definition":"A group of peripheral T-cell lymphomas that do not meet the criteria for any other category of specifically defined entities of peripheral T-cell lymphoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F33D84E5-7AD8-4906-E040-BB89AD434E8B","latestVersionIndicator":"Yes","beginDate":"2014-02-25","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2014-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F6B3760D-D691-8441-E040-BB89AD431F60","beginDate":"2014-04-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-04-10","modifiedBy":"ONEDATA","dateModified":"2014-04-10","deletedIndicator":"No"},{"value":"Acute Leukemia","valueDescription":"Acute Leukemia","ValueMeaning":{"publicId":"2590858","version":"1","preferredName":"Acute Leukemia","longName":"2590858","preferredDefinition":"leukemia in which the involved cell shows little or no differentiation, usually consisting of blast cells; two types are distinguished, acute lymphocytic and acute myelogenous leukemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Leukemia","conceptCode":"C9300","definition":"A clonal (malignant) hematopoietic disorder with an acute onset, affecting the bone marrow and the peripheral blood.  The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28446C9F-B57E-188F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-01-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F46DA4A4-156D-3FBD-E040-BB89AD431BE9","beginDate":"2014-03-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-12","modifiedBy":"ONEDATA","dateModified":"2014-03-12","deletedIndicator":"No"},{"value":"Adenocarcinoma","valueDescription":"Adenocarcinoma","ValueMeaning":{"publicId":"2567203","version":"1","preferredName":"Adenocarcinoma","longName":"2567203","preferredDefinition":"A common cancer characterized by the presence of malignant glandular cells. Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous). Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenocarcinoma","conceptCode":"C2852","definition":"A common cancer characterized by the presence of malignant glandular cells.  Morphologically, adenocarcinomas are classified according to the growth pattern (e.g., papillary, alveolar) or according to the secreting product (e.g., mucinous, serous).  Representative examples of adenocarcinoma are ductal and lobular breast carcinoma, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma (hepatoma), colon adenocarcinoma, and prostate adenocarcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D390-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F46DA4A4-1578-3FBD-E040-BB89AD431BE9","beginDate":"2014-03-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-12","modifiedBy":"ONEDATA","dateModified":"2014-03-12","deletedIndicator":"No"},{"value":"Adenoma","valueDescription":"Adenoma","ValueMeaning":{"publicId":"2574990","version":"1","preferredName":"Adenoma","longName":"2574990","preferredDefinition":"A neoplasm arising from the epithelium.  It may be encapsulated or non-encapsulated but non-invasive.  The neoplastic epithelial cells may or may not display cellular atypia or dysplasia.  In the gastrointestinal tract, when dysplasia becomes severe it is sometimes called carcinoma in situ.  Representative examples are pituitary gland adenoma, follicular adenoma of the thyroid gland, and adenomas (or adenomatous polyps) of the gastrointestinal tract.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenoma","conceptCode":"C2855","definition":"A neoplasm arising from the epithelium.  It may be encapsulated or non-encapsulated but non-invasive.  The neoplastic epithelial cells may or may not display cellular atypia or dysplasia.  In the gastrointestinal tract, when dysplasia becomes severe it is sometimes called carcinoma in situ.  Representative examples are pituitary gland adenoma, follicular adenoma of the thyroid gland, and adenomas (or adenomatous polyps) of the gastrointestinal tract.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F1FB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-05-23","modifiedBy":"COOPERM","dateModified":"2016-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F46DA4A4-1582-3FBD-E040-BB89AD431BE9","beginDate":"2014-03-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-12","modifiedBy":"ONEDATA","dateModified":"2014-03-12","deletedIndicator":"No"},{"value":"Alveolar","valueDescription":"Alveolar","ValueMeaning":{"publicId":"4214606","version":"1","preferredName":"Alveolar","longName":"4214606","preferredDefinition":"Of or relating to the alveoli.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alveolar","conceptCode":"C14155","definition":"Of or relating to the alveoli.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F46DA4A4-1598-3FBD-E040-BB89AD431BE9","latestVersionIndicator":"Yes","beginDate":"2014-03-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F46DA4A4-15B1-3FBD-E040-BB89AD431BE9","beginDate":"2014-03-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-12","modifiedBy":"ONEDATA","dateModified":"2014-03-12","deletedIndicator":"No"},{"value":"Immortalized Embryonic Fibroblast","valueDescription":"Immortalization Embryonic Fibroblast","ValueMeaning":{"publicId":"4379581","version":"1","preferredName":"Immortalization Embryonic Fibroblast","longName":"4379581","preferredDefinition":"Laboratory methods used to generate cells that are able to reproduce indefinitely.: Having to do with an embryo, which is an early stage in the development of a plant or animal.: A connective tissue cell that makes and secretes collagen proteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immortalization","conceptCode":"C82424","definition":"Laboratory methods used to generate cells that are able to reproduce indefinitely.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Embryonic","conceptCode":"C34100","definition":"Having to do with an embryo, which is an early stage in the development of a plant or animal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Fibroblast","conceptCode":"C12482","definition":"A connective tissue cell that makes and secretes collagen proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD386F36-4EF6-8B64-E040-BB89AD43596C","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD386F36-4F0F-8B64-E040-BB89AD43596C","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"ONEDATA","dateModified":"2014-07-02","deletedIndicator":"No"},{"value":"Glandular Intraepithelial Neoplasia Grade III","valueDescription":"Grade 3 Gland Intraepithelial Neoplasia","ValueMeaning":{"publicId":"4379582","version":"1","preferredName":"Grade 3 Gland Intraepithelial Neoplasia","longName":"4379582","preferredDefinition":"A morphologic qualifier indicating that a cancerous lesion is poorly differentiated.: An organ that makes one or more substances, such as hormones, digestive juices, sweat, tears, saliva, or milk. Endocrine glands release the substances directly into the bloodstream. Exocrine glands release the substances into a duct or opening to the inside or outside of the body.: A precancerous neoplastic process that affects the squamous, glandular, or transitional cell epithelium without evidence of invasion. According to the degree of nuclear atypia, number of mitotic figures, and presence of architectural distortion, it is classified as low grade (mild dysplasia) or high grade (moderate or severe dysplasia).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 3","conceptCode":"C28079","definition":"A morphologic qualifier indicating that a cancerous lesion is poorly differentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Gland","conceptCode":"C13319","definition":"An organ that produces and secretes hormones (e.g. endocrine gland), saliva or sweat (e.g. exocrine gland).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Intraepithelial Neoplasia","conceptCode":"C8366","definition":"A precancerous neoplastic process that affects the squamous, glandular, or transitional cell epithelium without evidence of invasion. According to the degree of nuclear atypia, number of mitotic figures, and presence of architectural distortion, it is classified as low grade (mild dysplasia) or high grade (moderate or severe dysplasia).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD386F36-4F23-8B64-E040-BB89AD43596C","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD386F36-4F3C-8B64-E040-BB89AD43596C","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"ONEDATA","dateModified":"2014-07-02","deletedIndicator":"No"},{"value":"Follicular Carcinoma","valueDescription":"Follicle Carcinoma","ValueMeaning":{"publicId":"4379583","version":"1","preferredName":"Follicle Carcinoma","longName":"4379583","preferredDefinition":"Any small spherical group of cells containing a cavity.: A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Follicle","conceptCode":"C61362","definition":"Any small spherical group of cells containing a cavity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD386F36-4F49-8B64-E040-BB89AD43596C","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD386F36-4F62-8B64-E040-BB89AD43596C","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"ONEDATA","dateModified":"2014-07-02","deletedIndicator":"No"},{"value":"ex Pleomorphic Adenoma Carcinoma","valueDescription":"Carcinoma ex Pleomorphic Adenoma","ValueMeaning":{"publicId":"3248469","version":"1","preferredName":"Carcinoma ex Pleomorphic Adenoma","longName":"3248469","preferredDefinition":"A carcinoma arising in a pre-existing pleomorphic adenoma. It most often occurs in the parotid gland and less often in the submandibular gland and minor salivary gland. Patients usually present with a history of a long-standing mass which recently had undergone rapid growth. The prognosis depends on the invasiveness of the malignant component. Patients with non-invasive or minimally invasive tumors usually have a good prognosis following surgical resection. Invasive tumors are usually aggressive and are associated with recurrences and metastases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carcinoma ex Pleomorphic Adenoma","conceptCode":"C4397","definition":"A carcinoma arising in a pre-existing pleomorphic adenoma. It most often occurs in the parotid gland and less often in the submandibular gland and minor salivary gland. Patients usually present with a history of a long-standing mass which recently had undergone rapid growth. The prognosis depends on the invasiveness of the malignant component. Patients with non-invasive or minimally invasive tumors usually have a good prognosis following surgical resection. Invasive tumors are usually aggressive and are associated with recurrences and metastases.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6B722DF-A84C-76E3-E040-BB89AD43333E","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD386F36-4F76-8B64-E040-BB89AD43596C","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"ONEDATA","dateModified":"2014-07-02","deletedIndicator":"No"},{"value":"Virilizing syndrome producing","valueDescription":"Virilizing syndrome producing","ValueMeaning":{"publicId":"4419631","version":"1","preferredName":"Virilizing syndrome producing","longName":"4419631","preferredDefinition":"The development of normal male puberty due to testosterone effect or the abnormal development of male secondary sexual characteristics in children and females due to excessive androgens.::0: a set of symptoms, usually three or more, which occur together and characterize a particular pathological state; for thorough searching see the Permuted Term Index for specific syndromes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Virilization","conceptCode":"C120262","definition":"The development of normal male puberty due to testosterone effect or the abnormal development of male secondary sexual characteristics in children and females due to excessive androgens.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Syndrome","conceptCode":"C28193","definition":"A group of signs, symptoms, and clinicopathological characteristics that may or may not have a genetic basis and collectively define an abnormal condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6D3778-2CDD-5529-E040-BB89AD43092C","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6D3778-2CF6-5529-E040-BB89AD43092C","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Dysplasia","valueDescription":"Dysplasia","ValueMeaning":{"publicId":"2838899","version":"1","preferredName":"Dysplasia","longName":"2838899","preferredDefinition":"A usually neoplastic transformation of the cell, associated with altered architectural tissue patterns.  The cellular changes include nuclear and cytoplasmic abnormalities.  Molecular genetic abnormalities are also often found and, in some instances, may lead to cancer. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dysplasia","conceptCode":"C4086","definition":"A usually neoplastic transformation of the cell, associated with altered architectural tissue patterns. The cellular changes include nuclear and cytoplasmic abnormalities. Molecular genetic abnormalities are also often found and, in some instances, may lead to cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62AB59ED-A4B7-4EBE-E040-BB89AD4348C8","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD386F36-4F9E-8B64-E040-BB89AD43596C","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"ONEDATA","dateModified":"2014-07-02","deletedIndicator":"No"},{"value":"Congenital Nevus","valueDescription":"Congenital Melanocytic Nevus","ValueMeaning":{"publicId":"4379584","version":"1","preferredName":"Congenital Melanocytic Nevus","longName":"4379584","preferredDefinition":"A melanocytic nevus that is present at birth. It may present as a small macular, papular, or plaque-like lesion or as a large brown to black hairy skin lesion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Melanocytic Nevus","conceptCode":"C3944","definition":"A melanocytic nevus that is present at birth. It may present as a small macular, papular, or plaque-like lesion or as a large brown to black hairy skin lesion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD386F36-4FAB-8B64-E040-BB89AD43596C","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD386F36-4FC4-8B64-E040-BB89AD43596C","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"ONEDATA","dateModified":"2014-07-02","deletedIndicator":"No"},{"value":"Chronic Myeloid Leukemia","valueDescription":"Chronic Myeloid Leukemia","ValueMeaning":{"publicId":"2573463","version":"1","preferredName":"Chronic Myeloid Leukemia","longName":"2573463","preferredDefinition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EC04-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-03-15","modifiedBy":"REEVESD","dateModified":"2014-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD386F36-4FCE-8B64-E040-BB89AD43596C","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"ONEDATA","dateModified":"2014-07-02","deletedIndicator":"No"},{"value":"Cervical Intraepithelial Neoplasia Grade III","valueDescription":"Grade 3 Cervical Intraepithelial Neoplasia","ValueMeaning":{"publicId":"4379585","version":"1","preferredName":"Grade 3 Cervical Intraepithelial Neoplasia","longName":"4379585","preferredDefinition":"A morphologic qualifier indicating that a cancerous lesion is poorly differentiated.: Squamous or glandular intraepithelial neoplasia that affects the cervical mucosal epithelium. There is no evidence of stromal invasion. According to the degree of cellular atypia and the associated architectural changes, it is classified as low or high grade.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 3","conceptCode":"C28079","definition":"A morphologic qualifier indicating that a cancerous lesion is poorly differentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cervical Intraepithelial Neoplasia","conceptCode":"C3782","definition":"Squamous or glandular intraepithelial neoplasia that affects the cervical mucosal epithelium. There is no evidence of stromal invasion. According to the degree of cellular atypia and the associated architectural changes, it is classified as low or high grade.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD386F36-4FDC-8B64-E040-BB89AD43596C","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD386F36-4FF5-8B64-E040-BB89AD43596C","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"ONEDATA","dateModified":"2014-07-02","deletedIndicator":"No"},{"value":"Cervical Intraepithelial Neoplasia Grade I","valueDescription":"Grade 1 Cervical Intraepithelial Neoplasia","ValueMeaning":{"publicId":"4379586","version":"1","preferredName":"Grade 1 Cervical Intraepithelial Neoplasia","longName":"4379586","preferredDefinition":"A morphologic qualifier indicating that a cancerous lesion is well differentiated.: Squamous or glandular intraepithelial neoplasia that affects the cervical mucosal epithelium. There is no evidence of stromal invasion. According to the degree of cellular atypia and the associated architectural changes, it is classified as low or high grade.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 1","conceptCode":"C28077","definition":"A morphologic qualifier indicating that a cancerous lesion is well differentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cervical Intraepithelial Neoplasia","conceptCode":"C3782","definition":"Squamous or glandular intraepithelial neoplasia that affects the cervical mucosal epithelium. There is no evidence of stromal invasion. According to the degree of cellular atypia and the associated architectural changes, it is classified as low or high grade.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD386F36-5002-8B64-E040-BB89AD43596C","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD386F36-501B-8B64-E040-BB89AD43596C","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"ONEDATA","dateModified":"2014-07-02","deletedIndicator":"No"},{"value":"Astrocytoma Grade IV","valueDescription":"Grade 4 Astrocytoma","ValueMeaning":{"publicId":"4379587","version":"1","preferredName":"Grade 4 Astrocytoma","longName":"4379587","preferredDefinition":"A morphologic qualifier indicating that a cancerous lesion is undifferentiated.: A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 4","conceptCode":"C28082","definition":"A morphologic qualifier indicating that a cancerous lesion is undifferentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Astrocytoma","conceptCode":"C60781","definition":"A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD386F36-5028-8B64-E040-BB89AD43596C","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD386F36-5041-8B64-E040-BB89AD43596C","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"ONEDATA","dateModified":"2014-07-02","deletedIndicator":"No"},{"value":"Astrocytoma Grade III","valueDescription":"Grade 3 Astrocytoma","ValueMeaning":{"publicId":"4379588","version":"1","preferredName":"Grade 3 Astrocytoma","longName":"4379588","preferredDefinition":"A morphologic qualifier indicating that a cancerous lesion is poorly differentiated.: A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 3","conceptCode":"C28079","definition":"A morphologic qualifier indicating that a cancerous lesion is poorly differentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Astrocytoma","conceptCode":"C60781","definition":"A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD386F36-504E-8B64-E040-BB89AD43596C","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD386F36-5067-8B64-E040-BB89AD43596C","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"ONEDATA","dateModified":"2014-07-02","deletedIndicator":"No"},{"value":"Astrocytoma Grade II","valueDescription":"Grade 2 Astrocytoma","ValueMeaning":{"publicId":"4379589","version":"1","preferredName":"Grade 2 Astrocytoma","longName":"4379589","preferredDefinition":"A morphologic qualifier indicating that a cancerous lesion is moderately differentiated.: A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 2","conceptCode":"C28078","definition":"A morphologic qualifier indicating that a cancerous lesion is moderately differentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Astrocytoma","conceptCode":"C60781","definition":"A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD386F36-5074-8B64-E040-BB89AD43596C","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD386F36-508D-8B64-E040-BB89AD43596C","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"ONEDATA","dateModified":"2014-07-02","deletedIndicator":"No"},{"value":"Astrocytoma Grade I","valueDescription":"Grade 1 Astrocytoma","ValueMeaning":{"publicId":"4379590","version":"1","preferredName":"Grade 1 Astrocytoma","longName":"4379590","preferredDefinition":"A morphologic qualifier indicating that a cancerous lesion is well differentiated.: A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 1","conceptCode":"C28077","definition":"A morphologic qualifier indicating that a cancerous lesion is well differentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Astrocytoma","conceptCode":"C60781","definition":"A tumor of the brain or spinal cord showing astrocytic differentiation. It includes the following clinicopathological entities: pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, pleomorphic xanthoastrocytoma, and subependymal giant cell astrocytoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD386F36-509A-8B64-E040-BB89AD43596C","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FD386F36-50B3-8B64-E040-BB89AD43596C","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-02","modifiedBy":"ONEDATA","dateModified":"2014-07-02","deletedIndicator":"No"},{"value":"Unclassifiable","valueDescription":"Unclassifiable","ValueMeaning":{"publicId":"4419632","version":"1","preferredName":"Unclassifiable","longName":"4419632","preferredDefinition":"A lesion that has overlapping histopathologic features that make its exact diagnosis and classification difficult.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified Lesion","conceptCode":"C128698","definition":"A lesion in which further histopathological and/or molecular characterization is not possible, available, or reported.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6D3778-2D00-5529-E040-BB89AD43092C","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6D3778-2D19-5529-E040-BB89AD43092C","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"WNT subtype","valueDescription":"WNT signaling pathway aberrant medulloblastoma","ValueMeaning":{"publicId":"4419656","version":"1","preferredName":"WNT signaling pathway aberrant medulloblastoma","longName":"4419656","preferredDefinition":"A molecular subtype of medulloblastoma associated with activation of the WNT pathway. TP53 mutations may be present or absent. WNT pathway activation in medulloblastomas is associated with good outcome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medulloblastoma, WNT-Activated","conceptCode":"C129440","definition":"A molecular subtype of medulloblastoma associated with activation of the WNT pathway. TP53 mutations may be present or absent. WNT pathway activation in medulloblastomas is associated with good outcome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6D3778-2D69-5529-E040-BB89AD43092C","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"GDEEN","dateModified":"2023-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6D3778-2D82-5529-E040-BB89AD43092C","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Junctional","valueDescription":"Junctional Nevus","ValueMeaning":{"publicId":"4413612","version":"1","preferredName":"Junctional Nevus","longName":"4413612","preferredDefinition":"A nevus characterized by the presence of an intraepidermal proliferation of nevus cells. The nevus cells form multiple nests in the dermal-epidermal junction. It presents as a small, slightly raised, pigmented skin lesion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Junctional Nevus","conceptCode":"C4231","definition":"A nevus characterized by the presence of an intraepidermal proliferation of nevus cells. The nevus cells form multiple nests in the dermal-epidermal junction. It presents as a small, slightly raised, pigmented skin lesion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF583E44-D715-5258-E040-BB89AD433239","latestVersionIndicator":"Yes","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF583E44-D72E-5258-E040-BB89AD433239","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"ONEDATA","dateModified":"2014-07-29","deletedIndicator":"No"},{"value":"Inflammatory epithelia","valueDescription":"Inflammatory Epithelial","ValueMeaning":{"publicId":"4413613","version":"1","preferredName":"Inflammatory Epithelial","longName":"4413613","preferredDefinition":"Relating to inflammation.: Refers to the cells that line the internal and external surfaces of the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inflammatory","conceptCode":"C25535","definition":"Relating to inflammation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Epithelial","conceptCode":"C13315","definition":"A term that refers to the cells that make up the epithelial tissues.  They are found in the skin, and in the parenchyma, surface and lumen of internal organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF583E44-D73B-5258-E040-BB89AD433239","latestVersionIndicator":"Yes","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF583E44-D754-5258-E040-BB89AD433239","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"ONEDATA","dateModified":"2014-07-29","deletedIndicator":"No"},{"value":"Immortalized fibroblast","valueDescription":"Immortalization Fibroblast","ValueMeaning":{"publicId":"4413614","version":"1","preferredName":"Immortalization Fibroblast","longName":"4413614","preferredDefinition":"Laboratory methods used to generate cells that are able to reproduce indefinitely.: A connective tissue cell that makes and secretes collagen proteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immortalization","conceptCode":"C82424","definition":"Laboratory methods used to generate cells that are able to reproduce indefinitely.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Fibroblast","conceptCode":"C12482","definition":"A connective tissue cell that makes and secretes collagen proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF583E44-D761-5258-E040-BB89AD433239","latestVersionIndicator":"Yes","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF583E44-D77A-5258-E040-BB89AD433239","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"ONEDATA","dateModified":"2014-07-29","deletedIndicator":"No"},{"value":"Immortalized epithelial","valueDescription":"Immortalization Epithelial","ValueMeaning":{"publicId":"4413615","version":"1","preferredName":"Immortalization Epithelial","longName":"4413615","preferredDefinition":"Laboratory methods used to generate cells that are able to reproduce indefinitely.: Refers to the cells that line the internal and external surfaces of the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immortalization","conceptCode":"C82424","definition":"Laboratory methods used to generate cells that are able to reproduce indefinitely.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Epithelial","conceptCode":"C13315","definition":"A term that refers to the cells that make up the epithelial tissues.  They are found in the skin, and in the parenchyma, surface and lumen of internal organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF583E44-D787-5258-E040-BB89AD433239","latestVersionIndicator":"Yes","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF583E44-D7A0-5258-E040-BB89AD433239","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"ONEDATA","dateModified":"2014-07-29","deletedIndicator":"No"},{"value":"Hurthle cell carcinoma","valueDescription":"Thyroid Gland Oncocytic Follicular Carcinoma","ValueMeaning":{"publicId":"4413616","version":"1","preferredName":"Thyroid Gland Oncocytic Follicular Carcinoma","longName":"4413616","preferredDefinition":"A follicular carcinoma of the thyroid gland, characterized by the presence of large cells with eosinophilic granular cytoplasm and pleomorphic nuclei with prominent, eosinophilic nucleoli.  The nuclear features that characterize the papillary carcinomas of the thyroid gland are absent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Oncocytic Carcinoma","conceptCode":"C4946","definition":"A follicular carcinoma of the thyroid gland, characterized by the presence of large cells with eosinophilic granular cytoplasm and pleomorphic nuclei with prominent, eosinophilic nucleoli.  The nuclear features that characterize the papillary carcinomas of the thyroid gland are absent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF583E44-D7AA-5258-E040-BB89AD433239","latestVersionIndicator":"Yes","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF583E44-D7C3-5258-E040-BB89AD433239","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"ONEDATA","dateModified":"2014-07-29","deletedIndicator":"No"},{"value":"Ependymoma Grade III IV","valueDescription":"Grade 3 Grade 4 Ependymoma","ValueMeaning":{"publicId":"4413617","version":"1","preferredName":"Grade 3 Grade 4 Ependymoma","longName":"4413617","preferredDefinition":"A morphologic qualifier indicating that a cancerous lesion is poorly differentiated.: A morphologic qualifier indicating that a cancerous lesion is undifferentiated.: A WHO grade II, slow growing tumor of children and young adults, usually located intraventricularly. It is the most common ependymal neoplasm. It often causes clinical symptoms by blocking cerebrospinal fluid pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 3","conceptCode":"C28079","definition":"A morphologic qualifier indicating that a cancerous lesion is poorly differentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Grade 4","conceptCode":"C28082","definition":"A morphologic qualifier indicating that a cancerous lesion is undifferentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Ependymoma","conceptCode":"C3017","definition":"A WHO grade 2, slow growing tumor of children and young adults, usually located intraventricularly. It is the most common ependymal neoplasm. It often causes clinical symptoms by blocking cerebrospinal fluid pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF583E44-D7D1-5258-E040-BB89AD433239","latestVersionIndicator":"Yes","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF583E44-D7EA-5258-E040-BB89AD433239","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"ONEDATA","dateModified":"2014-07-29","deletedIndicator":"No"},{"value":"Dysplastic","valueDescription":"Dysplasia","ValueMeaning":{"publicId":"2838899","version":"1","preferredName":"Dysplasia","longName":"2838899","preferredDefinition":"A usually neoplastic transformation of the cell, associated with altered architectural tissue patterns.  The cellular changes include nuclear and cytoplasmic abnormalities.  Molecular genetic abnormalities are also often found and, in some instances, may lead to cancer. -- 2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dysplasia","conceptCode":"C4086","definition":"A usually neoplastic transformation of the cell, associated with altered architectural tissue patterns. The cellular changes include nuclear and cytoplasmic abnormalities. Molecular genetic abnormalities are also often found and, in some instances, may lead to cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62AB59ED-A4B7-4EBE-E040-BB89AD4348C8","latestVersionIndicator":"Yes","beginDate":"2009-02-11","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-11","modifiedBy":"ONEDATA","dateModified":"2009-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF583E44-D7FE-5258-E040-BB89AD433239","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"ONEDATA","dateModified":"2014-07-29","deletedIndicator":"No"},{"value":"Dedifferentiated","valueDescription":"Cell Dedifferentiation","ValueMeaning":{"publicId":"4413619","version":"1","preferredName":"Cell Dedifferentiation","longName":"4413619","preferredDefinition":"A morphologic finding indicating the presence of a high-grade cellular component adjacent to or admixed with a low-grade cellular infiltarte.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cellular Dedifferentiation","conceptCode":"C129469","definition":"A morphologic finding indicating the presence of a high-grade cellular component adjacent to or admixed with a low-grade cellular infiltrate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF583E44-D80B-5258-E040-BB89AD433239","latestVersionIndicator":"Yes","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF583E44-D824-5258-E040-BB89AD433239","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"ONEDATA","dateModified":"2014-07-29","deletedIndicator":"No"},{"value":"Basal triple negative carcinoma","valueDescription":"Triple-Negative Breast Cancer Finding","ValueMeaning":{"publicId":"4413621","version":"1","preferredName":"Triple-Negative Breast Cancer Finding","longName":"4413621","preferredDefinition":"Triple-negative breast cancer is defined by a lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/neu).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Triple-Negative Breast Cancer Finding","conceptCode":"C71428","definition":"Triple-negative breast cancer finding is a negative test result that occurs when the cells in the tumor of a breast cancer patient lack the receptors for both estrogen and progesterone and the human epidermal growth factor receptor 2.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF583E44-D846-5258-E040-BB89AD433239","latestVersionIndicator":"Yes","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF583E44-D85F-5258-E040-BB89AD433239","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"ONEDATA","dateModified":"2014-07-29","deletedIndicator":"No"},{"value":"Ambiguous lineage","valueDescription":"Ambiguous cell lineage","ValueMeaning":{"publicId":"4360177","version":"1","preferredName":"Ambiguous cell lineage","longName":"4360177","preferredDefinition":"The developmental history of a differentiated cell as traced from the division of a stem cell.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cell Lineage","conceptCode":"C17895","definition":"The developmental history of a differentiated cell as traced from the division of a stem cell.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC2FF07C-5C24-E43C-E040-BB89AD4336C7","latestVersionIndicator":"Yes","beginDate":"2014-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-06-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF583E44-D873-5258-E040-BB89AD433239","beginDate":"2014-06-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"ONEDATA","dateModified":"2014-07-29","deletedIndicator":"No"},{"value":"Ependymoma Grade II","valueDescription":"Grade 2 Ependymoma","ValueMeaning":{"publicId":"4413622","version":"1","preferredName":"Grade 2 Ependymoma","longName":"4413622","preferredDefinition":"A morphologic qualifier indicating that a cancerous lesion is moderately differentiated.: A WHO grade II, slow growing tumor of children and young adults, usually located intraventricularly. It is the most common ependymal neoplasm. It often causes clinical symptoms by blocking cerebrospinal fluid pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Grade 2","conceptCode":"C28078","definition":"A morphologic qualifier indicating that a cancerous lesion is moderately differentiated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Ependymoma","conceptCode":"C3017","definition":"A WHO grade 2, slow growing tumor of children and young adults, usually located intraventricularly. It is the most common ependymal neoplasm. It often causes clinical symptoms by blocking cerebrospinal fluid pathways. Key histological features include perivascular pseudorosettes and ependymal rosettes. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF583E44-D880-5258-E040-BB89AD433239","latestVersionIndicator":"Yes","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"ONEDATA","dateModified":"2014-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF583E44-D899-5258-E040-BB89AD433239","beginDate":"2014-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-29","modifiedBy":"ONEDATA","dateModified":"2014-07-29","deletedIndicator":"No"},{"value":"Bronchioalveolar adenocarcinoma","valueDescription":"Bronchioalveolar Carcinoma","ValueMeaning":{"publicId":"3106712","version":"1","preferredName":"Bronchioalveolar Carcinoma","longName":"3106712","preferredDefinition":"A solitary adenocarcinoma arising from the lung measuring 3 cm or less. It is characterized by a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. It is usually a non-mucinous adenocarcinoma, but rarely may be mucinous.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Minimally Invasive Lung Adenocarcinoma","conceptCode":"C2923","definition":"A solitary adenocarcinoma arising from the lung and measuring 3 cm or less in size. It is characterized by a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension. It is usually a non-mucinous adenocarcinoma, but rarely may be mucinous.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"883834AB-0D26-C6A6-E040-BB89AD431A8D","latestVersionIndicator":"Yes","beginDate":"2010-06-04","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-06-04","modifiedBy":"COOPERM","dateModified":"2019-04-10","changeDescription":"Updated definition to match current NCIt. 4.10.19 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6EB603-0E2F-3DD7-E040-BB89AD4370CB","beginDate":"2014-07-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Unclassified","valueDescription":"Unclassified","ValueMeaning":{"publicId":"3027954","version":"1","preferredName":"Unclassified","longName":"3027954","preferredDefinition":"Not arranged or included in any specific grouping.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unclassified","conceptCode":"C64486","definition":"Not arranged or included in any specific grouping.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"82128AAE-65C2-DBAB-E040-BB89AD436C1D","latestVersionIndicator":"Yes","beginDate":"2010-03-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6CD43E-FB76-E71D-E040-BB89AD437276","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Spitzoid","valueDescription":"Spitzoid melanoma","ValueMeaning":{"publicId":"4419556","version":"1","preferredName":"Spitzoid melanoma","longName":"4419556","preferredDefinition":"No Value Exists","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Spitzoid melanoma","conceptCode":"C3495721","definition":"No Value Exists","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6CD43E-FB84-E71D-E040-BB89AD437276","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6CD43E-FB9D-E71D-E040-BB89AD437276","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Typical","valueDescription":"Typical Histology","ValueMeaning":{"publicId":"4419557","version":"1","preferredName":"Typical Histology","longName":"4419557","preferredDefinition":"That which is considered customary.: The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Usual","conceptCode":"C102843","definition":"That which is considered customary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Histology","conceptCode":"C16681","definition":"The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6CD43E-FBAA-E71D-E040-BB89AD437276","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6CD43E-FBC3-E71D-E040-BB89AD437276","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Spindle epithelial tumor","valueDescription":"Spindle epithelial tumor","ValueMeaning":{"publicId":"4419558","version":"1","preferredName":"Spindle epithelial tumor","longName":"4419558","preferredDefinition":"A primary endometrioid adenocarcinoma of the endometrium characterized by the presence of spindled malignant epithelial cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrial Endometrioid Adenocarcinoma with Spindled Epithelial Cells","conceptCode":"C27850","definition":"A primary endometrioid adenocarcinoma of the endometrium characterized by the presence of spindled malignant epithelial cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6CD43E-FBCD-E71D-E040-BB89AD437276","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6CD43E-FBE6-E71D-E040-BB89AD437276","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Spindle","valueDescription":"Spindle Cell Sarcoma","ValueMeaning":{"publicId":"4419560","version":"1","preferredName":"Spindle Cell Sarcoma","longName":"4419560","preferredDefinition":"A malignant mesenchymal neoplasm composed of spindle-shaped cells.  This is a morphologic term which can be applied to a wide range of sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Spindle Cell Sarcoma","conceptCode":"C27005","definition":"A malignant mesenchymal neoplasm composed of spindle-shaped cells.  This is a morphologic term which can be applied to a wide range of sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6CD43E-FBF3-E71D-E040-BB89AD437276","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6CD43E-FC0C-E71D-E040-BB89AD437276","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Small cell adenocarcinoma","valueDescription":"Small cell adenocarcinoma","ValueMeaning":{"publicId":"4419561","version":"1","preferredName":"Small cell adenocarcinoma","longName":"4419561","preferredDefinition":"An adenocarcinoma composed of small malignant cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Small Cell Adenocarcinoma","conceptCode":"C129449","definition":"An adenocarcinoma composed of small malignant cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6CD43E-FC16-E71D-E040-BB89AD437276","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6CD43E-FC2F-E71D-E040-BB89AD437276","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Simple","valueDescription":"Simple Histology","ValueMeaning":{"publicId":"4419562","version":"1","preferredName":"Simple Histology","longName":"4419562","preferredDefinition":"Easy, not involved or complicated, not elaborate, having few parts.: The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Simple","conceptCode":"C47880","definition":"Easy, not involved or complicated, not elaborate, having few parts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Histology","conceptCode":"C16681","definition":"The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6CD43E-FC3C-E71D-E040-BB89AD437276","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6CD43E-FC55-E71D-E040-BB89AD437276","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Pterygium","valueDescription":"Pterygium","ValueMeaning":{"publicId":"4419563","version":"1","preferredName":"Pterygium","longName":"4419563","preferredDefinition":"A congenital, usually bilateral, thick web-like fold of skin that extends from the acromion to the mastoid process. This deformity is associated with Turner Syndrome and Noonan Syndrome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pterygium Colli","conceptCode":"C87130","definition":"A congenital, usually bilateral, thick web-like fold of skin that extends from the acromion to the mastoid process. This deformity is associated with Turner Syndrome and Noonan Syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6CD43E-FC5F-E71D-E040-BB89AD437276","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6CD43E-FC78-E71D-E040-BB89AD437276","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Psammocarcinoma","valueDescription":"Psammocarcinoma","ValueMeaning":{"publicId":"4419564","version":"1","preferredName":"Psammocarcinoma","longName":"4419564","preferredDefinition":"A structure found in some benign (not cancer) or malignant (cancer) tumor cells. Psammoma bodies look like hardened concentric rings when viewed under a microscope. They can be a sign of chronic inflammation.::1: A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Psammoma Body Formation","conceptCode":"C27709","definition":"A structure found in some benign (not cancer) or malignant (cancer) tumor cells. Psammoma bodies look like hardened concentric rings when viewed under a microscope. They can be a sign of chronic inflammation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6CD43E-FC82-E71D-E040-BB89AD437276","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6CD43E-FC9B-E71D-E040-BB89AD437276","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Pingueculum","valueDescription":"Pinguecula","ValueMeaning":{"publicId":"4419565","version":"1","preferredName":"Pinguecula","longName":"4419565","preferredDefinition":"Yellowish deposits on the conjunctiva close to the edge of the cornea.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pinguecula","conceptCode":"C129468","definition":"Yellowish deposits on the conjunctiva close to the edge of the cornea.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6CD43E-FCA5-E71D-E040-BB89AD437276","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6CD43E-FCBE-E71D-E040-BB89AD437276","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Peritoneal mucinous surface proliferation benign","valueDescription":"Peritoneal mucinous surface proliferation benign","ValueMeaning":{"publicId":"4419534","version":"1","preferredName":"Peritoneal mucinous surface proliferation benign","longName":"4419534","preferredDefinition":"Multiplying or increasing in number.  In biology, cell proliferation occurs by a process known as cell division.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Proliferation","conceptCode":"C28378","definition":"Multiplying or increasing in number.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6C7035-3F27-8C07-E040-BB89AD4364B9","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6C7035-3F40-8C07-E040-BB89AD4364B9","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Peritoneal serous surface proliferation benign","valueDescription":"Peritoneal serous surface proliferation benign","ValueMeaning":{"publicId":"4419532","version":"1","preferredName":"Peritoneal serous surface proliferation benign","longName":"4419532","preferredDefinition":"Peritoneal serous surface proliferation benign","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6C7035-3EDC-8C07-E040-BB89AD4364B9","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6C7035-3EF5-8C07-E040-BB89AD4364B9","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Peritoneal serous surface carcinoma","valueDescription":"Peritoneal Serous Surface Papillary Carcinoma","ValueMeaning":{"publicId":"4419533","version":"1","preferredName":"Peritoneal Serous Surface Papillary Carcinoma","longName":"4419533","preferredDefinition":"Of or pertaining to the peritoneum.: An invasive serous adenocarcinoma arising from the ovary. Cases with identical morphology have been described arising in the peritoneum, almost exclusively in women. Morphologically, it may be a well, moderately, or poorly differentiated neoplasm. It is characterized by a papillary growth pattern often associated with the presence of psammoma bodies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Peritoneal","conceptCode":"C25313","definition":"Of or pertaining to the peritoneum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Serous Surface Papillary Carcinoma","conceptCode":"C4182","definition":"An invasive serous adenocarcinoma arising from the ovary and rarely the peritoneum. Morphologically, it may be a well, moderately, or poorly differentiated neoplasm. It is characterized by a papillary growth pattern often associated with the presence of psammoma bodies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6C7035-3F02-8C07-E040-BB89AD4364B9","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6C7035-3F1B-8C07-E040-BB89AD4364B9","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Oncocytoma","valueDescription":"Oncocytic Neoplasm","ValueMeaning":{"publicId":"3251524","version":"1","preferredName":"Oncocytic Neoplasm","longName":"3251524","preferredDefinition":"A usually benign neoplasm composed of large cells with abundant eosinophilic granular cytoplasm.  Representative examples include oncocytic neoplasms of the thyroid gland, and kidney. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oncocytic Neoplasm","conceptCode":"C7072","definition":"A usually benign neoplasm composed of large cells with abundant eosinophilic granular cytoplasm.  Representative examples include oncocytic neoplasms of the thyroid gland, and kidney. (NCI05)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A766EF05-0938-69EE-E040-BB89AD437928","latestVersionIndicator":"Yes","beginDate":"2011-07-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-07-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6C7035-3F4A-8C07-E040-BB89AD4364B9","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Oligodendroglioma Grade III","valueDescription":"WHO Central Nervous System Grade III Oligodendroglioma","ValueMeaning":{"publicId":"4419535","version":"1","preferredName":"WHO Central Nervous System Grade III Oligodendroglioma","longName":"4419535","preferredDefinition":"Describes central nervous system tumors that are generally malignant and infiltrative. They tend to recur after treatment.: A well-differentiated (WHO grade II), diffusely infiltrating neuroglial tumor, typically located in the cerebral hemispheres.  It is composed predominantly of cells which morphologically resemble oligodendroglia. The neoplastic cells have rounded homogeneous nuclei and, on paraffin sections, a swollen, clear cytoplasm ('honeycomb' appearance). (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"WHO Central Nervous System Grade 3","conceptCode":"C62396","definition":"Describes central nervous system tumors that are generally malignant and infiltrative. They tend to recur after treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Oligodendroglioma","conceptCode":"C3288","definition":"A well-differentiated (WHO grade 2), diffusely infiltrating neuroglial tumor, typically located in the cerebral hemispheres.  It is composed predominantly of cells which morphologically resemble oligodendroglia. The neoplastic cells have rounded homogeneous nuclei and, on paraffin sections, a swollen, clear cytoplasm ('honeycomb' appearance). (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6C7035-3F58-8C07-E040-BB89AD4364B9","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6C7035-3F71-8C07-E040-BB89AD4364B9","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Oligodendroglioma Grade II","valueDescription":"WHO Central Nervous System Grade II Oligodendroglioma","ValueMeaning":{"publicId":"4419536","version":"1","preferredName":"WHO Central Nervous System Grade II Oligodendroglioma","longName":"4419536","preferredDefinition":"Describes central nervous system tumors that are generally relatively slow growing and somewhat infiltrative. They may recur after treatment.: A well-differentiated (WHO grade II), diffusely infiltrating neuroglial tumor, typically located in the cerebral hemispheres.  It is composed predominantly of cells which morphologically resemble oligodendroglia. The neoplastic cells have rounded homogeneous nuclei and, on paraffin sections, a swollen, clear cytoplasm ('honeycomb' appearance). (Adapted from WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"WHO Central Nervous System Grade 2","conceptCode":"C62395","definition":"Describes central nervous system tumors that are generally relatively slow growing and somewhat infiltrative. They may recur after treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Oligodendroglioma","conceptCode":"C3288","definition":"A well-differentiated (WHO grade 2), diffusely infiltrating neuroglial tumor, typically located in the cerebral hemispheres.  It is composed predominantly of cells which morphologically resemble oligodendroglia. The neoplastic cells have rounded homogeneous nuclei and, on paraffin sections, a swollen, clear cytoplasm ('honeycomb' appearance). (Adapted from WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6C7035-3F7E-8C07-E040-BB89AD4364B9","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6C7035-3F97-8C07-E040-BB89AD4364B9","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Oligoastrocytoma Grade IV","valueDescription":"WHO Central Nervous System Grade IV Oligoastrocytoma","ValueMeaning":{"publicId":"4419537","version":"1","preferredName":"WHO Central Nervous System Grade IV Oligoastrocytoma","longName":"4419537","preferredDefinition":"Describes central nervous system tumors that are generally highly malignant, show rapid and aggressive growth, widely infiltrative, and prone to necrosis. They often recur rapidly after treatment.: A WHO grade II tumor composed of a conspicuous mixture of two distinct neoplastic cell types morphologically resembling the tumor cells in oligodendroglioma and diffuse astrocytoma. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"WHO Central Nervous System Grade 4","conceptCode":"C62397","definition":"Describes central nervous system tumors that are generally highly malignant, show rapid and aggressive growth, widely infiltrative, and prone to necrosis. They often recur rapidly after treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Oligoastrocytoma","conceptCode":"C4050","definition":"A WHO grade 2 tumor composed of a conspicuous mixture of two distinct neoplastic cell types morphologically resembling the tumor cells in oligodendroglioma and diffuse astrocytoma. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6C7035-3FA4-8C07-E040-BB89AD4364B9","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6C7035-3FBD-8C07-E040-BB89AD4364B9","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Oligoastrocytoma Grade III","valueDescription":"WHO Central Nervous System Grade III Oligoastrocytoma","ValueMeaning":{"publicId":"4419538","version":"1","preferredName":"WHO Central Nervous System Grade III Oligoastrocytoma","longName":"4419538","preferredDefinition":"Describes central nervous system tumors that are generally malignant and infiltrative. They tend to recur after treatment.: A WHO grade II tumor composed of a conspicuous mixture of two distinct neoplastic cell types morphologically resembling the tumor cells in oligodendroglioma and diffuse astrocytoma. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"WHO Central Nervous System Grade 3","conceptCode":"C62396","definition":"Describes central nervous system tumors that are generally malignant and infiltrative. They tend to recur after treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Oligoastrocytoma","conceptCode":"C4050","definition":"A WHO grade 2 tumor composed of a conspicuous mixture of two distinct neoplastic cell types morphologically resembling the tumor cells in oligodendroglioma and diffuse astrocytoma. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6C7035-3FCA-8C07-E040-BB89AD4364B9","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6C7035-3FE3-8C07-E040-BB89AD4364B9","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Oligoastrocytoma Grade II","valueDescription":"WHO Central Nervous System Grade II Oligoastrocytoma","ValueMeaning":{"publicId":"4419539","version":"1","preferredName":"WHO Central Nervous System Grade II Oligoastrocytoma","longName":"4419539","preferredDefinition":"Describes central nervous system tumors that are generally relatively slow growing and somewhat infiltrative. They may recur after treatment.: A WHO grade II tumor composed of a conspicuous mixture of two distinct neoplastic cell types morphologically resembling the tumor cells in oligodendroglioma and diffuse astrocytoma. (WHO)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"WHO Central Nervous System Grade 2","conceptCode":"C62395","definition":"Describes central nervous system tumors that are generally relatively slow growing and somewhat infiltrative. They may recur after treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Oligoastrocytoma","conceptCode":"C4050","definition":"A WHO grade 2 tumor composed of a conspicuous mixture of two distinct neoplastic cell types morphologically resembling the tumor cells in oligodendroglioma and diffuse astrocytoma. (WHO)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6C7035-3FF0-8C07-E040-BB89AD4364B9","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6C7035-4009-8C07-E040-BB89AD4364B9","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Complex","valueDescription":"Complex Histology","ValueMeaning":{"publicId":"4419331","version":"1","preferredName":"Complex Histology","longName":"4419331","preferredDefinition":"Hard, involved or complicated, elaborate, having many parts.: The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complex","conceptCode":"C47881","definition":"Hard, involved or complicated, elaborate, having many parts.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Histology","conceptCode":"C16681","definition":"The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6AFFD8-E2FA-FFDC-E040-BB89AD4313A0","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6AFFD8-E313-FFDC-E040-BB89AD4313A0","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Classic","valueDescription":"Classic Histology","ValueMeaning":{"publicId":"4419333","version":"1","preferredName":"Classic Histology","longName":"4419333","preferredDefinition":"A term that refers to the histologic image of a lesion which carries all the characteristic morphologic findings which are necessary to define this lesion.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Classic Histology","conceptCode":"C129470","definition":"A term that refers to the histologic image of a lesion which carries all the characteristic morphologic findings which are necessary to define this lesion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6AFFD8-E321-FFDC-E040-BB89AD4313A0","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6AFFD8-E33A-FFDC-E040-BB89AD4313A0","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"NK cell lymphoma","valueDescription":"Natural Killer cell lymphoma","ValueMeaning":{"publicId":"4419383","version":"1","preferredName":"Natural Killer cell lymphoma","longName":"4419383","preferredDefinition":"An aggressive immature hematologic neoplasm formerly known as blastic NK cell lymphoma, composed of cells with a lymphoblast-like morphology.  Recent evidence suggests derivation from a plasmacytoid monocyte.  Patients present with cutaneous tumors and bone marrow involvement.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blastic Plasmacytoid Dendritic Cell Neoplasm","conceptCode":"C7203","definition":"A clinically aggressive neoplasm derived from the precursors of plasmacytoid dendritic cells (also called professional type I interferon-producing cells or plasmacytoid monocytes), with a high frequency of cutaneous and bone marrow involvement and leukemic dissemination. (WHO 2017)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6AFFD8-E345-FFDC-E040-BB89AD4313A0","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6AFFD8-E35E-FFDC-E040-BB89AD4313A0","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"NK cell leukemia","valueDescription":"Natural Killer cell leukemia","ValueMeaning":{"publicId":"4419384","version":"1","preferredName":"Natural Killer cell leukemia","longName":"4419384","preferredDefinition":"A rare, highly aggressive, Epstein-Barr virus-associated leukemia, also known as aggressive NK-cell leukemia/lymphoma; it may represent the leukemic counterpart of nasal type extranodal NK/T-cell lymphomas. It affects primarily teenagers and young adults. It is characterized by the systemic proliferation of NK cells in the peripheral blood, bone marrow, liver, and spleen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aggressive NK-Cell Leukemia","conceptCode":"C8647","definition":"A rare, highly aggressive, Epstein-Barr virus-associated leukemia, also known as aggressive NK-cell leukemia/lymphoma; it may represent the leukemic counterpart of nasal type extranodal NK/T-cell lymphomas. It affects primarily teenagers and young adults. It is characterized by the systemic proliferation of NK cells in the peripheral blood, bone marrow, liver, and spleen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6AFFD8-E368-FFDC-E040-BB89AD4313A0","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6AFFD8-E381-FFDC-E040-BB89AD4313A0","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Mixed cell carcinoma","valueDescription":"Mixed cell carcinoma","ValueMeaning":{"publicId":"4419385","version":"1","preferredName":"Mixed cell carcinoma","longName":"4419385","preferredDefinition":"An adenoma characterized by the presence of a mixed epithelial cell population.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mixed Cell Adenoma","conceptCode":"C4157","definition":"An adenoma characterized by the presence of a mixed epithelial cell population.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6AFFD8-E38B-FFDC-E040-BB89AD4313A0","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6AFFD8-E3A4-FFDC-E040-BB89AD4313A0","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Luteinizing hormone subunit alpha","valueDescription":"Luteinizing hormone subunit alpha","ValueMeaning":{"publicId":"4419386","version":"1","preferredName":"Luteinizing hormone subunit alpha","longName":"4419386","preferredDefinition":"Luteinizing hormone subunit alpha","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6AFFD8-E3AE-FFDC-E040-BB89AD4313A0","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6AFFD8-E3C7-FFDC-E040-BB89AD4313A0","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Non-functioning","valueDescription":"Non-Functioning Endocrine Neoplasm","ValueMeaning":{"publicId":"4419388","version":"1","preferredName":"Non-Functioning Endocrine Neoplasm","longName":"4419388","preferredDefinition":"A tumor that is found in endocrine tissue but does not make extra hormones. Endocrine-inactive tumors usually do not cause symptoms until they grow large or spread to other parts of the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Functioning Endocrine Neoplasm","conceptCode":"C94760","definition":"A hormone producing or non-producing endocrine neoplasm, not associated with a hormonal syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6AFFD8-E3D4-FFDC-E040-BB89AD4313A0","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6AFFD8-E3ED-FFDC-E040-BB89AD4313A0","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Follicle stimulating hormone subunit alpha","valueDescription":"Follicle stimulating hormone subunit alpha","ValueMeaning":{"publicId":"4419389","version":"1","preferredName":"Follicle stimulating hormone subunit alpha","longName":"4419389","preferredDefinition":"Follicle stimulating hormone subunit alpha","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6AFFD8-E3F7-FFDC-E040-BB89AD4313A0","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6AFFD8-E410-FFDC-E040-BB89AD4313A0","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Ductolobular carcinoma","valueDescription":"Ductolobular carcinoma","ValueMeaning":{"publicId":"4419390","version":"1","preferredName":"Ductolobular carcinoma","longName":"4419390","preferredDefinition":"A breast carcinoma characterized by the presence of a lobular and a ductal component. The ductal component comprises less than 50 percent of the tumor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Mixed Ductal and Lobular Carcinoma","conceptCode":"C5160","definition":"A breast carcinoma characterized by the presence of a lobular and a ductal component. The ductal component comprises less than 50 percent of the tumor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6AFFD8-E41A-FFDC-E040-BB89AD4313A0","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6AFFD8-E433-FFDC-E040-BB89AD4313A0","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Hurthle cell tumor","valueDescription":"Hurthle cell tumor","ValueMeaning":{"publicId":"4419391","version":"1","preferredName":"Hurthle cell tumor","longName":"4419391","preferredDefinition":"An adenoma or carcinoma arising from the follicular cells of the thyroid gland.  It is composed of large oncocytic cells with abundant granular eosinophilic cytoplasm.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Oncocytic Neoplasm","conceptCode":"C46068","definition":"An adenoma or carcinoma arising from the follicular cells of the thyroid gland.  It is composed of large oncocytic cells with abundant granular eosinophilic cytoplasm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6AFFD8-E43D-FFDC-E040-BB89AD4313A0","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6AFFD8-E456-FFDC-E040-BB89AD4313A0","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Hurthle cell adenoma","valueDescription":"Hurthle cell adenoma","ValueMeaning":{"publicId":"4419392","version":"1","preferredName":"Hurthle cell adenoma","longName":"4419392","preferredDefinition":"A thyroid gland adenoma composed of large cells with abundant granular eosinophilic cytoplasm and large nuclei with prominent nucleoli.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thyroid Gland Oncocytic Adenoma","conceptCode":"C6042","definition":"A thyroid gland adenoma composed of large cells with abundant granular eosinophilic cytoplasm and large nuclei with prominent nucleoli.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6AFFD8-E460-FFDC-E040-BB89AD4313A0","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6AFFD8-E479-FFDC-E040-BB89AD4313A0","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Large cell undifferentiated carcinoma","valueDescription":"Large cell undifferentiated carcinoma","ValueMeaning":{"publicId":"4419393","version":"1","preferredName":"Large cell undifferentiated carcinoma","longName":"4419393","preferredDefinition":"A malignant epithelial neoplasm composed of large, atypical cells.::1: A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular, squamous, or transitional cell differentiation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Large Cell Carcinoma","conceptCode":"C3780","definition":"A malignant epithelial neoplasm composed of large, atypical cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Undifferentiated Carcinoma","conceptCode":"C3692","definition":"A usually aggressive malignant epithelial neoplasm composed of atypical cells which do not display evidence of glandular, squamous, or transitional cell differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6AFFD8-E483-FFDC-E040-BB89AD4313A0","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6AFFD8-E49C-FFDC-E040-BB89AD4313A0","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Large cell","valueDescription":"Large cell","ValueMeaning":{"publicId":"3243478","version":"1","preferredName":"Large cell","longName":"3243478","preferredDefinition":"A neoplastic cell with abundant amount of cytoplasm and/or large nucleus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplastic Large Cell","conceptCode":"C37162","definition":"A neoplastic cell with abundant amount of cytoplasm and/or large nucleus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A55A32E7-3610-D7C0-E040-BB89AD437508","latestVersionIndicator":"Yes","beginDate":"2011-06-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6AFFD8-E4A6-FFDC-E040-BB89AD4313A0","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Luminal carcinoma","valueDescription":"Luminal Carcinoma","ValueMeaning":{"publicId":"4419395","version":"1","preferredName":"Luminal Carcinoma","longName":"4419395","preferredDefinition":"Relating to the lumen of a blood vessel or other tubular structure.: A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Luminal","conceptCode":"C26456","definition":"Relating to the lumen of a blood vessel or other tubular structure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Carcinoma","conceptCode":"C2916","definition":"A malignant tumor arising from epithelial cells. Carcinomas that arise from glandular epithelium are called adenocarcinomas, those that arise from squamous epithelium are called squamous cell carcinomas, and those that arise from transitional epithelium are called transitional cell carcinomas. Morphologically, the malignant epithelial cells may display abnormal mitotic figures, anaplasia, and necrosis. Carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated. Carcinomas invade the surrounding tissues and tend to metastasize to other anatomic sites. Lung carcinoma, skin carcinoma, breast carcinoma, colon carcinoma, and prostate carcinoma are the most frequently seen carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FF6AFFD8-E4B5-FFDC-E040-BB89AD4313A0","latestVersionIndicator":"Yes","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"FF6AFFD8-E4CE-FFDC-E040-BB89AD4313A0","beginDate":"2014-07-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-07-30","modifiedBy":"ONEDATA","dateModified":"2014-07-30","deletedIndicator":"No"},{"value":"Telangiectatic","valueDescription":"Telangiectatic Osteosarcoma","ValueMeaning":{"publicId":"3179371","version":"1","preferredName":"Telangiectatic Osteosarcoma","longName":"3179371","preferredDefinition":"An osteosarcoma usually arising in the metaphysis of long bones. It is characterized by the presence of a cystic architecture with blood-filled spaces. The prognosis is similar to that of conventional osteosarcoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Telangiectatic Osteosarcoma","conceptCode":"C3902","definition":"An osteosarcoma usually arising from the metaphysis of long bones. It is characterized by the presence of a cystic architecture with blood-filled spaces. The prognosis is similar to that of conventional osteosarcoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9890B54F-87A9-2C65-E040-BB89AD4320B1","latestVersionIndicator":"Yes","beginDate":"2010-12-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-12-29","modifiedBy":"ONEDATA","dateModified":"2010-12-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"598F9D11-8BAD-1BA9-E053-F662850AFAE3","beginDate":"2017-09-19","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-09-19","modifiedBy":"ONEDATA","dateModified":"2017-09-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2229718","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F6EF4E2B-76AE-72C1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-16","modifiedBy":"ONEDATA","dateModified":"2005-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTD2:Cancer Target Discovery and Development","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F46DA4A4-1559-3FBD-E040-BB89AD431BE9","latestVersionIndicator":"Yes","beginDate":"2014-03-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-03-12","modifiedBy":"COOPERM","dateModified":"2019-03-21","changeDescription":"Curated to support CTD2 activity","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5646652","version":"1","longName":"CTD^2 (Cancer Target Discovery and Development","context":"OCG","ClassificationSchemeItems":[{"publicId":"5092552","version":"1","longName":"Approved CDEs","context":"OCG"}]},{"publicId":"5806857","version":"1","longName":"HCMI (Human Cancer Models Initiative)","context":"OCG","ClassificationSchemeItems":[{"publicId":"5806869","version":"1","longName":"Pediatric Osteosarcoma","context":"OCG"}]}],"AlternateNames":[{"name":"biospecimen_primary_histology_subtype","type":"HCMI Name","context":"OCG"},{"name":"BIOSPC_PMY_HIST_SBTY_NM","type":"COG GDE Short Name","context":"COG"}],"ReferenceDocuments":[{"name":"Biospecimen histology subtype","type":"Preferred Question Text","description":"Biospecimen histology subtype 1","url":null,"context":"OCG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Histology of germ cell tumor:","url":null,"context":"COG"},{"name":"HCMI Question Text","type":"Alternate Question Text","description":"Histological subtype","url":null,"context":"OCG"}],"origin":"CTD2:Cancer Target Discovery and Development","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8CB9F6A5-070B-65B5-E053-F662850A2B21","latestVersionIndicator":"Yes","beginDate":"2014-03-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-02","modifiedBy":"COOPERM","dateModified":"2019-07-02","changeDescription":"VM concept annotation complete and CDEs released. mc 10/7/16 Moved from CTD-2 to OCG Context per request by S.Jagu. mc 2/1/17 Versioned for non-numeric short name per NRG request for Rave. mc 7.2.19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}